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 Abstract 
 
Role of the host cell in the type III translocation of Pseudomonas aeruginosa 
exoenzyme S 
 
Elizabeth A. Rucks 
 
Exoenzyme S (ExoS) is a bifunctional toxin that is directly translocated into eukaryotic 
cells by the Pseudomonas aeruginosa (Pa) type III secretory (T3S) process. The N-
terminal region of ExoS includes a GTPase activating protein (GAP) activity and the C-
terminal region includes an ADP-ribosyltransferase (ADPRT) activity. The T3S-
translocation (T3S-T) of ExoS allows the bacteria to directly manipulate host cell 
function, thereby contributing the virulence of Pa. A cell culture model of infection was 
developed to study the effects of ExoS on cell function, which differentiates the effects 
of ExoS expression from other bacterial effects. Previous studies found that ExoS 
inactivates cell function, and this inactivation was largely attributed to the ADPRT 
activity. Bacterially translocated ExoS (T3S-T-ExoS) was also found to ADP-ribosylate a 
number of low molecular weight G-proteins (LMWG-proteins) within the cell. While the 
effects of T3S-T-ExoS on cell function were characterized, the role of the host cell in the 
T3S process remained unknown. Studies described in this dissertation characterize 
host cell influences in the targeting of ExoS ADPRT activity to specific eukaryotic 
substrates, characterize host cell mechanism of resistance to ExoS, and examine 
mechanisms associated with differences in host cell influence on T3S-T-ExoS ADPRT 
activity. Results from these studies identified two main patterns of T3S-T ExoS ADP-
ribosylation of eukaryotic proteins, a model system to examine the host cell influence on 
the Pa T3S-T process, and a method of tracking intracellular ExoS by examining ExoS-
eukaryotic protein interactions. Combined, these studies expand previous knowledge 
about the host cell influence on the Pa T3S-T process and provide methods to 
understand host cell mechanisms targeting T3S effector activity. 
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Chapter 1: Literature Review 
1 
 
Pseudomonas aeruginosa: Pseudomonas aeruginosa (Pa) is a gram-negative 
rod-shaped bacterium with a single polar flagellum (181). It is a ubiquitous 
environmental organism, which inhabits terrestrial, freshwater and marine habitats. Soil 
is thought to be primary ecological niche of Pa (83), where it plays a role in decay and 
degradation. Despite its association with life-threatening illness, Pa causes disease only 
upon gaining access to compromised plants, animals or humans. In the environment, 
Pa can colonize plants and healthy animals without disease (83, 118, 181) and is only 
overtly cytotoxic to phagocytic amoebae, presumably as a means of self-preservation 
(84). The success of Pa as an opportunistic pathogen closely correlates with its 
versatility as an environmental organism. Correspondingly, genes encoding regulation 
and environmental sensing proteins make up 8.4% of its 6.3 Mbp genome (225). 
Additionally, Pa can utilize many different types of compounds as a source of energy, 
produce multiple virulence factors, tolerate a wide range of temperatures, and, notably, 
is intrinsically resistant to a large number of antibiotics (83, 138, 140, 166, 181, 248). 
Since the late 1800’s, Pa had been linked to infections of wounds and surgical 
dressings. However, William Osler was the first to observe that the organisms inhabited 
previously damaged tissues and were not the primary cause of the infection, thus 
characterizing Pa as an opportunistic pathogen (181). In the 1960’s, Pa emerged as a 
major human pathogen due to its ability to infect cystic fibrosis and burn patients. 
Illustrating the opportunistic nature of Pa infections, Donald D. Stieritz and Ian Alan 
Holder developed an experimental burned mouse model (224). Mice were subjected to 
a nonlethal burn by ethanol flame, and the LD50 for Pa was determined after 
subcutaneous injection at the burn site at various time points from 0 hours to 7 days, 
2 
after the initial burn. The LD50 of control mice (mice not sustaining burn injury) was 1.3 x 
106 organisms. Inoculation of burn sites with fewer than 10 organisms resulted in death 
of 50% of the animals tested within the first 18 hours. However, the longer the recovery 
period (i.e. 24 hours to 7 days) before the tissue was inoculated with Pa, the closer the 
LD50 was to control mice. Interestingly, burned mice inoculated with Pa at nonburned 
skin sites were the least susceptible to Pa-associated morbidity and mortality, as 
compared to unburned mice (224). These studies validated the notion that Pa causes 
infections by gaining direct access to damaged tissues. In recent years, Pa has been 
reported to infect neutropenic recipients of chemotherapy, immunosuppressed 
individuals with AIDS, or drug addictions. However, Pa infections are primarily 
nosocomial and typically associated with severe burn victims, persons with cystic 
fibrosis (CF) and persons who wear contact lenses for extended periods of time (49, 
145, 181). 
Pa pathogenesis: Creating a cohesive model of Pa pathogenicity is complicated by 
the fact that there is no clear phenotypic or genetic delineation between environmental 
and disease-associated strains (199, 251). It is likely that any Pa residing in the natural 
environment has the potential to cause disease in a compromised individual. There are 
three stages to Pa pathogenesis (Figure 1): (1) colonization of the compromised tissue, 
(2) elaboration of virulence factors, and (3) persistence within the host. Synonymous 
with the ability of Pa to colonize compromised tissues is its ability to adhere to 
eukaryotic cells (253). Both bacterial and host factors are involved in Pa adherence to 
host tissues. Among the bacterial factors implicated in Pa binding to damaged tissue,  
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Figure 1. Model of Pa pathogenesis. 
A. In a healthy, non-compromised airway, Pa may bind to the viscous mucus and be 
cleared. In an alternative hypothesis, Pa binds to apical receptors, mainly CFTR, and is 
internalized. Infected epithelial cells are then desquamated and removed from the lung 
by the mucus (145). B. Within a compromised airway, depicted here as a CF lung, Pa is 
drawn to the epithelial cells by the viscous mucus. Bacterial adherence is established, 
which leads to the elaboration of virulence factors. Virulence factors are represented by 
proteases (yellow crosses), exotoxin A (ETA) (red stars), and T3S effector proteins 
(purple triangles). Also depicted are acyl homoserine lactones (AHLs) (small fluorescent 
green circles), when the AHLs reach a threshold density, Pa forms a biofilm, where it 
persists within the host. Within the biofilm, Pa loses motility as well as the ability to 
express virulence factors (103, 145, 146). 
4 
the most thoroughly studied are type IV pili and lipopolysaccharide (LPS) (185, 203, 
207, 254, 265). Specifically, type IV pili and LPS were found to bind purified glycolipid 
gangliotetraosylceramide (asialo GM1) (85), a receptor found on the apical surface of 
epithelial cells. There is much debate within the literature about which specific factors 
are necessary for adherence, and suggestions of a redundancy of Pa adherence 
mechanisms or lack of receptor specificity required for bacterial binding. 
Given the pathopneumonic nature of Pa infections within lungs of CF patients, 
distinguishing qualities of these tissues were investigated to try to identify host factors 
which facilitate bacterial binding. Affinity of Pa to CF lung tissues has been linked to 
increased exposure of asialo GM1 (107, 202), resulting in increased type IV pili 
receptors (204). Bolstering this hypothesis, it was found that respiratory epithelial cells 
recovering from stress or injury expressed greater amounts of asialo GM1 (41). In 1997, 
Pier et al. hypothesized that the CF transmembrane conductance regulator (CFTR) acts 
as a receptor that internalizes Pa, thus allowing healthy individuals to clear a Pa 
infection by desquamation of infected cells. However, mutant CFTR inhibited both 
internalization of Pa and subsequent clearance of Pa, resulting in a persistent infection 
in the lung (180). Interestingly, internalization of Pa via CFTR in corneal epithelial cells 
has been linked to increased infectivity, while mutant CFTR was protective against Pa 
corneal keratitis (266). Additionally, studies have found that Pa binds fibronectin and 
vitronectin (135, 187, 195), concordant receptors α5β1 and αvβ5 integrins , as well as 
other components of basement membranes (135, 195). Combined, these findings 
support an alternative hypothesis that Pa readily infects compromised tissue because of 
greater access to tight junctions and basolateral membranes (58, 59, 133). 
5 
Recent studies indicate that Pa utilizes membrane rafts to facilitate association with 
eukaryotic cells. Membrane rafts are distinct domains on the plasma membrane that are 
rich in cholesterol and sphingolipids and serve as dynamic platforms to cluster receptors 
and connect them to intracellular signaling pathways. Upon purification, membrane rafts 
are detergent insoluble and of low density, making them easily isolated from the rest of 
the plasma membrane by differential centrifugation (213). While rafts have been 
implicated in the pathogenesis of microorganisms (149), it is suggested that the use of 
membrane rafts by Pa provides host protection. Studies have shown that Pa bind to 
CFTR on membrane rafts and are internalized by epithelial cells. These cells are 
subsequently sloughed off and Pa is cleared (82, 121). Other contradictory studies have 
illustrated that Pa utilize membrane rafts during infection of type I pneumocytes in lung 
alveolar sacs and corneal infection (262, 264). The lack of a consensus about adhesion 
strategies used by Pa to associate with eukaryotic cells is likely illustrative of its 
versatility and ability to survive in multiple diverse environments. 
Once adherence to damaged tissue is established, Pa elaborates an arsenal of 
virulence factors to help promote its existence within the new environment. These 
virulence factors include hemolysin, elastase, alkaline protease, phospholipases, 
alginate, endotoxin, exotoxin A (ETA), and two type III secretory (T3S) effectors 
exoenzyme S (ExoS) and exoenzyme U (ExoU) (3, 12, 138, 140, 162-164, 212). In 
general, production of these virulence factors promotes the survival of Pa by causing 
tissue damage and the release of nutrients, promoting evasion from host immune 
defenses, and allowing dissemination within the host (8, 138, 140, 164, 174). ETA, 
which is the most toxic Pa virulence factor (138, 140), is an ADP-ribosyltransferase 
6 
(ADPRT) that targets elongation factor-2 (EF-2) (105). Resultant ETA-ADP-ribosylation 
of EF-2 inhibits cellular protein synthesis (105). 
Environmental queues, such as iron, phosphate, calcium and zinc chloride, 
influence the expression of multiple virulence factors, including ETA, alkaline protease, 
elastase, hemolysin and the T3S pathway (60, 139, 216). For example, in contrast to 
limited iron levels within the mammalian host, the natural environment provides an 
abundance of iron, which contributes to the growth and survival of Pa. Therefore, to 
survive within the host, Pa must have mechanisms to scavenge iron. In iron-limiting 
environments, such as the environment found within the host, Pa produces ETA, 
alkaline protease, elastase and siderphores. It is hypothesized that ETA and the 
proteases combine to cause cellular damage, thereby releasing iron for uptake by 
siderophores (239). To control the release of iron, expression of genes involved in iron 
acquisition are tightly regulated. The expression of ETA and siderophores are regulated 
in parallel, but independently of each other, by the repressor, Fur. In ETA regulation, 
iron-bound Fur negatively regulates the extracytoplasmic sigma factor, PvdS by binding 
to the promoter region of pvdS. However, in iron-limiting conditions, no repression of 
pvdS transcription by Fur occurs, ultimately resulting in the expression of ETA (23, 239).  
While ETA contributes significantly to tissue damage and mortality during Pa 
infection, it is recognized that Pa virulence factors act in concert to promote the survival 
of the microbe (164). Another virulence mechanism is the T3S pathway, which directly 
translocates bacterial effector proteins into mammalian cells to alter cellular function. 
Clinical isolates harboring T3S genes are associated with higher mortality and 
prolonged infection (52, 200). Genetically altered strains of Pa that no longer express 
7 
components of the T3S pathway have diminished virulence in the mouse burn model 
(96). Also in mouse models of infection, immunization against a T3S component, PcrV, 
which is required for effector translocation, was found to protect infected mice from 
morbidity and mortality (95, 161, 196, 208). To date there are four identified Pa T3S 
effector proteins, ExoS, ExoT, ExoU and ExoY (55, 258, 260, 261). Recent studies have 
shown that ExoU, an acute cytotoxin and phospholipase (55, 206), is the most cytotoxic 
Pa T3S effector protein (212). ExoS, a bifunctional GTPase activating (GAP) and 
ADPRT protein (77, 106), interferes with clearance from the initial site of infection, and 
aids in dissemination of the organism (212). Interestingly, clinical and environmental 
isolates commonly harbor either the exoU or exoS gene, but not both, indicating a 
mutually exclusive relationship, with exoS being more predominant than exoU (52, 54). 
While the production of virulence factors is advantageous for establishing infection, 
persisting within the host requires a different microbial strategy. Pa strains isolated from 
chronic infections of the CF lung are notably non-motile and T3S- negative (108, 144, 
148). When strains isolated from chronic infection were tested for virulence in mouse 
models of infection, the majority were found to be avirulent (143). Further examination 
of characteristics of clinical isolates from chronic infections revealed that microbes exist 
in chronic infections as biofilms and express the rhl quorum sensing system (214). 
These studies indicate a selective pressure from the host for Pa to alter its lifestyle to 
persist after establishing an infection. 
Biofilms are complex differentiated microbial communities. They originate from 
planktonic bacteria, which adhere as a monolayer to a substratum. These bacteria 
divide to form microcolonies that combine and differentiate to form fluid-filled 
8 
macrocolonies surrounded by a matrix of polysaccharide and proteins. Pa biofilms are 
resistant to phagocytosis, host antibodies and antibiotics, and contribute to chronic 
infections in CF lung and cornea. In addition, biofilms can contribute to Pa 
dissemination by regularly shedding single planktonic bacterium (201). The initiation of 
biofilm formation requires flagella, type IV pili and twitching motility (171). The 
differentiation of biofilms requires quorum sensing (247). Quorum sensing allows 
microbes to communicate with one another via diffusible extracellular signals which, in 
Pa, are acylated-homoserine lactones (AHLs). When cell density is high, the increased 
concentration of AHLs induces a downstream signaling cascade that leads to the 
expression of genes responsible for the formation of biofilms (179). While there is 
evidence that quorum sensing may play a more direct role in the virulence of Pa (175, 
201), it ultimately controls expression of components of a persistant infection, including 
biofilm formation and alginate, which is the polysaccharide component of biofilms (11, 
214, 247). 
Recent studies have indicated that the inverse relationship between a virulent state 
and a persistent state is genetically regulated through two main pathways. RetS, which 
is a hybrid sensor kinase/response regulator, controls signaling pathways involved in 
increasing the expression of the T3S pathway, type IV pili and ETA (78). In addition, 
RetS activity inhibits the expression of exopolysaccharide genes involved in biofilm 
matrix. Mutation of RetS results in hyperadhesion and loss of virulence mechanisms, 
such as expression of the T3S pathway or type IV pili (78). Acting in opposition to RetS 
is the GacS/GacA two-component regulatory system, which downregulates expression 
of virulence factors, such as the T3S pathway and type IV pili, and upregulates 
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components essential for biofilm formation (78, 173). Also, mutation of genes controlling 
expression of quorum sensing and biofilm maturation results in an up-regulation of T3S-
pathway expression (16, 125). The environmental signals that control the switch 
between factors favoring virulence to factors favoring biofilm formation are not yet clear. 
However, it is a common supposition that the environment created by Pa after initial 
infection requires further adaptation to support persistence within the host. 
Our studies have focused on the T3S effector, ExoS in Pa pathogenesis. Pa is not 
an overt pathogen and will only infect compromised tissues, which indicates that a 
compromised host environment allows or signals the initiation of an infection. Given the 
intimate interaction between the bacterium and host cell, which allows the T3S-
mediated translocation (T3S-T) of ExoS into the eukaryotic cell, we are interested in 
understanding how the host cell influences not only the translocation of ExoS, but also 
the intracellular targeting of its activity. 
Characterization of ExoS: Classical bacterial toxins are classified by their AB 
structure and their mechanism of action. The A portion of a toxin includes the enzymatic 
activity (A subunit), and the B portion includes the cell binding and translocation 
functions (B subunit). Three main AB toxin structures have been described. 1 AB toxins 
are synthesized as a single polypeptide, which includes an A (active) subunit and a B 
(binding) subunit. Connecting the amino-terminal A subunit to the carboxy-terminal B 
subunit is translocation or T domain. Once the toxin has bound and been translocated 
into the cells, the A subunit must be cleaved from the B subunit to express full catalytic 
activity. 2 In ABn toxins, the B subunit is synthesized as a separate polypeptide and 
forms an oligomer which binds to target host cells. The A polypeptide has a high affinity 
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for the oligomer and becomes enzymatically active when an internal site is cleaved. In 
these toxins, the translocation function has not yet been fully described. 3 Bipartite 
toxins are comprised of two distinct soluble proteins. One of the proteins is responsible 
for cell binding and membrane translocation, and the other confers enzymatic activity. 
Many toxins affect host cell function by targeting and modifying eukaryotic proteins, 
thereby altering their function (23). 
ETA is a classical AB toxin. The single polypeptide is a 71.5 kDa proenzyme that 
when denatured or proteolytically cleaved produces a 27 kDa enzymatically active 
fragment (A domain) and a 45 kDa enzymatically inactive fragment (B domain) (238). 
Further analysis identified 3 distinct structural domains: domains I and II for the B 
domain, while domain III is the enzymatically active, A domain (4). Domain I, within the 
N-terminal half of the molecule, forms an antiparallel β-structure (4) which binds to the 
eukaryotic cell receptor α2-macroglobulin receptor/low density lipoprotein receptor-
related protein (α2MR/LRP) (120). The ETA proenzyme is internalized by the host cell 
through receptor-mediated endocytosis (57). Once inside a vesicle, domain II, which is 
composed of mainly alpha helices (4), acts to translocate the processed A-subunit into 
the cytosol (109). Four sequentially formed disulfide bonds must be cleaved or 
denatured to form a catalytically active ETA molecule (4, 238). Domain III, within the 
carboxy-terminus, includes the ADPRT activity of ETA (4). Upon translocation to the 
cytosol, ETA’s ADPRT activity targets EF-2, thereby inhibiting host cell protein synthesis 
(105). ETA illustrates the efficient design of bacterial toxins, each distinct domain 
confers a distinct function that contributes to the action of the molecule as a whole. 
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ExoS was first identified as an ADP-ribosyltransferase distinct from ETA when more 
radioactive ADP-ribose was transferred in partially purified EF-2 preparation than could 
be accounted for by the calculated amount of available EF-2. ExoS was characterized in 
Pa strain 388, which does not produce ETA (106). Comparisons of the ADPRT activity 
of ETA to that of ExoS defined unique characteristics of ExoS. Activity was not 
neutralized by anti-ETA antibody and was destroyed by pretreatment with urea (ETA 
activity is promoted by urea treatment). In addition, ExoS was found to be more heat-
stable than ETA and did not target EF-2 (106). ExoS was found not to have one 
preferred eukaryotic substrate, but to ADP-ribosylate several different targets in wheat 
germ extract and reticulocyte lysates (106). In in vitro reactions, the preferential 
eukaryotic target proteins of ExoS were found to belong to the Ras family of low 
molecular weight G-proteins (LMWG-proteins) (10, 28, 30, 63, 65, 89, 153, 190), and 
ExoS was also found to target vimentin (26). In vivo analysis of ExoS ADPRT activity 
confirmed that ExoS targeted LMWG-proteins, as well as, cyclophilin A and ezrin, 
radixin and moesin proteins (ERMs) within the eukaryotic cell (44, 63, 65, 89, 150, 153). 
In order to ADP-ribosylate target proteins, ExoS requires a eukaryotic cofactor from the 
14-3-3 protein family, for catalytic activity (29, 68, 92). 
ExoS purified from culture supernatants of strain 388 was an aggregate of two 
proteins of 49 and 53 kDa (106, 127, 165). Originally it was hypothesized that the 53 
kDa protein was a proenzyme form of ExoS, since the 49 and 53 kDa proteins were 
immunologically cross-reactive (127, 165), shared a common amino-terminus (25), and 
produced common peptides following cleavage with cyanogen bromide and proteases 
(104). In support of this hypothesis and consistent with toxin structure/function models, 
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after extraction from an SDS-polyacrylamide gel only the 49 kDa form displayed ADPRT 
activity (29, 128, 165). The common origin of the 49 kDa and 53 kDa proteins was 
supported by their highly regulated coordinate expression. The production of both the 
49 kDa and 53 kDa proteins by the bacterium increased or decreased in parallel with 
changes in the culture medium (25, 104). Medium promoting maximal production 
contained a chelator, nitrilotriacetic acid (NTA), ethylenediamine tetraacetic acid (EDTA) 
(231) or ethyleneglycol tetraacetic acid (EGTA) (60). The production of both proteins 
was inhibited by the addition of calcium or zinc chloride salts (60). 
The cumulative data indicated that the 49 kDa and 53 kDa proteins were related, 
but confirmation of their being two forms of the same protein was lacking. A genetic 
approach was employed to explore if the proteins were produced by the same gene. For 
this, Pa strain PA103, which produced the 53 kDa protein, but not the enzymatically 
active 49 kDa protein (62) was transformed with the 49 kDa structural gene cloned from 
strain 388 and cultured under inducing conditions. Both the 49 kDa and 53 kDa proteins 
were produced in response to NTA (126). In addition, the allelic exchange of the 49 kDa 
ExoS gene with a tetracycline gene cartridge in strain 388 (forming strain 
388∆exoS::Tc), eliminated the production of 49 kDa ExoS, but the production of the 53 
kDa protein was unaffected (126). This was the first data that supported that 49 kDa 
ExoS and the 53 kDa protein were encoded by separate genes. An open reading frame, 
termed exoT, was identified by Southern blot analysis of 388∆exoS::Tc, using exoS to 
probe chromosomal digests (256). The exoT gene product was identified as the 53 kDa 
protein, first known as Exo53, then later as ExoT. While ExoT shares 75% amino acid 
identity to ExoS, the recombinant form of this protein displayed only 0.2% ADPRT 
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activity (256, 260). Together, these studies confirmed that 49 kDa ExoS and 53 kDa 
ExoT were distinct proteins, and that the 53 kDa protein was not a proenzyme form of 
ExoS. 
In determining the role of ExoS during the Pa infection process, a transposon Tn1 
mutant of strain 388, lacking ADP-ribosyltransferase activity, was generated and found 
to be 2,000-fold less virulent than the parent strain 388 (165). In an experimental mouse 
burn wound model, using strain 388 and the null ExoS strain (388exs1::Tn1), the 
production of ExoS did not alter the ability of Pa to colonize the site of the wound. 
However, without ExoS, the organism was compromised in the ability to disseminate, 
implicating ExoS at this stage of the infection process (162, 165). Yet, conflicting with 
evidence that ExoS played a role in the virulence of Pa was the fact that purified ExoS 
was not toxic to animals (162, 163) nor to cultured eukaryotic cells (25, 170). 
Additionally, culture supernatants obtained from ExoS-producing bacteria were nontoxic 
to cultured cells (7, 170). These data suggested that ExoS did not have a structural B 
domain that allowed its binding or translocation into eukaryotic cells. During the mid-
1990’s a common conclusion was that delivery of ExoS to eukaryotic cells was by a 
unique mechanism, not yet described for other toxins. 
Bacterial secretion systems: To date, there are five main processes described for 
a Gram-negative bacterium to secrete or transport a protein from the bacterial 
cytoplasm and across the inner membrane, periplasmic space and outer membrane 
(Figure 2) (88). These processes are grouped based on their dependence on the Sec 
pathway of protein export. The Sec pathway, also known as the general secretory  
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Figure 2. Bacterial secretion systems.  
Grouped by their dependence on Sec proteins for translocation of proteins into the 
periplasmic space, types I and III secretion pathways involve the one-step secretion of 
proteins, driven by inner membrane ATPases. Uncleaved signal sequences are found in 
the C-terminal end of proteins destined for the type I pathway, while signal sequences 
within the N-terminus identify proteins for secretion by the type III pathway. The type III 
pathway also differs in that it translocates bacterial proteins across eukaryotic cell 
membranes. Proteins destined for type II and V pathways contain cleavable N-terminal 
consensus sequences. The proteins are processed in the periplasmic space before final 
translocation across the outer membrane. Type V secreted proteins are known as 
autotransporters and they oligomerize to form a pore, allowing self-translocation across 
the outer bacterial membrane. Type IV secretion uses a Sec-dependent process to 
translocate DNA-protein complexes and large protein complexes either outside the 
bacterial cell or, via a pilus-like structure, inside the eukaryotic cell. The figure is based 
on text by Stathopoulus et al., 2000 (219) and Henderson et al., 2004 (88). OM, outer 
membrane; P, periplasmic space; IM, inner membrane. 
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pathway, exports proteins from the bacterial cytoplasm into the periplasmic space, 
utilizing an inner membrane ATPase and a chaperone protein that binds the  
presecretory protein. Sec-dependent transport processes are types II, IV and V, while 
Sec-independent transport processes are types I and III. All pathways are highly 
conserved among Gram-negative bacterium (88, 205). 
Type II secretion (T2S) occurs in two steps and requires that the secreted proteins 
have a concensus signal sequence within the first 30 amino-terminal amino acids, which 
targets proteins for Sec inner membrane transport. This signal sequence is then 
cleaved within the periplasmic space and the protein becomes partially folded. 
Transport across the outer membrane requires a multimeric outer membrane 
component termed secretin (88, 102, 205). T2S was first described as the secretion 
mechanism that Klebsiella aerogenes used to transport pullulanase (113, 230). 
Homologous systems were later identified for other Gram-negative bacteria (205). ETA 
is an example of a Pa virulence factor secreted via the type II secretory pathway (249). 
The type IV secretion pathway (T4SP) is the least understood of the secretory 
processes, but appears to be closely related to ancestral bacterial conjugation systems. 
The T4SP allows the transfer of DNA/protein macromolecular complexes (T-DNA) from 
the bacterium to the host cell (22, 88, 249). In this regard, the best characterized T4SP 
is in Agrobacterium tumefaciens which utilizes membrane transport protein VirB to 
secrete a single-stranded DNA molecule across bacterial membranes and into plant 
cells, where the DNA integrates into the genome, ultimately resulting in tumor growth 
(269). T4SP also allows the secretion of large oligomeric protein complexes, such as 
the large A-B5 pertussis toxin (243). It is now thought that secretion of T-DNA occurs in 
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one step, while the transfer of protein complexes occurs in two steps and utilizes the 
Sec inner membrane secretion system (22, 88). The two seemingly divergent transport 
pathways are classified together because the related transporters share architectural 
similarities to VirB (183). 
The type V secretion pathway (T5SP) describes the secretion mechanism of a 
group of proteins known as autotransporters. Proteins secreted by this pathway exhibit 
an extended N-terminal signal sequence that identifies the proprotein for secretion by 
the Sec inner membrane translocation machinery. Once in the periplasmic space, the 
signal sequence is cleaved and the remaining N-terminal portion of the molecule forms 
a β-barrel structure that inserts into the bacterial outer membrane to form a pore. The C-
terminal active portion of the molecule either remains attached to the pore by the linker 
region or is cleaved upon secretion. It is thought that the folding of the β-barrel pore 
structure provides the energy to translocate the active portion from the periplasmic 
space across the outer membrane (88). 
Type I secretion (T1S) is Sec-independent and is a single-step continuous process 
from the bacterial cytoplasm across both inner and outer membranes. Proteins secreted 
by this pathway are not processed nor do they have a periplasmic intermediate. The 
secretion signal sequence is located within the C-terminal 60 amino acids. The type I 
secretion complex includes an inner membrane ATPase, a channel forming membrane 
fusion protein and an outer membrane pore. Examples of proteins secreted by this 
process include E. coli alpha-hemolysin and Pa alkaline protease (88, 102, 205, 219). 
T3S, which is also Sec-independent, displays similarities to both types I and II 
secretion. T3S was recognized in the early 1990’s in association with pathogenicity 
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determinates of Yersinia enterocolitica termed Yersinia outer proteins (Yops) (156). 
Effector proteins secreted by this pathway do not require processing, but include a 
signal for secretion within the first 10 to 15 residues (5, 88, 102, 142, 205). The T3S 
secretion apparatus forms a needle-like syringe, termed the injectisome, which 
translocates bacterial effector proteins in one continuous step from the bacterial 
cytoplasm across the inner and outer membranes, followed by the eukaryotic host cell 
membrane into the cytosol. Proteins that form the injectisome are conserved among 
Gram-negative bacteria and are thought to have common evolutionary origins with 
flagella (102, 147, 155, 205). T3S-effector proteins are bacterium specific, thus allowing 
different bacteria to manipulate the host cell according to its unique survival needs. 
Characterization of Pa ExoS secretory mechanism: Since its discovery in the 
late 1970’s, the biochemical properties of ExoS have been well studied, but how ExoS 
ADPRT affected eukaryotic cells remained a mystery, because the purified protein was 
not toxic when added to cultured cells or administered to animals (25, 162, 163, 170). 
Comparison of genes affecting ExoS production with those involved in Yersinia Yops 
production helped to understand how ExoS might be affecting host cells. ExoS did not 
include an N-terminal consensus signal or N-terminal processing sequences (128, 256), 
indicating that the secretion of ExoS was Sec-independent. Mutations within the 
carboxy-terminus and internal sequence of ExoS, that would be predicted to alter T1S, 
did not alter ExoS secretion (258). However, the first nine amino-terminal residues were 
necessary for ExoS secretion. The activation of a gene encoding the ExsA protein was 
also absolutely required for ExoS expression. ExsA acts as a trans-regulatory protein 
and contains a DNA-binding helix-turn-helix motif (61). ExsA is homologous to AraC of 
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Escherichia coli and VirF/LcrF (two terms referring to the same protein) of Yersinia 
enterocolitica (61, 99, 257). VirF/LcrF controls the expression of Y. enterocolitica Yops 
(93, 130, 155). Dnase I-footprint analysis of promoters controlled by ExsA found the 
concensus binding site of ExsA to be similar to the concensus binding sites of VirF (99). 
A map depicting the organization of the Pa T3S-regulon in Figure 3 shows the clustering 
of genes involved in T3S, ExsA binding sites, and the non-contiguous locations of 
genes that encode the effector proteins, ExoS, ExoT, ExoY, ExoU (Figure 3). 
The expression of the ExoS operon in vitro requires growth of Pa in a cation-
depleted medium, similar to the medium required to promote production of Yops (231), 
indicating similarities between the regulation of ExoS and Yops. The amino-terminus of 
ExoS displays sequence homology to a secreted effector protein, YopE, indicating that 
similarities between the Yops and ExoS systems extended beyond regulation (259). In 
addition, a locus containing an ExsA-dependent promoter and encoding gene products 
termed PscB-L, was identified and found to be homologous to the YscB-L proteins of 
Yersinia (258). Mutations within the pscC gene prevented secretion of ExoS. PscC is 
homologous to a Yersinia protein, YscC, which is involved in T3S of Yops (258). The 
regulation and homology data suggested that ExoS was secreted by the T3S pathway 
(258). Therefore, it was recognized that ExoS can only affect eukaryotic cell function if 
translocated into the host cell after bacterial contact. 
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Figure 3. Organization of the Pa T3S regulon. 
The individual gene products of the Pa T3S system and effector proteins, ExoU, 
ExoS, ExoT and ExoY are represented by colored arrows. Different colors identify 
operons based on promoter mapping, transcriptional fusion, or DNA-binding analyses. 
The effectors and known chaperones (ExoU and SpcU; ExoS and Orf1; ExoT; ExoY) 
are located at different sites within the chromosome, and are separate from genes 
encoding proteins involved in the regulation and formation of the T3S apparatus. ExsA 
consensus and imperfect binding sites are indicated. This figure was published in the 
book entitled Bacterial Protein Toxins, (ed. Drusilla L. Burns, Joseph T. Barbieri, 
Barbara H. Iglewski and Rino Rappuoli, ASM press, Washington D.C., 2003). 
Permission to use the figure was given by ASM press and Dara Frank, who developed 
the original figure. 
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Structural analysis of the T3S process: The conserved nature of the T3S process 
among pathogenic Gram-negative bacteria is consistent with genes encoding the T3S 
pathway being obtained either through horizontal gene transfer (HGT) or from a 
common ancestor. In support of the HGT hypothesis, genes encoding T3S systems 
reside within plasmids or as gene clusters located in pathogenicity islands, bounded by 
the remnants of insertion sequences, bacteriophage genes or transposable elements. 
Pathogenicity islands are also recognized by differences in G+C content when 
compared to the entire bacterial chromosome (70, 102, 249). In contrast to the T3S 
regulons of other pathogenic bacteria, the G+C content of the genes encoding the Pa 
T3S regulon (67.3%), is similar to the G+C content of the entire Pa genome (69%), 
indicating that Pa T3S regulons do not reside on a pathogenicity island (60). This finding 
is consistent with the hypothesis that T3S is not just involved in pathogenesis but an 
integral Pa survival mechanism. 
Translocation of proteins via the T3S pathway requires the bacterium and 
eukaryotic cell to be in close contact, allowing insertion of the bacterial T3S-needle-like 
apparatus into the host cell membrane (Figure 4 C). The result is the delivery of 
bacterial effector proteins directly into the host cell cytosol, allowing the bacteria to 
strategically hijack host cell processes (70, 76, 102). Purified T3S complexes from 
Salmonella typhimurium and Shigella flexneri resemble needles (18, 124). Similarities 
between flagella and the T3S apparatus are evident both structurally and based on 
protein homology (Figure 4 A and B) (19, 76, 147). The base of the S. typhimurium 
needle complex was observed to be similar to that of a flagellar basal body, with two  
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 C. T3S injectisome with the host cell
 
 
 
 
 
 
 
 
Figure 4. Comparison of flagellar and injectisome structure. 
 (A) Depicts the dimensions of the flagellar hook-basal body and (B) depicts the T3S 
apparatus or injectisome of Salmonella. CM, bacterial cytoplasmic membrane; PG, 
peptidoglycan layer; OM, bacterial outer membrane. (C) Depicts a T3S apparatus in 
contact with the eukaryotic cell. The needle is drawn based on electron microscopy 
images (see inset), with several ring structures spanning the inner and outer 
membranes. The needle filament (green protrusion) is thought to engage a bacterial 
pore-forming complex (translocator) that becomes lodged in the eukaryotic host cell 
membrane. The diagram also depicts effector proteins, awaiting translocation, 
associated with their cognate chaperones. 
Parts A and B of the figure were originally published in Molecular Microbiology 
(2005, 56(2): 303-308) in an article entitled, “Measure for measure in the control of type 
III secretion hook and needle length”, authored by Tohru Minamino and Anthony P. 
Pugsley. The image appears by permission of Blackwell Publishing. Part C of the figure 
was originally published in Nature Reviews Molecular Cell Biology (2003, 4: 738-743) in 
an article entitled, “Priming virulence factors for delivery into the host”, authored by C. 
Erec Stebbins and Jorge E. Galan. The image appears by permission of Nature 
publishing and C. Erec Stebbins. 
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upper and two lower rings (124), with the needle portion of the complex resembling the 
flagellar hook (19, 76, 147). 
Interestingly, the proteins forming the needle base of the T3S process are localized 
and positioned within the bacterial inner membrane, periplasmic space and outer 
membrane in a Sec-dependent manner (116, 228). Further assembly of the needle 
complex requires this basal body structure. Similar to the energy requirements of 
functional flagella, treatment with sodium azide, which abolishes oxidative 
phosphorylation, also inhibits T3S (17). The protein that makes up the outer membrane 
ring of the T3S apparatus differs from the outer membrane ring of flagella. This 
component, InvG, initially characterized in S. typhimurium, is a member of the secretin 
family of proteins (116) (InvG is labeled OM in Figure 4B and is depicted by the yellow 
box in Figure 4C). Secretins usually function alone and are involved in the transport of 
large macromolecular structures, including the T2S of type IV pili components (137). 
However, InvG serves a different purpose in the T3S process as it is associated with 2 
other proteins consisting of the needle complex basal body (116, 228). InvG is 
homologous to the Pa T3S protein, PscC, and Yersinia T3S protein YscC (60, 76). 
While the exact location of PscC within the Pa T3S apparatus is currently unknown, 
YscC has been found to form a stable oligomeric complex, which forms a channel in the 
bacterial outer membrane (119). Pa strains lacking a functional pscC structural gene do 
not secrete T3S effector proteins (258). 
The needle component, first visualized by electron microscopy in S. typhimurium, is 
thinner than a flagellar organelle, only 7- to 8- nm wide, and 60 nm long (124). However, 
the needle-length was found to be organism specific (76). Much like a component of the 
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flagellar hook apparatus, T3S needle complexes have a protein that determines the 
length of the needles. These proteins lack sequence homology to the flagellar protein, 
FliK, but are functional equivalents in that their mutation or deletion result in T3S 
needles of variable length, with only shorter needles found incapable of T3S-T (263). A 
recent study of the Y. enterocolitica needle proposes that T3S needle length is related 
to the distance between bacterium and host cell created by adhesion molecules 
attaching bacteria to the host cell (159). 
Once the needle is assembled, certain bacteria, including S. flexneri, Yersinia, and 
Pa, secrete proteins termed translocators, which form the end of the needle and insert a 
channel into eukaryotic membranes (76). In S. flexneri IpaB and IpaC insert into the 
host cell membrane comprising a channel for the translocation of Shigella effector 
proteins (17). IpaB and IpaC share structural similarities to Yersinia proteins YopB and 
YopD, respectively (17). YopB and YopD direct the translocation of effector proteins 
across the host cell membrane and are functionally interchangeable with Pa proteins, 
PopB and PopD (67). In Pa T3S, PopD was found to be required for the transport of 
ExoS across CHO cell membranes. The lack of PopD resulted in secretion of effector 
proteins from the bacterium, without translocation into eukaryotic cells (236). Attempts 
at detecting PopD in eukaryotic cell membranes during a Pa infection PopD have been 
unsuccessful. However, recently PopD was shown to bind to ghost erythrocyte 
membranes and form oligomers and ring structures in cholesterol-rich liposomes, 
indicating its potential to form pores in eukaryotic cell membranes (81, 210). 
Assembly of the needle structure precedes the translocation of effector proteins. 
The signal sequence targeting effectors for T3S is within the amino-terminus. However, 
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whether the source of the secretion signal is an amino acid or mRNA sequence remains 
controversial. Deletion of the first 15 amino acids of T3S proteins abolishes secretion 
(155, 218, 250), which is consistent with either the first 15 amino acids or the mRNA 
encoding this region being required for secretion. Analysis of T3S-secretion of Y. 
entercolitica effector proteins revealed a role for mRNA sequence in targeting effectors 
for T3S.  Construction of frameshift mutations, which would alter mRNA codons 
translation, but not the actual mRNA sequence in the sequence encoding YopQ, did not 
block T3S (6). 
Proteins translocated shortly after needle assembly are thought to be translated and 
sequestered in the bacterial cytoplasm by a chaperone protein. In Salmonella, it has 
been shown that chaperones maintain T3S effector proteins in a partially unfolded 
confirmation, while protecting them from aggregation and degradation (220). The ability 
of effector proteins to unfold prior to translocation, excludes other cytoplasmic proteins 
from T3S transport (51). However, not all effector proteins have known cognate 
chaperones. This is true of Pa in which ExoS and ExoU have chaperones Orf1 and 
SpcU, respectively, while ExoT and ExoY do not (56, 60). Previous studies have 
indicated that T3S effectors have different efficiencies when binding to chaperones, 
thereby, allowing for certain effectors to be translocated before others (20). Additionally, 
it has been reported that there is a translation hierarchy of T3S effectors. For example, 
blockage of the Y. enterocolitica T3S pathway resulted in translation of YopE, but not 
YopQ, supporting evidence that YopE is T3S-T earlier than YopQ (6). In summary, 
effectors which are T3S-T early after needle assembly seem to rely on interaction with a 
chaperone protein, while effectors which are T3S-T later are shuttled to the T3S 
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apparatus based on their N-terminal mRNA sequence (19). A hierarchy of secretion 
underscores the highly regulated manner in which bacteria can manipulate eukaryotic 
cells to their benefit. 
Regulation of Pa T3S. Over 40 genes, which encode regulators, apparatus-
structure proteins, translocator proteins and effector proteins, are involved in the T3S 
pathway (60, 70, 102). Expression of the Pa T3S pathway responds to environmental 
factors such as low calcium, presence of serum or contact with the eukaryotic host cell 
(60, 236). However, recent work has shown that some components of the Pa T3S 
pathway are constitutively expressed at basal levels, but further induced by appropriate 
environmental signals (252). Expression of the Pa T3S is also controlled by global 
regulators that sense environmental changes, including adenylate cyclase and cyclic 
AMP regulators (2, 215, 227, 245, 252),fimL , a member of a chemosensory pathway 
(246), and retS, a hybrid sensor kinase/response regulator (78). 
At the level of transcription, Pa T3S is controlled by an intricate network of bacterial 
cytoplasmic regulators, ExsA, ExsD, ExsC (Figure 5) (40, 61, 152). ExsA is a 
transcriptional activator that promotes the expression of Pa T3S genes (60, 61, 257). 
Prior to induction of a functional T3S apparatus, ExsA is bound to ExsD, thus repressing 
ExsA activity. Deletion of exsD results in constitutive expression of T3S genes. This 
occurs even in the presence of a mutation affecting outer membrane protein PscC, 
which prevents the formation of a functional T3S apparatus (152). Also indicating 
another layer of T3S regulation, mutation of exsC results in very low T3S expression 
(40, 79). 
26 
D
D
A
C
C
E
E
host cell
exoS
exoS
A
S SS
S
A. High calcium
T3S transcription repressed
B. Contact with host cell
T3S transcription derepressed
Bacterial
membrane
Bacterial
membrane
T3S apparatus
 
 
 
 
 
 
 
 
 
 
Figure 5. Transcriptional regulation of Pa T3S. 
Transcription of Pa T3S is activated by ExsA. In conditions that do not favor T3S, 
such as high calcium (depicted in A), ExsD sequesters and prevents ExsA from 
activating transcription of T3S genes, such as exoS. In T3S-favorable conditions 
(depicted in B), ExsC recruits ExsD from ExsA, freeing ExsA to initiate transcription of 
T3S genes. ExsA activity is further regulated by ExsE, which binds to ExsC in T3S-
unfavorable conditions, preventing ExsC from recruiting ExsD. ExsE is thought to be the 
molecular sensor of T3S-apparatus readiness. T3S-T of ExsE frees ExsC to interact 
and recruit ExsD from ExsA. This diagram is based on work by Mark L. Urbanowski, 
Guinevere L. Lykken and Timothy L. Yahr in a paper entitled “A secreted regulatory 
protein couples transcription to the secretory activity of the Pseudomonas aeruginosa 
type III secretion system”, which appeared in Proc. Natl. Acad. Sci. USA in July 2005 
(102 (28): 9930-9935. 
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Further analysis indicated that overexpression of exsC mimicked the deletion of exsD, 
and that ExsC binds to ExsD. These data indicated that in favorable conditions, ExsC 
binds to ExsD, thereby freeing ExsA to activate transcription of other T3S genes (40). 
ExsC exhibits characteristics of a T3S chaperone in that it has a low molecular mass, 
an acidic isoelectric point, and a carboxy-terminal amphipathic alpha-helix (51, 172). 
This suggested the possibility that in unfavorable conditions for T3S, ExsC is bound to 
another protein, which is secreted or translocated upon favorable T3S conditions, 
thereby freeing ExsC to bind ExsD and ultimately free ExsA (40). Interestingly, 
immediately downstream of exsC is an open reading frame that encodes an 8.7 kDa 
protein, termed ExsE. Recent studies have shown that ExsC binds to ExsE, and ExsE is 
secreted from the bacteria in low calcium conditions (191, 234). However, the absence 
of ExsE does not have any affect on the regulatory activity of ExsD, indicating that there 
are multiple regulatory checkpoints in the induction and expression of Pa T3S (234). 
Manipulation of the host cell by T3S effector proteins: The T3S-injection of 
effector proteins into the eukaryotic cell provides a mechanism for Gram-negative 
bacteria to manipulate host cell function in a manner that promotes their specific life-
style. While the structure of the T3S-apparatus is conserved among Gram-negative 
bacteria, effector proteins are species specific. To evade the immune system, Yersinia 
T3S-translocates multiple effector proteins which coordinately inhibit inflammation and 
phagocytosis, while inducing macrophage apoptosis (36, 37). In contrast, the T3S-T of 
Salmonella effectors promotes bacterial invasion into the host cell, thus allowing 
intracellular propagation (37). Underlying the broad effects of T3S-T effectors on 
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eukaryotic cells is the intricate manner in which they hijack host cell signaling and mimic 
the activities of eukaryotic proteins (221). 
One example of eukaryotic cell mimicry involves a group of T3S effectors which 
function similarly to eukaryotic Rho GTPase activating proteins (GAPs). G-proteins are 
molecular switches, which cycle between active, GTP-bound, and inactive, GDP-bound 
states. GAPs control G-proteins by accelerating the hydrolysis of phosphate from GTP, 
forming an inactive GDP-bound-G-protein (237). Rho GAP proteins target Rho, Rac and 
Cdc42, proteins that control the actin cytoskeleton network (229, 237). T3S effector 
proteins that have been found to contain Rho GAP activity include: Yersinia YopE (242), 
Pa ExoS and ExoT (77, 122, 178), and Salmonella SptP (69). Consistent with their GAP 
activities targeting Rho, Rac and Cdc42, the transfection or T3S-T of YopE, ExoS and 
ExoT is associated with cell rounding/actin cytoskeleton rearrangement and 
antiphagocytic effects (38, 66, 74, 178, 192, 242). 
An example of multiple T3S effectors coordinately manipulating host cell function 
was first illustrated with Salmonella typhimurim proteins, SptP and SopE. Epithelial cells 
lining the gastrointestinal tract do not normally engulf bacteria. However, Salmonella 
must enter these epithelial cells to evade the host immune system and initiate the 
infectious process. T3S-T of SopE activates Rac and Cdc42, resulting in localized actin 
reorganization and membrane ruffling, which stimulates the host cell to engulf the 
organism (45, 86). Following internalization, S. typhymurium resides within a specialized 
vacuole. To protect its new niche, the T3S effector SptP acts as a GAP towards Rac 
and Cdc42, thereby reversing the effects of SopE and allowing the host cell’s actin 
cytoskeleton to recover (45, 69, 221). The sequential action of SopE and SptP activities 
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highlights the sophisiticated manner in which bacteria are able to usurp host cell 
signaling pathways. 
Structure/function relationships of T3S-T-ExoS. While ExoS was characterized 
as an ADP-ribosyltransferase in 1978 (106), further examination of the functional 
domains revealed that the N-terminal region of ExoS includes a GAP domain, which 
targets Rho GTPases (77), while the ADPRT activity resided within the C-terminal 
portion of the molecule (117). Arginine at position 146 (R146) was found to be required 
for ExoS GAP activity (77). The co-crystal structure of the N-terminal GAP domain of 
ExoS with Rac1 revealed that the positioning of the R146 mimics that of catalytic 
arginines found in eukaryotic GAP molecules without sharing structural homology (255). 
Two glutamic acid residues control ExoS ADPRT activity. In vitro kinetic analysis found 
the glutamic acid at position 379 (E379) to modulate the transfer of the ADP-ribose 
moiety to the target eukaryotic protein, and the glutamic acid at position 381 (E381) to 
confer the NAD glycohydrolase activity (186). In vitro analysis also found that mutation 
of the E381 catalytic residue inhibited in vitro ExoS ADPRT activity (186). As previously 
indicated, the first nine amino acids are required for T3S-T (258). Additionally, ExoS 
contains a membrane localization domain (MLD) between residues 52 and 71 (176). 
Studies of Petterson et. al. support that T3S-T-ExoS is processed at a site within the 
first 78 residues upon translocation into the eukaryotic cell (177). For maximal ADPRT 
activity, ExoS requires interaction between amino acids 420-429 and a eukaryotic co-
factor, 14-3-3 protein (90). The functional regions of ExoS are depicted in Figure 6. 
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Figure 6. Linear model of ExoS. 
ExoS contains 453 amino acids and consists of two separate catalytic domains. 
Within the N-terminal region is the GAP activity, which targets Rho, Rac and Cdc42 
(77). The ADPRT activity is within the C-terminal region (117). The first nine amino 
acids of ExoS are required for T3S-translocation (258), and the region between amino 
acids 52 and 71 (MLD), targets ExoS to eukaryotic membranes (176, 188). ExoS binds 
its cofactor 14-3-3 between amino acids 420-429 (90). 
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Since the effects of ExoS on cell function can only be realized upon T3S-T, a co-
culture system was developed in which established eukaryotic cell cultures are treated 
with ExoS producing bacteria. To differentiate the effects of ExoS from other bacterial 
factors, the effects of an ExoS producing strain (388) were compared to the effects of 
an isogenic ExoS-deletion mutant strain (388∆S) (170). In co-culture analyses of 
epithelial cells, T3S-T-ExoS caused a general inactivation of cell function, including an 
inhibition of DNA synthesis, loss of re-adherence and cytoskeletal alterations (169). In 
other cell culture models of infection, ExoS has been implicated as a cytotoxin and an 
anti-phagocytic or anti-invasive factor (38, 66, 192). The complex effects of ExoS on 
eukaryotic cell function are believed to relate to its bi-functional mode of action. The 
GAP activity of ExoS has been linked to transient cytoskeletal alterations (178) and 
antiphagocytic capabilities (66, 192), while the ADPRT activity of ExoS was found to be 
required for the effects of T3S-T-ExoS on human epithelial cell DNA synthesis, re-
adherence and permanent cytoskeletal alterations (64). 
T3S-T-ExoS ADPRT activity targets multiple cellular LMWG-proteins (63, 65, 89, 
153). Ras was the first cellular protein to be identified as a substrate by T3S-T-ExoS 
ADPRT activity. ADP-ribosylation of Ras results in an alteration in protein mobility 
detected by SDS-PAGE and two-dimensional electrophoresis (2DE). To confirm that the 
alteration in mobility related to the transfer of an ADP-ribose moiety, in vitro reactions, 
which included purified ExoS, recombinant Ras, 14-3-3 and NAD were performed, and 
the alteration in Ras mobility corresponded to that caused by T3S-T-ExoS. Additionally, 
when cellular pools of NAD were radiolabeled, and cells were incubated with ExoS 
producing bacteria radiolabeled ADP-ribose was transferred to immunoprecipitated Ras. 
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This study confirmed that T3S-T-ExoS ADP-ribosylates cellular Ras (153). Using a 
similar strategy to identify other LMWG-proteins ADP-ribosylated by ExoS, in vivo and 
in vitro ExoS ADPRT reactions were performed and alterations in protein mobility were 
compared by SDS-PAGE and 2DE. These studies led to the identification of RalA, 
Rab5, Rab7, Rab8, Rab11 and Rac1, but not Rab4 or Rho as cellular substrates of 
T3S-T-ExoS ADPRT activity (Figure 7) (63, 65). Cdc42, a member of the Rho family of 
proteins, was also ADP-ribosylated by T3S-T-ExoS, but not as efficiently as other 
proteins examined (65). Notably, Rab4 was not ADP-ribosylated by T3S-T-ExoS, but 
was ADP-ribosylated by ExoS in vitro (30, 65), indicating that the host cell confers T3S-
T-ExoS target protein specificity. More recent studies have also identified non-LMWG-
protein targets of T3S-ExoS ADPRT activity including ezrin/radixin/moesin proteins, 
which help regulate actin cytoskeleton structure, (150), and cyclophilin A, a peptidyl-
prolyl cis-trans isomerase (44). 
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Figure 7. Proteins ADP-ribosylated by ExoS. 
(A and C) In vivo analysis: HT-29 cells were grown to 50-65% confluency and co-
cultured with 1 x 107 colony forming units (cfu)/ml of 388 or 388∆S (∆S) for 4 to 5 hours. 
To examine Ras modification, cells were lysed and Ras was immunoprecipitated from 
cell lysates. To examine other proteins, eukaryotic cells were lysed in Laemmli sample 
buffer (129). Samples were resolved by SDS-PAGE and probed for the indicated 
LMWG-protein by Western blot analysis. (B) In vitro analysis: 1 µg of purified protein (H-
Ras or Rac1) or 50 µl of HT-29 cell lysates (Rab proteins) were incubated without or 
with 0.2 µM purified ExoS, 10 mM NAD and a source of 14-3-3 protein. Reactions were 
terminated by the addition of 4X Laemmli sample buffer and heated at 95ºC prior to 
resolution by SDS-PAGE and Western blot analysis. Relative molecular mass of the 
LMWG-proteins, and ADP-ribosylated (M) and un-ADP-ribosylated (U) proteins are 
indicated. The results are representative of multiple independent studies. 
This figure originally was originally published in Biochem. Biophys. Res. Commun 
(291: 91-100, 2002) in an article entitled, “Eukaryotic cell determination of ExoS ADP-
ribosyltransferase substrate specificity” by J. E. Fraylick, E. A. Rucks, D. M. Greene, T. 
S. Vincent and J. C. Olson. The figure and selected text from the original figure legend 
appears with permission by Elsevier Science (USA). 
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To determine if the cellular localization of the LMWG-proteins influences ADP-
ribosylation by ExoS, HT-29 cells were fractionated into S100, cytosol, and P100 
membrane fractions following treatment with ExoS producing bacteria. Proteins that 
localize to the plasma membrane fraction, like RalA and Rab5, were the first to be ADP-
ribosylated by T3S-T-ExoS (65). These results are consistent with the notion that the 
MLD of ExoS targets ExoS to eukaryotic membranes where its ADPRT activity is 
enhanced (176, 188). The cellular fractionation studies revealed a different finding 
relative to the ADP-ribosylation of Rac1, which localizes primarily to the cytosol. While 
Rac1 was ADP-ribosylated in both the cytosolic and membrane fractions (193), the 
majority of T3S-T-ExoS ADP-ribosylated Rac1 was found in the membrane fraction (65, 
193). 
Since the cellular localization of LMWG-proteins appeared to influence the targeting 
ExoS ADPRT activity in the membrane fraction (65, 193). Time course studies were 
performed to examine trafficking patterns of ExoS ADPRT activity within HT-29 cells 
(Figure 8). After a 3 hour exposure to ExoS-producing bacteria, Ras and RalA, both of 
which localize primarily to the plasma membrane, displayed small shifts in mobility, as 
did Rab5, which localizes to early endosomes. By 4 hours, Rab8 and Rab11, both of 
which localize to recycling endosomes, were ADP-ribosylated. The last proteins to be 
modified by T3S-T-ExoS, following a 5 hour exposure to bacteria, were Rab7, which 
localizes to late endosomes, and Rac1, which is primarily a cytosolic protein that cycles 
to the plasma membrane when GTP-bound (65). Combined, these studies indicate that 
features of the host cell determine the specificity and order in which eukaryotic proteins 
are targeted by T3S-T-ExoS ADPRT activity. 
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Figure 8. Time course analysis of T3S-T-ExoS substrate modification. 
HT-29 cells were co-cultured with strain 388 or 388∆S (∆S) for 2 to 5 hours. 
Substrate modification was analyzed as described in Figure 7. The results compare 
substrate modification on the same samples from one experiment, and are 
representative of studies performed three times. The mobilities of ADP-ribosylated 
proteins (M) and unmodified proteins (U) are indicated. 
This figure originally was originally published in Biochem. Biophys. Res. Commun 
(291: 91-100, 2002). The title of the article is, “Eukaryotic cell determination of ExoS 
ADP-ribosyltransferase substrate specificity” and authors are J. E. Fraylick, E. A. Rucks, 
D. M. Greene, T. S. Vincent and J. C. Olson. The figure and selected text from the 
original figure legend appears with permission by Elsevier Science (USA). 
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ExoS was found to ADP-ribosylate specific arginine residues within eukaryotic 
substrates (30). The arginine residues targeted are often within functional domains of 
the LMWG-proteins involved in guanine nucleotide binding. This is the case for Ras, 
RalA, and Rac1 (63, 71, 193, 241). In assessing the consequences of ExoS ADP-
ribosylation, Ras modification was linked to the effects of ExoS on DNA synthesis. In 
addition, a direct correlation was observed between the severity of the effect of ExoS on 
DNA synthesis and the efficiency of Ras ADP-ribosylation (153). In concordance with 
this finding, ADP-ribosylation of Ras was found to inhibit its ability to interact with its 
guanine nucleotide exchange factor (GEF), which activates G-proteins by exchanging 
GTP for GDP. Additionally, T3S-T-ExoS ADP-ribosylation of Ras interfered with its 
interaction with downstream effector Raf-1, thereby interfering with activation of the 
MAP-kinase, Erk-2 pathway that leads to cellular proliferation (73, 92, 241). However, 
mutating R41 in Ras, which prevents T3S-T-ExoS ADP-ribosylation at the site of Ras 
that interferes with GEF interaction, did not inhibit the effects of ExoS on DNA synthesis 
(J.C. Olson and T.S. Vincent, unpublished observation). These results support that 
ExoS ADP-ribosylation of Ras does not alone explain the effects of ExoS on DNA 
synthesis. 
RalA is involved in signaling processes that affect cell proliferation, vesicular 
transport and cytoskeletal structure (50, 158, 226, 229). ADP-ribosylation of RalA by 
ExoS was found to inhibit interaction with its downstream effector Ral binding protein 1 
(63), implicating modification of RalA in the cellular effects elicited by ExoS. Rab 
proteins control distinct pathways in endocytosis and vesicular trafficking that affect 
membrane recycling (194). In vitro analysis found the ADP-ribosylation of Rab5 by 
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ExoS to interfere with its ability to bind EEA1, retarding endosome-endosome fusion 
(10). Thus, T3S-T-ExoS has the potential to interfere with multiple cell signaling 
pathways. It has been difficult for investigators to assign a individual target proteins to 
each phenotype caused by ExoS ADP-ribosylation since there is cross-talk between 
many of these pathways. However, it is likely that the effects of ExoS on proliferation, 
cytoskeleton and readherence mechanisms relate to the targeting of multiple eukaryotic 
cell substrates. 
The examination of multiple human cell lines has identified differences in cellular 
sensitivities to T3S-T-ExoS. Normal, confluent, polarized epithelial monolayers were 
found to be highly resistant to the effects of T3S-T-ExoS (58, 154). However, when 
these cell monolayers were disrupted with EDTA-treatment or tested subconfluently, 
cells became sensitive to the effects of T3S-T-ExoS and ADP-ribosylation of Ras was 
observed (154). In examining the effects of ExoS producing bacteria on epithelial cell 
lines derived from different tissues, it was noted that tumor-derived cell lines were highly 
sensitive to the effects of ExoS on cell growth (Figure 9) (154). The detection of cellular 
differences in sensitivity to T3S-T-ExoS, along with the finding that alterations in cellular 
physiology can affect sensitivity to ExoS, supported the notion that eukaryotic cell 
factors can influence the T3S-T and ultimately the toxicity of ExoS. The purpose of the 
studies in this dissertation is to examine the host cell role in the T3S-T of ExoS, and 
subsequent cellular targeting of T3S-T-ExoS ADPRT activity. 
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Figure 9. Differential effects of T3S-T-ExoS on DNA synthesis. 
Different cell lines were assayed for the effect of T3S-T-ExoS on DNA synthesis 
based on [3H]Thymidine incorporation after a 4 to 5 hour co-culture with strains 388 or 
388∆S (170). The difference in inhibition of DNA synthesis between non-ExoS 
producing strain, 388∆S, and ExoS producing strain, 388, is attributed to an ExoS 
specific effect on DNA synthesis. Data shown is representative of studies performed 
multiple times and the mean and standard deviation of [3H]Thymidine incorporation 
relative to non-bacterial treated controls are shown. 
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Research Objectives: 
 
Hypothesis: 
The host cell can influence the T3S-T of effector proteins at the level of 
membrane translocation or, once translocated, through the intracellular targeting 
of effector protein activity. 
 
Specific Aim 1: To characterize eukaryotic cell differences in the function and substrate 
specificity of ExoS ADPRT activity when translocated by Pseudomonas T3S. 
 
Specific Aim 2: To determine the cellular mechanism associated with phorbol ester-
induction of sensitivity in T3S-ExoS-resistant HL-60 cells. 
 
Specific Aim 3: To determine the mechanism associated with ExoS substrate specificity 
as it may relate to the trafficking, processing or localization of ExoS within the 
eukaryotic cell. 
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Chapter 2: Cell line differences in bacterially translocated ExoS ADP-
ribosyltransferase substrate specificity 
 
 
 
 
 
 
Contents of this chapter were originally published in 2003 in Volume 149 of 
Microbiology, pages 319-331 and appear with permission from the Society for General 
Microbiology. Authors of the published manuscript are E. A. Rucks, J. M. Fraylick, L. M. 
Brandt, T. S. Vincent, and J. C. Olson. 
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Abstract 
Exoenzyme S (ExoS) is an ADP-ribosyltransferase (ADPRT) directly translocated 
into eukaryotic cells by the type III secretory (T3S) process of Pseudomonas aeruginosa 
(Pa). Comparisons of the effects of ExoS on human epithelial and murine fibroblastic 
cells found that human epithelial cells exhibited an overall increased sensitivity to the 
effects of bacterially translocated ExoS on cell proliferation, morphology and re-
adherence. ExoS was also found to ADP-ribosylate a greater number of low molecular 
weight G- (LMWG-) proteins in human epithelial cells, as compared to murine 
fibroblasts. Examination of the mechanism for differences in ExoS ADPRT substrate 
modification found that the more restricted pattern of substrate modification in murine 
fibroblasts was not linked to the efficiency of bacterial adherence or to the efficiency of 
ExoS internalization by the T3S process. In exploring the nature of patterns of substrate 
modification, more extensive substrate modification was detected in human and simian 
cell lines, while rodent cell lines, including rat, mouse and hamster, consistently 
exhibited the more limited pattern of LMWG-protein ADP-ribosylation. Patterns of 
substrate modification were not altered by transformation and occurred independently of 
cell type. These studies suggest that properties related to the animal origin of eukaryotic 
cells affect the substrate targeting of ExoS ADPRT activity, and that this in turn can 
influence the severity of effects of ExoS on host cell function. 
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Introduction 
Pa is a ubiquitous environmental organism that can thrive in a variety of 
environmental niches, including soil, rivers, and biofilms. If it is allowed to transverse 
normal physical or immunological barriers, Pa can adapt to become a highly virulent 
opportunistic pathogen. The success of Pa as an opportunistic pathogen relates to its 
ability to produce a large number of virulence factors and to its high antibiotic 
resistance. One virulence factor produced by Pa, ExoS, is an ADPRT that is directly 
translocated into eukaryotic cells by the T3S process (258). Although the precise role of 
ExoS in Pa virulence is not fully understood, the exoS gene is found in a majority of 
clinical isolates (52), and there is a 6-fold greater risk of mortality associated with the 
expression of T3S effectors, including ExoS, in Pa lower respiratory and systemic 
infections (196). In cell culture models of infection, ExoS has been implicated as an anti-
phagocytic or anti-invasive factor (38, 66). In analyses of epithelial cells, bacterial 
translocation (T3S-T) of ExoS has been associated with a general inactivation of cell 
function, including an inhibition of DNA synthesis, loss of re-adherence and cytoskeletal 
alterations (169).  
The complex effects of ExoS on eukaryotic cell function are believed to relate to its 
bi-functional mode of action. ExoS includes a GTPase activating (GAP) function within 
its amino-terminus (77), and an ADPRT activity within its carboxy-terminus (117). The 
GAP activity of ExoS has been linked to cytoskeletal alterations (178), while the ADPRT 
activity of ExoS is required for the effects of T3S-T-ExoS on human epithelial cell DNA 
synthesis, re-adherence and long-term cytoskeletal alterations (64). When translocated 
by T3S, ExoS ADPRT activity targets multiple cellular LMWG-proteins (63, 65, 153) and 
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requires a eukaryotic cofactor, 14-3-3, for catalytic activity (29, 68, 90). ADP-ribosylation 
of cellular targets, Ras and RalA, has been found to interfere with their respective signal 
transduction pathways (63, 73, 91, 241), thereby linking a cellular mechanism to the 
effects of ExoS on eukaryotic cell function. Recent studies have drawn attention to 
possible modulatory influences the eukaryotic cell can have on ExoS function. Notably, 
ExoS ADPRT activity was found to be enhanced in the membrane compartment of 
epithelial cells when T3S-T (64, 188). In addition, an E381A mutant form of ExoS, which 
is unable to ADP-ribosylate Ras in vitro, was found to modify Ras when translocated 
into cells by the T3S process. 
The examination of multiple human epithelial cell lines has identified differences in 
cellular sensitivities to T3S-T-ExoS. Normal, confluent, polarized epithelial monolayers 
were found to be highly resistant to the effects of T3S-T-ExoS (58, 154). However, 
when normal epithelial cell monolayers were disrupted or subconfluent, cells became 
sensitive to ExoS (154). In examining the effects of ExoS producing bacteria on 
epithelial cell lines derived from different tissues, it was noted that tumor-derived cell 
lines were highly sensitive to the effects of ExoS on cell growth (154). The detection of 
cellular differences in sensitivity to T3S-T-ExoS, along with the finding that alterations in 
cellular physiology can affect sensitivity to ExoS, support the notion that eukaryotic cell 
factors can influence the toxicity of ExoS.  
To clarify how the eukaryotic cell might contribute to the toxicity of T3S-T-ExoS, we 
examined how different cell lines compared in their response to ExoS producing 
bacteria. Our studies found murine fibroblasts to be more resistant to the effects of 
ExoS than human epithelial cells. The increased resistance of murine fibroblastic cells 
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to ExoS was associated with less efficient ADP-ribosylation of cellular substrates by 
ExoS, and occurred independently of detectable differences in the efficiency of T3S-T of 
ExoS. In examination of a rodent, simian, and human cell lines, distinct patterns of ExoS 
ADPRT substrate modification were detected, with human cell lines showing both more 
efficient and more extensive LMWG-protein substrate modification. These studies 
support that once internalized, host cell properties can influence the substrate specificity 
of ExoS ADPRT activity, which corresponds with alterations in the severity of effects of 
ExoS on cell function. 
Methods and Materials 
Bacterial strains and culture conditions. Pa strains used in this study include the 
prototype ExoS producing strain 388 (106) and its isogenic mutant, strain 388∆exoS, 
which lacks ExoS production due to an allelic exchange of the majority of the exoS 
structural gene for a tetracycline resistance gene cartridge (126). Complementation 
studies have confirmed that differences in the effects of strains 388 and 388∆S on 
eukaryotic cell function relate to the production of ExoS (169). To further rule out the 
role of ExoT in our analyses (which is expressed by strains 388 and 388∆S) a 
388∆ExoT mutant (256) was included in all experiments as a control. All bacterial 
strains used in this study were kindly provided by Dara Frank from the Medical College 
of Wisconsin, Milwaukee, WI. Bacteria were grown and prepared for co-culture studies 
with eukaryotic cells as previously described (153, 170).  
Eukaryotic cell culture. CHO-K1, Cos-1, Detroit 532, HT-1080, HT-29, LNCaP, NIH-
3T3, Swiss-3T3, TCMK-1, T24 and Vero cells used in this study were obtained from the 
American Type Culture Collection (ATCC; Rockville, MD). RHEC cells were provided by 
45 
Carwile LeRoy, and WI-38 and WI-38 SV40 transformed cells were kindly provided by 
Daohong Zhou, both from the Medical University of South Carolina, Charleston, SC. 
Characteristics of cell lines used in this study are shown in Table 1. Cell lines were 
cultured, as described below, in their respective medium containing 10% v/v fetal bovine 
serum (FBS) and 100 units/ml penicillin and 100 µg/ml streptomycin (PS) at 37°C in 5%-
CO2-95% air. All cell culture media and components were purchased from Gibco-BRL 
(Gaithersburg, MD). 
 Epithelial cell lines. CHO-K1 cells (ATCC CCL 61) were cultured in Ham’s F12K 
medium and split 1:6 at confluency and passaged. HT-1080 (ATCC CCL-121), RHEC, 
TCMK-1 (ATCC CCL 139), and Vero cells (ATCC CCL 81) were cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM), split 1:6-1:10 at confluency and passaged. HT-29 
cells (ATCC HTB 38) were maintained in McCoy’s 5A medium, as previously described 
(169). LNCaP cells (ATCC CRL 1740) were cultured in RPMI medium and split 1:4 at 
confluency and passaged. T24 cells (ATCC HTB 4) were grown in McCoy’s 5A medium, 
split 1:6 at confluency and passaged twice weekly. 
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 Table 1. LMWG-protein substrate modification by T3S-T-ExoS in different cell 
lines.  
*Cell type, immortality and tumorgenicity as indicated by the ATCC, except for the 
RHEC cell line, which was obtained from Carwile LeRoy. † +, ADP-ribosylation by 
ExoS; ++, two ExoS ADP-ribosyl-modified isoforms; -, not ADP-ribosylated by ExoS. ‡ 
SV-40 transformed. 
 
 Fibroblastic cell lines. Detroit 532 cells (ATCC CCL 54) were grown in RPMI medium 
and maintained as previously described (170). Cos-1 cells (ATCC CRL 1650), NIH-3T3 
cells (ATCC CRL 1658), Swiss-3T3 cells (ATCC CCL 92), WI-38 and WI-38 SV40 
transformed (WI-38t) were cultured in DMEM and split 1:6 and passaged twice a week. 
Co-culture of eukaryotic cells with bacteria. For bacterial/eukaryotic cell co-culture 
studies, eukaryotic cells were detached with 0.05% w/v trypsin-0.53 mM EDTA (trypsin-
EDTA) and seeded at 1 x 105 cells/ml in 6, 24 or 48-well plates or culture dishes  
(Costar; Cambridge, MA). Cells were grown for either 24 hours or 48 hours (depending 
on the growth rate of the cell line) to obtain 60-80% confluency prior to co-culture with 
47 
bacteria. Strain 388 or 388∆S bacteria were diluted, based on culture OD590, to 1x107 
cfu/ml in medium specific for each eukaryotic cell line containing 0.6% w/v bovine serum 
albumin (BSA). A multiplicity of infection (MOI). range of 10 to 100 was used in these 
studies, unless otherwise indicated, and bacteria were co-cultured with eukaryotic cells 
for 2 to 6 hours. Control cells received the respective medium with no bacteria. Effects 
of bacteria on eukaryotic cell function were analyzed as described below. 
 Quantification of DNA synthesis. Following a 4 hour co-culture period, bacteria were 
removed and cells were washed with culture medium containing 10% FBS, 200 µg/ml 
gentamicin and 100 µg/ml ciprofloxacin (GC-medium) to inhibit further bacterial growth. 
Cells were pulsed for 20 hours in GC-medium containing 1 µCi/ml [methyl-3H]thymidine 
(25 Ci mmol-1; Amersham, Arlington Heights, IL). DNA synthesis was quantified as 
previously described (170) and is reported as the percent of [3H]thymidine incorporated 
relative to that of non-bacterial treated control cells. 
Analysis of cell viability. Cell viability was examined following a 3, 4.5 and 6 hour co-
culture period, after which bacteria were removed, and total cell viability was determined 
by trypan blue exclusion immediately after removal of bacteria and following an 
extended 20 hour culture period in GC medium.  
Examination of cell morphology. To compare long-term effects of ExoS on cellular 
morphology, cells were co-cultured with bacteria for 4 hours, bacteria were removed, 
cells were washed with PBS and cultured in GC-medium for an additional 20 hours. 
Morphological alterations were examined by phase contrast microscopy. 
Analysis of eukaryotic cell adherence. The effects of ExoS producing bacteria on 
eukaryotic cell adherence to matrix were assessed after a 2 to 6 hour co-culture period 
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by quantifying adherent and non-adherent cells, using trypan blue exclusion, 20 or 40 
hours after bacteria were removed. To assess the effects of ExoS on re-adherence, 
cells were detached with trypsin-EDTA following co-culture with bacteria, washed, 
resuspended in GC-medium, re-plated and allowed to re-adhere for 20 hours (HT-29, 
NIH-3T3, Swiss-3T3 cells) or 48 hours (LNCaP cells). (LNCaP cells were previously 
recognized to require a longer adherence time (98)). The number and viability of non-
adherent and trypsinized, adherent cells were determined after this time based on 
trypan blue exclusion. The percentage of viable and non-viable, adherent or non-
adherent cells was calculated relative to total cell number. 
Bacterial association with eukaryotic cells. To compare the adherence of bacteria to 
different eukaryotic cell lines, cells were seeded in 24-well plates, as described above, 
and co-cultured with bacteria at a MOI of approximately 200:1 for 4.5 hours (HT-29, 
NIH-3T3, and Swiss-3T3 cells) or 3 hours (LNCaP cells). (The limited time of exposure 
of LNCaP cells related to their increased sensitivity to bacterial effects on cell viability.) 
Bacteria were removed, and 1 ml HEPES buffered saline (HBS) (137 mM NaCl, 4 mM 
KCl, 10 mM Hepes pH 7.4, 11 mM glucose) was added to wells. Cells were detached by 
scraping, transferred to microcentrifuge tubes, and washed three times with HBS, 
centrifuging cells at 400 g for 4 minutes at 4°C between washes. Eukaryotic cells were 
lysed in PBS containing 0.25% v/v Triton X-100 for 30 minutes on ice, and lysates were 
diluted 1:1000 and plated on Luria broth (LB) agar plates. Bacterial colonies were 
counted 16 hours later, and the number of bacteria associated per eukaryotic cell was 
determined. Data were analyzed for statistical significance using one-way factorial 
ANOVA (http://members.aol.com/johnp71/anova1sm.html). 
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ADP-ribosylation of cellular substrates by bacterially translocated ExoS.  
In vivo. In vivo ADP-ribosylation of LMWG-protein substrates by bacterially translocated 
ExoS was assessed based on altered protein mobility by SDS-PAGE following co-
culture with bacteria for 4 or 6 hours, as previously described (64, 65, 153). To examine 
Ras modification, cells were lysed in TBS-TDS (10 mM Tris, pH 7.4, 140 mM NaCl, 1% 
v/v Triton X-100, 0.5% w/v sodium deoxycholate, 0.1% w/v SDS), and cellular Ras was 
immunoprecipitated using Y13-259 anti-pan Ras antibody, as previously described 
(153). Precipitates were resolved by SDS-12.5% PAGE (129), transferred to PVDF 
membranes (Millipore; Bedford, MA) (233), and Ras was detected using 100 ng/ml 
LA045 pan-Ras antibody or 100 ng/ml LA069 H-Ras specific antibody (Quality Biotech; 
Camden, NJ), followed by horseradish peroxidase (HRP)-conjugated anti-mouse IgG 
(Jackson Immuno Research; West Grove, PA) and visualized by enhanced 
chemiluminescence (ECL) (Amersham). RalA, Rab5, Rab7, Rab8, Rab11 and Rac1 
modification was detected following lysis of cells with Laemmli electrophoresis sample 
buffer, and lysates were resolved by SDS-12% PAGE and transferred to PVDF 
membranes, as described above. Individual LMWG-proteins were detected using the 
following antibodies: RalA, 50 ng/ml mouse anti-RalA monoclonal antibody 
(Transduction Laboratories; Lexington, Kentucky); Rab5, 10 ng/ml rabbit anti-Rab5B (A-
20) polyclonal antibody (Santa Cruz Biotechnology; Santa Cruz, California); Rab7, 0.7 
µg/ml goat anit-Rab7 (C-19) polyclonal antibody (Santa Cruz); Rab8, 250 ng/ml mouse 
anti-Rab8 monoclonal antibody (Transduction Laboratories); Rab11, 250 ng/ml mouse 
anti-Rab11 monoclonal antibody (Transduction Laboratories); and Rac1, 250 ng/ml 
mouse anti-Rac1 monoclonal antibody (Transduction Laboratories). Immunoblots were 
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developed with HRP-conjugated anti-mouse IgG (Sigma) or anti-rabbit IgG 
(Transduction Laboratories), as appropriate, and visualized by ECL. 
In vitro. In vitro ADP-ribosylation of fibroblastic RalA, Rab proteins, or Rac1 was 
performed, as previously described (65), using 0.2 µM purified ExoS (153), 10 mM NAD 
(Sigma) and 40 µl of NIH-3T3 or Swiss-3T3 fibroblast cell lysate (as a source of the 
endogenous proteins and 14-3-3 cofactor) in a 100 µl reaction volume, which was 
incubated for 30 minutes at room temperature. Reactions were stopped with 4x 
Laemmli sample buffer and heating at 95ºC for 5 minutes. Fibroblast cell lysates were 
prepared by incubating cells on ice for 30 minutes in lysis buffer containing 50 mM Tris, 
0.1% Triton X-100, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 1mM EDTA and 100 µM 
PMSF. Lysates were cleared of nuclei and unbroken cells by centrifugation at 16,000 x 
g for 5 minutes prior to use in reactions. Following the ADPRT reactions, proteins were 
resolved by SDS-12% PAGE and immunoblotted for the specific proteins, as described 
above. 
Time course analysis of ExoS internalization. Substrate modification and the 
internalization of ExoS ADPRT activity was assessed in fibroblastic and epithelial cells 
seeded in 100 mm dishes and co-cultured with bacteria for 3, 4.5 or 6 hours. Following 
removal of bacteria, cell monolayers were washed twice with PBS, and adherent cells 
were detached with trypsin-EDTA. Cells were recovered from washes by centrifugation 
at 400 g for 10 min and combined with trypsin-detached cells. The treatment of cells 
with trypsin in these studies minimized the likelihood that extracellularly bound ExoS 
would remain in cellular fractions. The cell pellet was resuspended in 100 µl of cell 
permeabilization solution (0.2% w/v saponin, 100 mM NaCl, 250 mM sucrose, 5 mM 
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EDTA, 1 mM PMSF, 10 µg/ml, each, leupeptin and aprotinin (Sigma) and 100 µg/ml 
ciprofloxacin) and lysed on ice for 30 minutes. Lysates were centrifuged at 16,000 g for 
20 minutes at 4°C. The supernatant (cytosolic fraction) was removed, and the pellet was 
resuspended in 100 µl of cell permeabilization solution containing 1% v/v Triton X-100 
and vortexed for 15 seconds every 5 minutes four times to solubilize membrane 
proteins. The solubolized pellets were centrifuged at 16,000 g for 10 minutes, and the 
supernatant (membrane fraction) was removed. To analyze substrate modification in the 
cytosolic and membrane fractions, a 50 µl aliquot of each sample was mixed with 4x 
Laemmli sample buffer, and an equivalent volume of each fraction was resolved by 
SDS-PAGE and immunoblotted for RalA, Rab proteins, or Rac1, as described above. 
ExoS ADPRT activity in remaining portions of cytosolic and membrane fractions was 
quantified, as previously described (54), and related to total protein concentrations in 
the respective sample determined using the Sigma Diagnostics Lowry-based protein 
assay (Sigma). Data were analyzed for statistical significance using one-way factorial 
ANOVA, as described above. 
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Results 
Comparison of effects of ExoS on cell function. We previously found that effects 
of T3S-T-ExoS on eukaryotic cell function could be assessed in a bacterial/eukaryotic 
cell co-culture model of infection by comparing alterations caused by ExoS producing 
strain 388 to that of the isogenic, non-ExoS producing strain 388∆S (169, 170). In 
comparisons of different cell lines for the effects of T3S-T-ExoS, we recognized a 
general increase in sensitivity of human epithelial cells to ExoS as compared to NIH-
3T3 and Swiss-3T3 fibroblastic cells. This difference in cell sensitivity to ExoS was 
consistent with previous studies which found Detroit 532 fibroblasts to be sensitive to 
effects of ExoS on DNA synthesis, but relatively resistant to effects of ExoS on cell 
morphology (170). To gain a better understanding of cellular differences in the effects of 
ExoS and the mechanisms associated with these differences, HT-29 and LNCaP 
human epithelial cells and NIH-3T3 and Swiss-3T3 fibroblastic cells were used as 
model cell lines to further explore differences in the effects of ExoS on cell function. 
In examining effects of T3S-T-ExoS on DNA synthesis, HT-29 and LNCaP epithelial 
cells were found to be more sensitive to effects of ExoS on DNA synthesis, showing a 
51.6% ±0.5% and 88.6% ±1.0% inhibition of DNA synthesis, respectively, relative to that 
of strain 388∆S. This compared to a 36.0% ±1.3% and 20.3% ±0.7% inhibition of DNA 
synthesis caused by strain 388 in NIH-3T3 and Swiss-3T3 murine fibroblasts, 
respectively, relative to strain 388∆S. In determining how effects of ExoS on cell viability 
related to effects on DNA synthesis, cell viability was assayed, based on trypan blue 
exclusion, under the same co-culture conditions and at the same time point as DNA 
synthesis analyses. In these studies, LNCaP and NIH-3T3 cells exhibited a greater loss 
53 
of viability (95.2% ± 0.4% and 44.6% ±0.9%, respectively). This compared to a minimal 
6.1% ±0.9% and 6.8% ±0.2% loss of viability caused by bacterially translocated ExoS in 
HT-29 and Swiss-3T3 cells, respectively. These studies found that human epithelial 
cells were more sensitive than murine fibroblasts to effects of ExoS on DNA synthesis, 
and that the effects on DNA synthesis did not necessarily correlate with effects of ExoS 
on cell viability. 
Previous studies from our laboratory found permanent, long-term effects of strain 
388 on HT-29 epithelial cell rounding to be directly associated with ExoS ADPRT 
activity (64, 169). This differed from transient effects on cell morphology caused by the 
non-ExoS producing strain 388∆S, which were less severe and reversible upon removal 
of bacteria. In comparing the effects of ExoS on the morphology of these four different 
cell lines, severe cell rounding persisted in HT-29 and LNCaP epithelial cells 20 hours 
after exposure to strain 388, while long-term rounding was limited in NIH-3T3 cells and 
absent from Swiss-3T3 fibroblastic cells (Figure 10). 
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 Figure 10. Effects of T3S-T-ExoS on epithelial and fibroblastic cell morphology. 
HT-29, LNCaP, NIH-3T3 and Swiss-3T3 cells were seeded at 1 x 105 cells/ ml in 48-well 
plates, either 24 hours (fibroblasts) or 48 hours (epithelial) prior to the addition medium 
containing no bacteria (0), or 107 cfu/ml of strain 388 or 388∆S (∆S) for 4 hours. 
Bacteria were removed, cells were washed with PBS and cultured in GC-medium for an 
additional 20 hours. Long-term effects on cell morphology were examined by phase 
contrast microscopy at 20 hours, and images are representative of a minimum of three 
independent experiments. 
55 
The functional detachment and reattachment of epithelial and fibroblastic cells to 
extracellular matrix is required for cell mobility and the maintenance of cellular barriers. 
This function was previously found to be affected in HT-29 cells following treatment with 
ExoS-expressing bacteria (169). In assessing whether differences exist in the sensitivity 
of the four cell lines to the effects of ExoS on cellular adherence and re-adherence, it 
was first noted that minimal direct loss of adherence occurred following the co-culture of 
HT-29, NIH-3T3 and Swiss-3T3 cells with ExoS-producing bacteria for 4 to 5 hours. In 
comparison, LNCaP cells were found to detach from the culture plate or become loosely 
adherent within a 4 hour exposure to bacteria (data not shown). Effects of ExoS on the 
reattachment processes were examined by detaching cells from plates with trypsin, 
following exposure to bacteria, replating, and allowing cells to re-adhere for 20 or 48 
hours. In these analyses, HT-29 cells began to lose the ability re-establish adherence to 
matrix after a 2 to 3 hour exposure to strain 388 (Figure 11). LNCaP cells, which were 
sensitive to direct effects of ExoS on cell adherence, displayed a generalized sensitivity 
to bacterial effects on re-adherence, independently of ExoS production. NIH-3T3 cells 
required a greater than 4 hour exposure to strain 388 before re-attachment processes 
were lost, and Swiss-3T3 cells tolerated a greater than 6 hour exposure to strain 388 
before loss of re-adherence. These studies found that bacterially translocated ExoS 
interfered with re-adherence processes differently in each cell line, but that overall, 
murine fibroblasts appeared more resistant to effects of ExoS on adherence processes. 
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Figure 11. Effects of T3S-T-ExoS on epithelial and fibroblastic cell re-adherence. 
HT-29, LNCaP, NIH-3T3 and Swiss-3T3 cells were seeded and cultured with no 
bacteria (open triangle) or strain 388 (filled square) or 388∆S (open square) for 2 to 6 
hours, as in Figure 1. Bacteria were removed, cells were washed, detached with trypsin-
EDTA, replated, and allowed to re-adhere for 20 hours (HT-29, NIH-3T3, Swiss-3T3) or 
44 hours (LNCaP). The number and viability of non-adherent and trypsinized adherent 
cells were determined after this time based on trypan blue exclusion. The percentage of 
viable, adherent cells was calculated relative to total cell number. Results are expressed 
as percent viable adherent cells following the indicated co-culture time. The mean and 
SE of three to four independent experiments are represented. 
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In summarizing comparisons of the effects of T3S-T-ExoS on these four cell lines, it 
was found that the two human epithelial cells examined were, in general, more sensitive 
than the murine fibroblastic cell lines to effects of ExoS on DNA synthesis, alterations in 
morphology, and effects on re-adherence processes. However, individual cell line 
variations in the effects of ExoS were also evident in these studies, highlighting the 
ability of eukaryotic cells to modulate, or contribute to, the effects of ExoS on cell 
function in a cell line-dependent manner. 
Comparison of bacterial association to cellular sensitivity to ExoS. Contact 
between bacteria and eukaryotic cells is required for the T3S-T of effector proteins 
(102). To assess whether the differential sensitivity among the cell lines to ExoS might 
relate to efficiency of bacterial adherence, bacterial association with the different cell 
lines was quantified after a 3 or 4.5 hour exposure to bacteria. Bacterial adherence to 
LNCaP cells was assayed after a shorter, 3 hour period since this cell line begins to 
loose viability after a 4 hour co-culture period (refer to previous section). As shown in 
Figure 12, an average of 2 bacteria associated with each HT-29 epithelial cell, with 5 to 
6 bacteria associating with each LNCaP cell. In analysis of the NIH-3T3 and Swiss-3T3 
fibroblastic cells, an average of 20 bacteria were associated per cell, which was 
significantly greater (P < 0.006) than the number adhering to epithelial cells. 
Comparisons of the size of epithelial and fibroblastic cells as cultured monolayers, 
found fibroblasts to have about a 2.5 times greater surface area than epithelial cells, 
making the association of bacteria per surface area still slightly greater for fibroblastic 
than epithelial cells. Based on these analyses, and consistent with previous reports (58, 
154), we were unable to relate the efficiency of bacterial association with cells to  
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Figure 12. Bacterial association with HT-29, LNCaP, NIH-3T3 (NIH) and Swiss-3T3 
(Swiss) cells. 
Mammalian cells were seeded in 24-well plates as in Figure 1, and cultured with 388 
(hatched bars) or 388∆S (open bars) bacteria (MOI, 200:1) for either 3 hours (LNCaP) 
or 4.5 hours (HT-29, NIH-3T3 (NIH), Swiss-3T3 (Swiss)). A higher MOI. was used in 
these studies to maximize bacterial association. Bacteria were removed, eukaryotic 
cells were detached by scraping into HEPES buffered saline (HBS) and washed three 
times in HBS. Eukaryotic cells were lysed in PBS containing 0.25% v/v Triton X-100, 
and the lysate was diluted and plated on LB agar plates. Bacterial colonies were 
counted after 16 hours. Assays were performed in quintuplicate, and the number of 
associated bacteria per eukaryotic cells was calculated. The mean and SE of three to 
four independent experiments are represented. A statistically significant difference was 
detected between the association of strain 388 and strain 388∆S with epithelial and 
fibroblastic cells, based on ANOVA; *, P = 0.307 in the comparison of adherence of 
388∆S and 388 to NIH-3T3 cells, indicating that the differences noted were not 
statistically significant. 
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differences in cellular sensitivity to the effects of ExoS. Also evident in Figure 12, is the 
lack of significant difference in the association of strain 388 or 388∆S bacteria with the 
different cell lines, indicating no influence of ExoS production on bacterial adherence in 
these studies. 
ADP-ribosylation of cellular substrates by T3S-T-ExoS.  Previous studies 
confirmed the requirement of ExoS ADPRT activity for effects of T3S-T-ExoS on 
epithelial cell DNA synthesis and morphology (64). To examine how differences in the 
sensitivity of cell lines to ExoS might relate to cellular targets of ExoS ADPRT activity, 
identified LMWG-protein substrates of T3S-T-ExoS (63, 65, 153) were examined for 
modification in the different cell lines. Cellular substrates examined in these studies 
included Ras, RalA, Rab5, Rab7, Rab8, Rab11 and Rac1, and modification was 
determined based on a shift in molecular mass by SDS-PAGE, previously shown to 
relate to ExoS ADP-ribosylation (63, 65, 153). 
While Ras appeared to be modified similarly in the human epithelial and murine 
fibroblasts, based on SDS-PAGE analyses, a difference was detected in the 
modification of the other LMWG-proteins between the two cell types (Figure 13 A). Two 
modified forms of RalA were detected in HT-29 and LNCaP cells, but only one modified 
form of RalA was detected in NIH-3T3 or Swiss-3T3 fibroblastic cell lines. Comparisons 
of the ADP-ribosylation of Rab proteins by T3S-T-ExoS, found Rab5, Rab7, Rab8 and 
Rab11 to be modified in the human epithelial cell lines, but no modification of Rab 
proteins was detected in murine fibroblasts. (Representative results of Rab5 and Rab8 
are shown in Figure 13 A.) Also, Rac1 modification was detected in human epithelial but 
not murine fibroblastic cells. The different number of modification bands observed in  
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Figure 13. Cell line-related effect of substrate modification by T3S-T-ExoS. 
(a) ADPRT substrate modification by T3S-T-ExoS: Cellular substrate modification was 
examined following a 4 to 5 hour co-culture period with strain 388 or 388∆S (∆S), as in 
Figure 1. To analyze Ras modification, cells were lysed in TBS-TDS, Ras was 
immunoprecipitated using Y13-259 anti-pan Ras antibody, and immunoprecipitates 
were resolved on SDS 12.5%-PAGE. Ras was detected by immunoblot analyses and 
visualized using enhanced chemiluminescence (ECL). To analyze the modification of 
RalA, Rab5, Rab8 and Rac1, cells were lysed in 1x Laemmli sample buffer and lysates 
resolved by SDS 12%- PAGE. The individual LMWG-proteins were also detected by 
immunoblot analyses (b) Substrate modification by ExoS in an in vitro ADPRT reaction: 
ADP-ribosylation of fibroblastic RalA, Rab5 and Rab8 was examined in vitro using 0.2 
µM purified ExoS, 10 mM NAD and 40 µl of NIH-3T3 or Swiss-3T3 fibroblast cell lysate 
as a source of both the endogenous protein and the 14-3-3 cofactor, in a 100 µl reaction 
volume. Reactions were incubated for 30 minutes at room temperature and stopped 
with 4x Laemmli sample buffer and heating at 95ºC for 5 minutes. Proteins were 
resolved by SDS-12% PAGE and immunoblotted. Positions of ADPRT modified (M) and 
unmodified (U) proteins are indicated, and immunoblots are representative of a 
minimum of 3 independent experiments. 
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individual LMWG-proteins was previously shown to relate to the sequential addition of 
ADP-ribose moieties (63, 65). 
To assess whether differences in patterns of substrate modification in these cell 
lines related to intrinsic protein differences or in situ cellular influences, RalA, Rab 
proteins and Rac1 from fibroblast cell extracts were incubated with purified ExoS in an 
in vitro ADPRT reaction. As shown in Figure 13 B, fibroblastic derived RalA, Rab5, 
Rab8 (and Rac1, not shown) were able to be ADP-ribosylated by purified ExoS in vitro 
as efficiently as their respective epithelial proteins were in vivo. Also, because ADPRT 
reactions were performed using fibroblastic extracts as a source of eukaryotic cell 
proteins, neither the absence of functional 14-3-3 eukaryotic co-factor, nor the presence 
of endogenous ADPRT inhibitors appeared to be contributing to the limited ADPRT 
substrate modification detected in murine fibroblasts. 
Time-course analysis of T3S-T and substrate modification by ExoS ADPRT 
activity. To further explore whether the limited substrate specificity of fibroblastic cells 
related to less efficient T3S-T of ExoS into cells, LMWG-protein substrate modification 
was monitored relative to the internalization of ExoS ADPRT activity into the eukaryotic 
cell in a time-dependent study. In these experiments, cytosolic and TX-100 solubilized 
membrane fractions of cells were analyzed for ExoS ADPRT activity and RalA, Rab5, 
Rab8 and Rac1 modification following a 3, 4.5, or 6 hour exposure to bacteria. Our 
studies examined ExoS ADPRT activity, rather than the ExoS protein, because of our 
ability to quantify ExoS ADPRT activity precisely and because of previous difficulties in 
detecting ExoS protein by immunoblot analyses (64).  
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Consistent with the studies shown in Figure 13 A, patterns of LMWG-protein 
substrate modification in human epithelial and murine fibroblastic cells remained 
distinctly different, even with increasing time of exposure to bacteria (Figure 14 A). The 
difference in substrate modification was specifically recognized in the single 
modification of RalA and absence of modification of Rab5, Rab8 or Rac1 in murine 
fibroblastic cells, compared with two modifications of RalA, two modifications of Rab5 
and a single modification of Rab8 and Rac1 detected in human epithelial cells. Analysis 
of all cell lines was similar in that substrate modification was more efficient in the TX-
100 membrane fraction when compared with the cytosolic fraction. Also, while variations 
in levels of individual LMWG-proteins were detected between the cytosolic and 
membrane compartments, the relative distribution of these proteins was generally 
consistent in all cell lines. For example, there was a general preferential localization of 
RalA to the membrane fraction, Rab proteins were somewhat equally distributed in both 
the cytosolic and membrane fractions, and Rac1 preferentially localized to the cytosolic 
fraction. The lack of prominent differences in the cellular localization of LMWG-proteins 
is supportive of this not being a factor in differences observed in patterns of ExoS 
substrate modification in human epithelial and murine fibroblastic cells. 
In time course analyses of ExoS ADPRT activity, increases in ADPRT activity were 
found to closely parallel increases in the efficiency of cellular patterns of substrate 
modification (Figure 14 B). ADPRT activity was significantly higher in the membrane 
than cytosolic fraction (p < 0.009, except for data received for HT-29 cells at 3 hrs), and 
progressively increased in both fractions with time in association with the increased 
efficiency of substrate modification. Notable in comparisons of ExoS ADPRT activity  
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Figure 14. Time course analysis of ExoS substrate modification and 
internalization of ExoS ADPRT activity 
(a) ADPRT substrate modification. Epithelial and fibroblastic cells were seeded in 100 
mm dishes and co-cultured with strain 388∆S (∆) or 388 (S), as in Figure 1, for 3, 4.5, or 
6 hours. Cell monolayers were washed twice with PBS, non-adherent cells were 
recovered and combined with adherent, trypsin detached cells. The cells were washed 
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with PBS, resuspended in 100 µl of cell permeabilization solution (defined in Methods) 
and placed on ice for 10 min to release the cytosolic fraction. Permeabilized cells were 
centrifuged at 16,000 g for 20 minutes at 4°C. The supernatant (cytosolic fraction) was 
removed, and the pellet was resuspended in 100 µl of cell permeabilization solution 
containing 1% v/v Triton X-100 and vortexed for 15 sec every 5 minutes, four times to 
solubilize membrane proteins. The membrane TX-100 soluble protein fraction was 
obtained by centrifugation at 16,000 g for 10 min. To analyze substrate modification in 
the cytosolic and membrane fractions, 4x Laemmli sample buffer was added to a 40 µl 
aliquot of each sample, and RalA, Rab5, Rab8 and Rac1 modification was examined as 
described in Fig. 4. Positions of ADPRT modified (m) and unmodified (u) proteins are 
indicated. (H) HT-29 cells; (L) LNCaP cells; (N) NIH-3T3 cells; (S) Swiss-3T3 cells; (*) 
indicates a longer exposure to film, relative to the other samples, was required for the 
ECL signal shown. 
(b) Internalization of ExoS ADPRT activity. ExoS ADPRT activity was quantified in the 
cytosolic and membrane fractions of HT-29, LNCaP, NIH-3T3 and Swiss-3T3 cells in a 
1 hour in vitro ADP-ribosylation reaction, containing 1.2 µM [14C]NAD and 100 µM 
soybean trypsin inhibitor (SBTI) as the ADP-ribose acceptor. ADPRT activity is reported 
as fmol per min of ADP-ribose incorporated into SBTI per µg of cellular protein. ADPRT 
assays were performed in duplicate and the mean and SD (not evident) of samples 
represented in (a) are shown. The results are representative of 3 independent 
experiments. Open squares, cytosol, strain 388∆S; open circles, cytosol, strain 388; 
filled squares, membrane strain 388∆S; filled circles, membrane, strain 388. 
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was the high level of activity detected in both the cytosolic and membrane fractions of 
murine fibroblastic cells, even though more restricted patterns of substrate modification 
were detected. The high levels of ExoS ADPRT activity detected in fibroblasts further 
support the notion that ExoS activity is not tethered in murine fibroblasts by endogenous 
ADPRT inhibitors. While levels of ExoS ADPRT activity were calculated relative to total 
cellular protein concentration in Figure 14 B, higher levels of activity were also evident 
in murine fibroblastic cells when related to total cell numbers (data not shown). In 
addition, while studies represented in Figure 14 were performed at an MOI of 10, the 
same pattern of substrate modification was detected in murine fibroblasts at a MOI 
>250, highlighting the defined nature of murine fibroblastic cell substrate modification 
pattern. We conclude from these studies that the limited substrate modification by 
bacterially translocated ExoS in murine fibroblasts was not linked to the inefficient 
internalization of ExoS ADPRT activity by the Pa T3S system, but rather reflected in situ 
differences in ExoS function.  
Patterns of ExoS substrate modification in different cell lines. To explore the 
specificity of the ExoS ADPRT substrate modification pattern relative to cell type or 
animal origin, we compared substrate modification by T3S-T-ExoS in fibroblasts, 
epithelial and endothelial cell lines from rodents, monkeys and humans (Table 1; Figure 
15). Rodent-derived CHO-K1 and TCMK-1 epithelial cells, and RHEC endothelial cells, 
exhibited the same pattern of substrate modification as that of murine NIH-3T3 and 
Swiss-3T3 cells; that is, showing more limited modification of RalA and no modification 
of Rab proteins or Rac1. Simian-derived Cos-1 fibroblasts and Vero epithelial cells 
showed a similar pattern of substrate modification as human HT-29 and LNCaP cell  
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Figure 15. Patterns of LMWG-protein substrate modification by T3S-T-ExoS in 
different cell lines. 
Eukaryotic cells were seeded at 105 cells/ml in 6-well plates for 24 hours prior to co-
culture with 106 cfu/ml 388, 388∆S (∆S) (MOI 10-20:1), or no bacteria. After a 4.5 hour 
co-culture period, bacteria were removed, cells were washed in PBS and lysed in 200 µl 
1x Laemmli sample buffer. Lysates were resolved by SDS 12%-PAGE and 
immunobloted for RalA, Rab5, Rab8 and Rac1, as described in Figure 4. ADPRT-
modified (m) and unmodified (u) proteins are labeled. Immunoblots shown are 
representative of at least 4 independent studies. 
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lines, although modification was consistently less efficient. Human-derived HT-1080 
fibrosarcoma and T24 transitional cell carcinoma cells also displayed the same pattern 
of substrate modification as LNCaP and HT-29 cells. Since previous studies found 
tumor derived cells to be highly sensitive to the effects of ExoS (154), we examined 
whether oncogenic transformation or viral transformation of cell lines could influence 
substrate specificity. When substrate modification in normal and SV40-transformed 
human WI-38 fibroblasts (WI-38t) was compared, the pattern of substrate modification 
of both cell lines was similar to that of other human cell lines, indicating that viral 
transformation did not alter ExoS substrate modification. In addition, substrate 
modification by T3S-T-ExoS in the WI-38t cells did not differ from that detected in the 
HT-29, LNCaP, HT-1080 and T24 cells, indicating that neither viral nor oncogenic 
transformation influenced the substrate specificity of ExoS. The one cell line exception 
to the pattern of substrate modification observed for human cells was the Detroit 532 
fibroblastic cells, which exhibited a more limited pattern of substrate modification, similar 
to that of rodent cell lines. 
We conclude from these studies that patterns of ExoS substrate modification are 
linked more closely to the origin of the cell line, rather than cell type or state of cellular 
transformation. However, as evident from Detroit 532 human fibroblasts, this 
relationship is not absolute, and differences in individual cell lines can also alter ExoS 
substrate-modification patterns. 
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Discussion 
The T3S system is thought to be evolutionarily derived from bacterial flagellar 
machinery and was an adaptation that allowed the bacterium to directly translocate 
effector proteins and manipulate the function of eukaryotic cells (102). The conservation 
of the genetically complex T3S regulon among a broad range of Gram-negative 
organisms implies its general importance to bacterial survival. While it has been 
recognized that differences exist in the sensitivity of eukaryotic cells to T3S processes, 
the cellular mechanism for these differences, and the contribution of the eukaryotic cell 
to the T3S process remain largely unknown.  
We have used the T3S-T of ExoS by Pa to explore how the host cell might influence 
the translocation and cellular effect of T3S-effector proteins. Previous studies found that 
macrophage and epithelial cell lines responded differently to the Pa T3S process, with 
cell morphology being affected in epithelial cell lines and cell viability being affected in 
macrophages (27). ExoS is the most extensively studied of the Pa T3S-effector 
proteins, and comparisons of different epithelial cell lines identified differences in cell 
sensitivity to T3S-T-ExoS (154). Notable in these comparisons was that epithelial cell 
sensitivity to ExoS appeared to parallel the opportunistic nature of Pa infections, 
implying a relationship between the T3S process and cells targeted by Pa. Since 
studies supported that the host cell can influence the outcome of T3S-T events, we 
reasoned that we might be able to gain insight into these eukaryotic cell influences by 
comparing the cellular mechanism of ExoS in cell types that respond differently to T3S-
T-ExoS. 
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We had previously observed differences in sensitivities of human carcinoma and 
mouse fibroblastic cells to the effects of T3S-T-ExoS. Based on these observations, we 
used HT-29 and LNCaP human epithelial cells and NIH-3T3 and Swiss-3T3 murine 
fibroblasts to explore how the host cell might contribute to differences in the toxicity of 
ExoS. Previously defined effects of ExoS on epithelial cells, which include inhibition of 
DNA synthesis, long-term cell rounding and loss of re-adherence (169), were used as 
criteria for functional comparisons of the toxicity of ExoS. Two strains of bacteria, 388 
and 388∆S, were used to distinguish the effects of ExoS from other bacterial factors. 
Studies performed in parallel using strain 388∆ExoT confirmed that the cellular effects 
being monitored related to ExoS, and not ExoT, which is also expressed by strain 388 
(data not shown). Our studies identified individual cell line variations in the effects of 
ExoS on cell function, but overall, human epithelial cells examined were more sensitive 
than murine fibroblastic cells to the effects of ExoS on DNA synthesis, morphology and 
cellular adherence. Of these four cell lines, LNCaP epithelial cells were the most 
sensitive to the effects of T3S-T-ExoS, and Swiss-3T3 fibroblasts were the most 
resistant. We also found that decreased sensitivity to ExoS did not relate to decreased 
bacterial association. 
In defining the mechanism for the differential effects of ExoS on cell function, our 
studies focused on ExoS ADPRT activity, rather than GAP activity, since previous 
studies linked toxic effects of T3S-T-ExoS on epithelial cell morphology and DNA 
synthesis to ExoS ADPRT activity (64). ExoS ADPRT activity was functionally evaluated 
based on the efficiency of ADP-ribosylation of cellular substrates. T3S-T-ExoS has been 
found to ADP-ribosylate multiple LMWG-proteins in HT-29 epithelial cells, with Ras and 
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RalA modification detected first, followed by the modification of Rab proteins, then Rac1 
(65). A different pattern of LMWG-protein substrate modification by T3S-T-ExoS was 
detected in murine fibroblasts. Although no differences in Ras modification were evident 
in the two cell types based on SDS-PAGE, differences were detected by two-
dimensional electrophoresis (2DE), with one modification of Ras detected in murine 
fibroblasts (E. A. Rucks, unpublished results), while two or three sites of Ras 
modification have been detected in human epithelial cells (64, 241). Differences in RalA 
modification were also detected, with only one modification of RalA detected in murine 
fibroblasts by SDS-PAGE, while two modifications were evident in human epithelial 
cells. In analyses of Rab proteins, Rab5, Rab7, Rab8 and Rab11 were all modified in 
human epithelial cells, while no modification of Rab proteins was detected in murine 
fibroblastic cell lines. Consistent with previous reports identifying LMWG-protein targets 
of ExoS ADPRT activity in NIH-3T3 fibroblast membranes (26), when murine fibroblastic 
cell extracts were used as a source of endogenous LMWG-proteins in in vitro ADPRT 
reactions using purified ExoS, RalA, Rab proteins and Rac1 were found to be modified 
by ExoS as efficiently as that observed in human epithelial cells. These results support 
the notion that the decreased efficiency of RalA, Rab, and Rac1 modification in murine 
fibroblasts did not relate to intrinsic protein properties, but rather to in situ cellular 
effects.  
The decreased efficiency of LMWG-protein modification in murine fibroblasts 
suggested that the T3S process functioned differently in murine fibroblastic and human 
epithelial cells relative to either the efficiency of ExoS internalization or the action of 
ExoS once it was T3S-translocated. In comparing the efficiency of ExoS internalization 
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in the two cell types, ExoS was found to be translocated as (or slightly more) efficiently 
in murine fibroblasts when compared to human epithelial cells, supporting that the T3S 
apparatus was functional in murine fibroblasts. Consistent with the translocation of 
ExoS through the membrane into cytosol via the T3S apparatus, levels of ExoS ADPRT 
activity and the efficiency of substrate modification was higher in membrane than 
cytoplasmic fractions of all cell lines, as has been previously recognized (64, 188). Our 
analyses of ExoS internalization relied on quantification of ExoS ADPRT activity, rather 
than ExoS protein, for we have had difficulty in detecting ADPRT-active ExoS within 
cells by immunoblot analyses using antibodies against ExoS (64). The more limited 
modification of LMWG-protein substrates in murine fibroblastic cells, in association with 
efficient ExoS internalization, indicated that cellular factors, beyond membrane 
translocation, were influencing the ADP-ribosylation of substrates by ExoS within the 
cell.  
Differences in substrate modification between human epithelial and murine 
fibroblasts prompted us to examine how the pattern of ExoS substrate modification 
related to cell type, the animal origin of the cells, or the state of viral or oncogenic 
cellular transformation. In comparing ExoS substrate modification in murine, rat, 
hamster, simian or human cells, of epithelial, endothelial and fibroblastic cell types, two 
basic patterns of substrate modification were identified. One pattern showed more 
restricted substrate ADP-ribosylation, detecting limited modification of RalA and no 
modification of Rab proteins or Rac1. This pattern was common to rodent cell lines and 
independent of cell type. The second pattern showed more extensive LMWG-protein 
substrate ADP-ribosylation, with T3S-T-ExoS modifying RalA more efficiently and also 
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modifying Rab proteins and Rac1. This pattern was apparent in human and simian cell 
lines, but modification in simian cell lines appeared less efficient. Notably, one human 
cell line, Detroit 532 fibroblasts, was found to have the more limited ExoS substrate 
modification pattern seen in rodent cells. The mechanistic link between the restricted 
ExoS ADPRT substrate pattern observed in Detroit fibroblasts is not known. In 
assessing the role of viral or oncogenic transformation in ADPRT substrate modification, 
no alterations in patterns were detected in any of the cell lines in association with 
cellular transformation. 
The cellular mechanism for the different patterns of ADPRT substrate modification 
is not yet understood. Factors that could alter the substrate specificity of T3S-T-ExoS 
include differences in the subcellular targeting or localization of ExoS within cells and/or 
differences in co-localization of the ExoS eukaryotic cofactor, 14-3-3 protein. Relative to 
the functional co-localization of the 14-3-3 cofactor, based on our in vitro ExoS ADPRT 
reactions, we know that the cofactor is present and functional in murine fibroblastic cell 
extracts which exhibit the more restricted cellular substrate-modification pattern. It has 
also been found that 14-3-3 protein co-localizes to endosomes with Rab4 (15), although 
Rab4 does not appear to be a substrate of ExoS when internalized by the T3S process 
in either epithelial cells (65) or fibroblasts (E. A. Rucks, unpublished observation). 
These data imply that co-localization of 14-3-3 co-factor by itself is not sufficient for 
ExoS substrate ADP-ribosylation. An alternative, more likely explanation for altered 
patterns of ExoS ADPRT substrate modification, based on current available data, is that 
differences in targeting of ExoS within the cell affect its ADPRT substrate specificity. 
Consistent with this hypothesis, both an N-terminal processing site and a membrane 
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localization domain have been identified within the first 78 amino acids of ExoS (176, 
177). These sites appear to influence the subcellular localization of ExoS and may also 
prove to influence the substrate targeting specificity of ExoS ADPRT activity. 
In relating substrate patterns of ADP-ribosylation by T3S-T-ExoS to effects of ExoS 
on cell function, ExoS has previously been found to affect the function of several of its 
LMWG-protein substrates. The ADP-ribosylation of Ras by ExoS is known to interfere 
with guanine nucleotide exchange factor (GEF) catalyzed GDP to GTP exchange, and 
the interaction of Ras with its downstream effector Raf-1 and activation of the MAP-
kinase, Erk-2 (73, 91, 241). In addition, the modification of Ras has been found to 
correlate with the ExoS-dependent inhibition of DNA synthesis (153). RalA is involved in 
signaling processes that affect cell proliferation, vesicular transport and cytoskeletal 
structure (50, 158, 226, 229). Recent studies have shown that the ADP-ribosylation of 
RalA by ExoS interferes with RalA interaction with its downstream effector, Ral binding 
protein 1 (63). Rab proteins control distinct pathways in endocytosis and vesicular 
trafficking which affect membrane recycling (194). In vitro analysis found the ADP-
ribosylation of Rab5 by ExoS to interfere with its ability to bind early endosomal 
autoantigen 1 (EEA1), which retarded endosome-endosome fusion (10), which, in turn, 
could influence the regeneration of adherence procces. Together, these data implicate 
the potential role for ExoS-associated alterations of Ras, RalA and Rab protein function 
to contribute together to the cellular effects of T3S-T-ExoS.  
Consistent with a functional relationship between substrate modification and effects 
of T3S-T-ExoS on cell function, LMWG-protein ADP-ribosylation was more extensive in 
human HT-29 and LNCaP epithelial cells, in association with their greater sensitivity to 
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effects of ExoS on cell growth, morphology and re-adherence, when compared to 
murine fibroblasts. However, while a direct relationship was observed between 
efficiency of substrate modification and increased sensitivity to the effects of T3S-T-
ExoS, an absolute link between patterns of substrate modification and specific cellular 
effects of ExoS was not evident, based on analyses used in our studies. For example, 
effects on DNA synthesis, cell rounding and re-adherence, which were associated with 
human epithelial cell responsiveness to ExoS were also detectable in NIH-3T3 cells, 
which had more limited ExoS substrate modification; albeit the responses of NIH-3T3 to 
T3S-T-ExoS were less severe. We suspect that an inability to observe a direct 
relationship between functional effects of ExoS and specific patterns of substrate 
modification reflects the functional interrelationship of the LMWG-proteins targeted by 
ExoS within the cell. The function of Ras, Ral, Rac and Rab proteins are all linked to 
each other through a hierarchy of cellular network interactions. It therefore might be 
predicted that a more limited pattern of Ras and Ral modification could equate to 
cellular effects associated with more extensive patterns of substrate modification if 
given more time or upon more prolonged exposure to ExoS. Such a dose-response 
functional relationship of ExoS was evident in cellular re-adherence studies in which 
NIH-3T3 cells required a longer exposure to ExoS-producing bacteria than HT-29 cells 
to obtain a similar loss of adherence (Figure 11). While the complexity of cellular 
signaling events might mask distinct relationships between ExoS substrate modification 
and effects on cell function, what is clearly evident in comparisons of different cell lines 
is that the host cell can influence the efficiency of the intracellular targeting of ExoS 
ADPRT activity.  
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We conclude from these studies that the cellular response to T3S-T-ExoS is 
dictated to varying degrees by the host cell targeted by Pa. ADPRT substrate 
modification by T3S-T-ExoS is more restricted in rodent cells, when compared to human 
and simian cells, yet the T3S-T process appears equally efficient in these cells. It 
becomes apparent from these studies that the host cell is not a passive recipient during 
the bacterial driven T3S process, but rather cell properties are able to influence the 
activity and targeting of T3S-effector proteins. 
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Chapter 3: Characterization of an ExoS type III translocation-resistant cell line 
 
 
 
 
 
 
 
Contents of this chapter were published as a Note in the January 2005 (Volume 
73) issue of Infection and Immunity, pages 638-643, and appears with permission from 
the American Society of Microbiology Press and with permission from the authors, E. A. 
Rucks and J. C. Olson. 
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Abstract 
Pseudomonas aeruginosa (Pa) ExoS is a type III secreted (T3S), bifunctional 
protein that inactivates eukaryotic cell function. The co-culture of Pa strains expressing 
ExoS with HL-60 myeloid cells revealed the cell line to be resistant to the effects of T3S-
T-ExoS. Differentiation of HL-60 cells with phorbol 12-myristate 13-acetate (TPA) 
rendered the cell line sensitive to ExoS. To understand the cellular basis for the 
alteration in sensitivity, undifferentiated and TPA differentiated HL-60 cells were 
compared for differences in bacterial adherence, T3S induction, and ExoS T3S-T. 
These comparisons found that ExoS was translocated more efficiently in TPA-
differentiated HL-60 cells than in undifferentiated cells. The studies support the idea that 
the eukaryotic cell has the ability to influence Pa T3S at the level of membrane 
translocation. 
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Introduction 
The type III secretory (T3S) process allows the direct translocation of bacterial 
effector proteins into eukaryotic cells and is associated with the virulence of many 
Gram-negative bacteria (70, 102). Four virulence factors, ExoS, ExoT, ExoU and ExoY, 
are known to be translocated into eukaryotic cells by Pa T3S (258, 260). Unlike many 
Gram-negative bacteria, both clinical and environmental P. aeruginosa isolates maintain 
the T3S system, implying the integral role of T3S to P. aeruginosa survival in general 
(52, 54, 200). Also, consistent with its opportunistic life-style, normal, healthy epithelial 
barriers and monolayers remain resistant to P. aeruginosa infection and T3S (59, 115, 
154). The purpose of these studies is to further understand the cellular basis of host-cell 
resistance to Pa T3S using the type III effector, ExoS, as a tool to monitor T3S. 
In analysis of human epithelial cells, bacterially translocated ExoS (T3S-T-ExoS) 
has been found to cause a general inactivation of host cell function, as recognized by 
effects on cell growth, adherence, morphology and phagocytic processes (66, 169, 170, 
193). ExoS affects eukaryotic cell function through a bi-functional mode of action. The 
N-terminal region of ExoS includes a GTPase activating (GAP) activity (77), which can 
affect eukaryotic cell morphology and phagocytosis (178, 193). The C-terminal region of 
ExoS includes an ADP-ribosyltransferase (ADPRT) activity that targets specific cellular 
proteins, including low molecular weight G- (LMWG-) proteins in the Ras superfamily 
(30, 63, 65, 89, 153). The ADPRT activity of ExoS is required for the irreversible effects 
of ExoS on cellular proliferation, re-adherence and morphology (64, 169).  
This study focuses on the effects of T3S-T-ExoS on HL-60 myeloid cell function. 
The HL-60 cell line originated from peripheral blood leukocytes of a patient with 
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promyelocytic leukemia (32). When treated with specific compounds, HL-60 cells can be 
induced to terminally differentiate into granulocytes or monocytes (33, 134). We found 
HL-60 cells to be resistant to the toxic effects of ExoS in their undifferentiated form. 
However, upon differentiation with TPA, HL-60 cells became sensitive to ExoS. The 
identification of a T3S-T-resistant cell line that can be induced to become T3S-T-
sensitive provides a model system for studying eukaryotic cell factors that influence the 
establishment of a functional Pa T3S process. 
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Materials and Methods 
Bacterial strains and culture conditions. Pa strains used in this study include:  i) 
the prototype ExoS producing strain, 388 (106), ii) an isogenic ExoS mutant 388∆exoS 
(388∆S) (126), iii) strain 388∆popD::Tc* (388∆PopD), which lacks production of the 
PopD T3S translocation protein (236), and strain 388exs1::Tn1 (388-11), which contains 
a Tn1 insertion in the pscC gene, predicted to encode an outer membrane component 
of the Pa T3S process (60, 119, 258). All Pa strains were provided by Dara Frank 
(Medical College of Wisconsin, Milwaukee, WI). Strain PA103∆exoU,exoT::Tc 
(PA103∆UT), a derivative of strain PA103, which lacks production of T3S effectors, 
ExoU, ExoS, ExoT and ExoY (235), served as the host strain for production and T3S 
translocation of pUCP encoded hemagglutinin-tagged ExoS (ExoS-HA). ExoS-HA was 
provided by Joseph Barbieri (Medical College of Wisconsin, Milwaukee, WI).  
To allow induction and T3S-translocation of ExoS, P. aeruginosa were cultured in 
T3S-induction medium (TSBD-N) (106) for 16 hours prior to co-culture with eukaryotic 
cells. In preparation for co-culture, bacteria were diluted based on OD590 to 107 cfu/ml, 
as previously described (170) in RPMI 1640 medium (Gibco-BRL, Gaithersburg, MD) 
supplemented with 0.6% bovine serum albumin (Sigma, St. Louis, MO) (RPMI-BSA) 
and were added to eukaryotic cells at a multiplicity of infection (MOI) of approximately 
30:1, unless otherwise indicated. 
Eukaryotic cell culture. The non-adherent HL-60 human leukemia cell line was 
obtained from the American Type Culture Collection (ATCC, CCL 240, Manassas, VA) 
and maintained in RPMI 1640 medium containing 10% or 20% fetal bovine serum and 
100 U/ml penicillin and 100 µg/ml streptomycin (Gibco-BRL) (RPMI-FBS) at 37ºC in 5% 
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CO2-95% air. In preparation for culture with bacteria, HL-60 cells were centrifuged for 
10 min at 400 g and seeded at 5 x 105 cells/ml in either polystyrene tubes or tissue 
culture plates, 48 hours prior to the addition of bacteria (Costar, Cambridge, MA). HL-60 
cells were differentiated into mature monocytes by the addition of 20 ng/ml TPA 
(phorbol 12-myristate 13-acetate) (Sigma) to cell culture medium and incubation for 48 
hours (111) (TPA-HL-60). For co-culture studies, cell medium was replaced with RPMI-
BSA containing no bacteria or 107 cfu/ml bacteria, then cultured for 3 to 6 hours, as 
indicated, and assayed for changes in cell function and internalization of ExoS, as 
described below. 
Effects of T3S-T-ExoS on cell function. 
i) Quantification of DNA synthesis. Following a 3 to 4 hour co-culture period, cells 
were washed with phosphate buffered saline (PBS) and pulsed for 20 hours with 1 
µCi/ml of [methyl-3H]thymidine (25 mCi/mmol; Amersham Life Sciences, Arlington 
Heights, IL) in RPMI-FBS containing 200 µg/ml gentamicin (Sigma) and 100 µg/ml of 
ciprofloxacin (Bayer, West Haven, CT) (RPMI-FBS-GC). DNA synthesis was quantified 
as previously described (170) and is reported as percent [3H]thymidine incorporation 
relative to non-bacterial treated cells.  
ii) Examination of cellular morphology by scanning electron microscopy 
(SEM). Prior to co-culture with bacteria, HL-60 cells were seeded at 106 cells/ml on 12 
mm-diameter glass Thermanox coverslips (Nalge Nunc, Naperville, IL) and cultured for 
48 hours in 35 mm tissue culture dishes, in the presence or absence of TPA. Following 
a 3.5 hour co-culture period, bacteria were removed; cells were fixed with 2% 
cacodylate glutaraldehyde for 30 min as a primary fixative then with 2% acqueous 
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osmium tetroxide for 30 min as a secondary fixative. Samples were rinsed with distilled 
water, dehydrated with 100% ethanol and incubated with hexamethyldisilazane (Sigma) 
until dry. The samples were then mounted and sputter-coated with gold palladium (20-
nm coating) and examined using a JEOL SEM-LV5410 scanning electron microscope. 
ADP-ribosylation of LMWG-proteins by T3S-T-ExoS. ADP-ribosylation of 
LMWG-proteins of undifferentiated or TPA-HL-60 cells was assessed based on altered 
protein mobility following a 4 hour co-culture period with strain 388, 388∆S or no 
bacteria, as previously described (63, 65, 153) (Chapter 2, Methods and Materials). 
Bacterial association with HL-60 cells. Effects of TPA differentiation on bacterial 
adherence to HL-60 cells were assessed after a 4 hour co-culture period of HL-60 or 
TPA-HL-60 cells with strains 388 or 388∆S, at a high MOI (100:1) to optimize detection 
of bacterial association. Bacteria were removed and cells were washed three times with 
HEPES buffered saline (HBS) (137 mM NaCl; 4 mM KCl; 10 mM HEPES, pH 7.4; 11 
mM glucose). Bacterial association was quantified by lysing cells in PBS containing 
0.25% Triton X-100, diluting samples 1:1000 and plating 50 µl of lysate onto LB agar 
plates. Bacterial colonies were counted 24 hours later and the number of bacteria per 
eukaryotic cell was calculated. 
Monitoring induction Pa T3S process. To assess T3S induction, strains 388 and 
388∆PopD were cultured in a non-T3S induction medium (TSBD supplemented with 5 
mM CaCl2) prior to co-culture with eukaryotic cells. Undifferentiated or TPA-HL-60 cells 
were then co-cultured with or without bacteria for 4 hours, in Hanks Balanced Salt 
Solution (Sigma), which was found to minimize background induction of PopD and 
maintain eukaryotic and bacterial cell growth. After a 4 hour co-culture period, Laemmli 
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sample buffer was added to co-culture wells, to harvest both, i) cell pellets containing 
eukaryotic cells and associated bacteria, and ii) co-culture supernatants containing 
bacteria and secreted proteins, within the same sample. Samples were heated at 95o C 
for 5 min, resolved by SDS-PAGE, immunoblotted using an anti-PopD antibody 
(provided by Dara Frank), and visualized by ECL. Comparable eukaryotic cell growth 
and protein loading were confirmed by immunoblotting for the eukaryotic housekeeping 
enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Chemicon International 
Inc., Temecula, CA). 
T3S-T of ExoS into HL-60 cells.  
i) Detection of T3S-T-ExoS ADPRT activity. Undifferentiated and TPA-HL-60 cells 
were co-cultured with strains 388 or 388∆S for 3, 4.5 or 6 hours, at a low MOI (<10:1) to 
facilitate detection of differences in the efficiency of ExoS translocation. Bacteria were 
removed, cells were washed, treated with 0.5% trypsin/0.53 mM EDTA (trypsin-EDTA) 
(Gibco-BRL) to proteolyze extracellular ExoS, then were lysed in 0.2% saponin, 100 
mM NaCl, 250 mM sucrose, 5 mM EDTA, containing the protease inhibitor, P8340 
(Sigma). Cellular lysates were centrifuged at 16,000 g for 20 min to obtain the cytosolic 
(supernatant) fraction. The TX-100 soluble membrane fraction was obtained by treating 
cellular pellets with 1% TX-100 and vortexing for 15 sec every 5 min for 20 min, then 
centrifuging at 16,000 g for 10 min. ExoS ADPRT activity was quantified in an in vitro 
ADPRT reaction, using soybean trypsin inhibitor (SBTI) as substrate, as previously 
described (54, 117, 186). ExoS ADPRT activity in cellular fractions was calculated 
relative to total protein determined using the Sigma Diagnostics Lowry-based protein 
assay (Sigma). To compare ExoS ADPRT activity to substrate modification, an aliquot 
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of each fraction was analyzed by SDS-PAGE and immunoblotted for RalA, Rab5 and 
Rac1, as described previously.  
ii) Detection of T3S-T-ExoS protein. T3S-T-ExoS was detected using HA-tagged 
ExoS (ExoS-HA). In these studies, undifferentiated and TPA-HL-60 cells were co-
cultured for 4 hours with strain PA103∆UT expressing ExoS-HA.  Cells were washed 
and lysed in a digitonin extraction buffer (0.01% digitonin, 10 mM Pipes, 300 mM 
sucrose, 100 mM NaCl, 3 mM MgCl2, 5 mM EDTA) and separated into cytosolic and 
membrane fractions by centrifugation at 16,000 g for 15 min at 4ºC. Cytosolic and 
membrane fractions were equilibrated relative to volume in Laemmli sample buffer, 
samples were resolved by SDS-PAGE, immunoblotted using 2 µg/ml anti-HA antibody 
(Upstate Biotechnology, Lake Placid, NY) and visualized using ECL. Comparable 
eukaryotic cell protein loading was assessed by immunoblotting for GAPDH. 
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Results 
Induction of HL-60 cell sensitivity to ExoS. As part of a series of experiments 
examining the effects of T3S-T-ExoS on different cell types, the effects of ExoS on HL-
60 cell function were assessed in co-culture studies comparing Pa strain 388 and the 
isogenic non-ExoS producing strain, 388∆S. Using [3H]thymidine incorporation as a 
measure of cellular proliferation (170), exposure to Pa bacteria was found to cause an 
approximate 45% inhibition of HL-60 DNA synthesis. However, no ExoS specific effect 
on DNA synthesis was detected (strain 388 caused a 45.0% ± 2.0% and strain 388∆S 
caused a 44.7% ± 2.0% inhibition). Unlike epithelial cells, HL-60 cells have a round 
morphology, which precludes the use of cell rounding as a measure of the effects of 
ExoS on cell morphology. Instead, scanning electron microscopy (SEM) was used to 
examine whether ExoS alters cell surface structures. We previously detected that T3S-
T-ExoS caused microvilli effacement in HT-29 epithelial cells (169). After a 3.5 hour co-
culture period, no alteration in HL-60 cell surface structure was evident following 
treatment with strain 388 (Figure 16 A). The lack of ExoS-specific effects on DNA 
synthesis and cell morphology suggested that HL-60 cells were resistant to the effects 
of T3S-T-ExoS.  
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Figure 16. SEM analysis of the morphological effects of ExoS on HL-60 or TPA-
HL-60 cells. 
HL-60 cells were seeded on glass cover slips in 35 mm tissue culture dishes and 
cultured for 48 hours in the absence (A) or presence (B) of 20 ng/ml TPA. Cell 
monolayers were washed and cultured with 388∆S, 388 or no bacteria for 3.5 hours. 
Bacteria were removed and cells were fixed, sputter coated with gold, and examined 
using a JOEL SEM-LV5410 scanning electron microscope. Noted in comparisons of 
these images is the loss of microvilli in TPA-HL-60 cells upon exposure to ExoS-
producing bacteria. 
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To assess whether HL-60 cell-sensitivity to ExoS could be altered by treatments 
that induce differentiation, cells were terminally differentiated into adherent monocytes 
by treatment with TPA, then co-cultured with strains 388, 388∆S or no bacteria, as 
above. Terminal differentiation of eukaryotic cells halts cellular proliferation, thereby 
precluding the examination of effects of ExoS on the cellular proliferation of TPA-HL-60 
cells. In SEM analyses, exposure of TPA-HL-60 cells to ExoS producing strain 388 
resulted in an increased loss of cell surface microvilli, when compared with TPA-HL-60 
cells exposed to 388∆S or no bacteria. The effect of strain 388 on cell-surface microvilli 
provided an initial indication that TPA differentiation altered HL-60 cell sensitivity to 
T3S-T-ExoS. Notably, cell membrane ruffling, which was induced in HL-60 cells by 
TPA-treatment, was still evident following exposure to ExoS-producing bacteria. These 
results support that TPA treatment induced alterations in HL-60 cell sensitivity to T3S-T-
ExoS, but effects of ExoS on cell structure were preferentially targeted to microvilli 
projections.  
TPA-induced alterations in HL-60 cell sensitivity to T3S-T-ExoS were also 
recognized at the level of ExoS ADPRT substrate modification. The ADP-ribosylation of 
LMWG-proteins by ExoS has previously been found to be lead to alterations in protein 
mobility, based on SDS-PAGE analyses (30, 63, 65, 89, 153). When TPA-HL-60 cells 
were co-cultured with strain 388, 388∆S or no bacteria for 4 hours and analyzed for 
ADP-ribosylation of LMWG-proteins, shifts in the mobility of Ras, RalA, Rab proteins 
and Rac1 were apparent (Figure 17). In comparison, only a slight modification of Rab 
proteins was detected in undifferentiated HL-60 cells co-cultured with strain 388.  
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Figure 17. ExoS ADPRT substrate modification in HL-60 and TPA-HL-60 cells. 
HL-60 cells were cultured for 48 hours in the presence or absence of TPA, prior 
to co-culture with strain 388∆S (∆S) or 388 for 4 hours. Bacteria were removed, and 
cells were processed and analyzed for ADP-ribosylation of the indicated LMWG-
proteins based on altered mobility by SDS-PAGE and immunoblot analyses. Results are 
representative of at least 3 independent experiments. ADP-ribosylated (M) and 
unmodified (U) proteins are labeled. 
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The studies support that TPA differentiation induces HL-60 cell sensitivity to T3S-T-
ExoS as evident in ExoS ADP-ribosylation of cellular proteins, which correlate with 
alterations in microvilli structure. 
Mechanisms of induction of ExoS sensitivity. Although ExoS is secreted by Pa 
into culture supernatants, it is not toxic to eukaryotic cells in the absence of a T3S 
appartus (170, 258). Possible mechanisms by which TPA could induce alterations in 
sensitivity to ExoS include: i) indirect effects on T3S that facilitate bacterial adherence 
or non-T3S mediated diffusion of ExoS into cells, or ii) through direct effects on T3S that 
alter the induction or efficiency of the T3S-T process.  
i) Indirect mechanisms. To examine whether TPA treatment induces cell surface 
alterations that enhance Pa adherence, rendering HL-60 cells more sensitive to the 
bacterial contact-mediated T3S process, bacterial association to non-differentiated and 
TPA-HL 60 cells was assayed. In these studies, cells were co-cultured with strain 388 or 
388∆S for 4 hours at a high MOI (100:1) to facilitate detection of bacterial association. 
Using a plating assay to quantify bacterial association, 25.8 ± 2.6 bacteria were found to 
associate per undifferentiated HL-60 cell, which compared with 8.5 ± 0.8 bacteria per 
TPA-HL-60 cell. In similar comparisons of 388 and 388∆S, bacterial association to 
eukaryotic cells was not significantly altered with ExoS expression (data not shown). 
The results indicate that TPA treatment did not affect HL-60 membrane properties in a 
manner that enhanced bacterial association with cells.  
Another means by which TPA-treatment might indirectly affect ExoS internalization 
is through alterations in membrane properties that allow direct diffusion of ExoS into 
cells. To examine this possibility, TPA-HL-60 cells were cultured with soluble ExoS for 
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4.5 hours in the presence and absence of bacteria. In addition to strains 388 and 
388∆S, these studies included the T3S mutant strains, 388-11 (a PscC mutant defective 
in T3S-mediated secretion and translocation (258)) and 388∆PopD (a PopD mutant 
defective in T3S-mediated translocation, but not secretion (236)) to assess ExoS 
diffusion independently of a functional T3S-process. Previous studies have shown that 
in the absence of PscC and PopD, ExoS is unable to exert toxic effects on eukaryotic 
cell function (169, 236). To allow an endogenous form of ExoS to be evaluated in these 
studies, strain 388 culture supernatant (500 µl) containing 1.1 µg of ExoS in the 
presence of other Pa secreted factors, served as the source of ExoS. Using ExoS ADP-
ribosylation of cellular substrates to detect ExoS internalization, no substrate 
modification was detected in TPA-HL-60 cells cultured with soluble ExoS in the 
presence of strain 388∆S, 388-11 or 388∆PopD (data not shown). In addition, no 
enhancement of ExoS substrate modification was detected when soluble ExoS was 
added to TPA-HL-60 cells co-cultured with strain 388. The results support that TPA 
treatment does not alter HL-60 membrane integrity in a manner that allows ExoS 
internalization independently of the TTS process.  
ii) Direct mechanisms. Differences in the sensitivity of undifferentiated and TPA-
HL-60 cells to ExoS might also relate to alterations in cellular properties that affect host-
cell induction of the T3S process. Prior to coculture, strains 388 and 388∆PopD were 
cultured in medium that does not allow T3S induction (TSBD supplemented with 5 mM 
CaCl2). Bacteria were then co-cultured with HL-60 or TPA-HL-60 cells for 4 hours in 
Hanks balanced salt solution (Sigma). Total PopD was examined by adding 4X Laemmli  
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Figure 18. Analysis of PopD induction by HL-60 and TPA-HL-60 cells. 
HL-60 cells were cultured in the presence or absence of TPA for 48 hours prior to 
co-culture with strains 388 or 388∆PopD (∆D) for 4 hours, then processed and resolved 
by SDS-PAGE and immunoblotted for PopD and GAPDH. Bacterial supernatant 
obtained from strain 388 cultured in inducing medium was used as a positive control 
(SN). Results are representative of at least three independent experiments. (–) HL-60, 
bacterial strains cultured in co-culture medium for 4 hours in the absence of eukaryotic 
cells. 
92 
sample buffer (129) to tissue culture wells, which allowed the combined harvest of 
eukaryotic cells, bacteria and co-culture supernatants. Cells treated with strain  
388∆PopD, no bacteria or bacteria cultured in the absence of eukaryotic cells served as 
negative controls in these experiments. As shown in Figure 18, the induction of PopD by 
HL-60 cells closely corresponded to that of TPA-differentiated HL-60 cells. These 
results confirm that undifferentiated HL-60 cells are effective in inducing T3S 
components, which mediate T3S-T. 
Collectively, these data point to the likelihood that the increased sensitivity of TPA-
HL-60 cells to ExoS relates to an increased efficiency of ExoS T3S-T. To assess the 
efficiency of ExoS translocation in HL-60 and TPA-HL-60 cells, time-course, co-culture 
studies were performed, examining ExoS ADPRT activity in cytosolic and Triton X-100 
membrane soluble fractions. In these analyses, ExoS ADPRT activity was found to be 
5-6 fold higher in both the cytosolic and TX-100 membrane fractions of TPA- HL-60 
cells, as compared to that of undifferentiated HL-60 cells (Figure 19 A). The efficiency of 
ExoS ADPRT internalization was also found to directly correlate with the degree of 
ExoS ADPRT substrate modification (Figure 19 B). ADP-ribosylation of RalA, Rab5 and 
Rac1 was most efficient in the TX-100 membrane fractions of TPA-HL-60 cells, in 
association with the highest levels of ExoS ADPRT activity. Rab5 modification was less 
efficient and Rac1 was not modified in the cytosolic fraction of TPA-HL-60 cells in 
association with lower levels of ExoS ADPRT activity in these fractions. RalA 
modification could not be assessed since it was not detected in the cytosolic fraction. 
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Figure 19. Time-course analysis of T3S-T-ExoS ADPRT activity and substrate 
modification. 
HL-60 and TPA-HL-60 cells were co-cultured with strain 388 or 388∆S for 3, 4.5 
or 6 hours. Bacteria were removed, cells were washed, and cytosolic and Triton X-100 
(membrane soluble) fractions were obtained, as described in Materials and Methods. A. 
Internalized ExoS ADPRT activity. ADPRT activity is reported as fmol per min of ADP-
ribose incorporated into the artificial substrate (SBTI) per µg of cellular protein, and the 
mean and standard deviation of assays performed in duplicate are shown. B. ExoS 
ADPRT substrate modification. Cell fractions in (A) were examined for ExoS ADP-
ribosylation of eukaryotic LMWG-proteins by resolution by SDS-12% PAGE and 
immunoblot analysis using RalA, Rab5 and Rac1 antibodies. ADP-ribosylated (m) and 
unmodified proteins (u) are labeled. The results are representative of 3 independent 
experiments. 
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Minimal substrate modification was detected in the membrane fractions of 
undifferentiated HL-60 cells, as would be predicted based the limited ExoS ADPRT 
activity detected in these samples. Only a slight modification of Rab5 was detected after 
a 4.5 hour co-culture time. No ADP-ribosylation of cellular substrates was detected in 
the cytosolic fraction of undifferentiated HL-60 cells.  
To further assess intracellular ExoS, undifferentiated HL-60 cells and TPA-HL-60 
cells were co-cultured with Pa strain PA103∆UT expressing ExoS-HA (176). We have 
previously been unable to detect T3S-T-ExoS protein in eukaryotic cells by Western blot 
analysis (64, 197). However, the addition of the HA-tag to ExoS allowed detection of 
T3S-T-ExoS in eukaryotic cell extracts, without reported effects on ExoS function (176). 
Consistent with studies quantifying the internalization of ExoS ADPRT activity, ExoS 
protein was found predominately in the membrane fraction of TPA-HL-60 cells (Figure 
20 A). Confirming TPA-HL-60 internalization of ExoS, the T3S-T-ExoS was detected in 
the cytosolic fraction of TPA-HL-60 cells. As shown in Figure 20 B, levels of T3S-T-
ExoS correlate with the efficiency of Rab5 ADP-ribosylation in the respective fractions. 
These results are consistent with the resistance of HL-60 cells to ExoS relating to the 
less efficient ExoS translocation, and that TPA differentiation induces cellular changes 
that allow a functional T3S apparatus to form and translocate ExoS. 
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Figure 20. T3S-T of ExoS protein into HL-60 and TPA-HL-60 cells. 
Cytosolic (C) and membrane (M) fractions of undifferentiated HL-60 or TPA-HL-60 
cells were obtained by digitonin extraction and centrifugation. Fractions were resolved 
by SDS-PAGE and immunoblotted with (A) anti-HA antibody to detect ExoS-HA and (B) 
anti-Rab5 antibody to detect ExoS ADPRT substrate modification. Modified (M) and 
unmodified (U) Rab5 proteins are labeled. ExoS-HA, obtained from T3S-induced 
bacterial culture supernatants (SN), was included as a positive control. 
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Discussion 
It has become evident from studies of different cell lines that the host cell can 
influence the effectiveness of Pa T3S. Polarized confluent epithelial monolayers remain 
resistant to Pa infection and T3S, but become sensitive to both when the epithelial layer 
is compromised (58, 154, 182). The host cell can also influence the toxicity and 
substrate targeting of T3S effectors, as evident in decreased ExoS toxicity, in 
association with alterations in LMWG-protein substrate modification patterns (192, 197). 
In studying the effects of ExoS on the promyelocytic HL-60 cell line function, we 
identified another cell line that was resistant to Pa T3S. A notable finding relative to HL-
60 cells was that sensitivity to T3S-T-ExoS could be induced by treatment with the 
phorbol ester, TPA. 
Treatment of spherical, non-adherent HL-60 cells with TPA induces their 
differentiation into mature adherent monocytes that exhibit microvilli, pseudopodia and 
lamellipodia on their cell surface. Induction of HL-60 T3S-T-sensitivity by TPA treatment 
was initially recognized morphologically, by a loss of microvilli, with little or no change in 
expression of pseudopodia or lamellipodia following exposure to T3S-T-ExoS. Previous 
studies have linked effacement of microvilli to toxic effects of T3S-T-ExoS on actin 
cytoskeleton structure in epithelial cells and macrophages (66, 169, 192). Functional 
effects of T3S-T-ExoS on microvilli structure in TPA-HL-60 cells correlated with the 
increased internalization of ExoS-HA and increased ExoS ADP-ribosylation of LMWG-
proteins. Our studies support that HL-60 resistance to T3S-T-ExoS relates to the lack of 
efficient ExoS translocation and corresponding ExoS ADPRT substrate modification, 
which can be induced by treatment with TPA. 
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Several mechanisms were tested to explain the higher levels of T3S-T-ExoS in 
TPA-HL-60 vs. HL-60 cells. These included: i) alterations in the efficiency of bacterial 
adherence to HL-60 cells, which is required for T3S-T, ii) alterations in host cell 
induction of T3S proteins, or iii) TPA-induced membrane alterations that allow direct 
internalization of ExoS, independently of the T3S apparatus. None of these 
mechanisms accounted for the differences in the effects of ExoS on cell function and 
ADP-ribosylation of substrates in HL-60 and TPA-HL-60 cells. Another possible 
mechanism that might explain the decreased levels of T3S-T-ExoS in HL-60 cells is an 
increased rate of ExoS degradation. Studies examining this possibly also provided 
negative results. In in vitro ExoS ADPRT reactions, purified ExoS was found to 
efficiently ADP-ribosylate LMWG-proteins in HL-60 cell lysates, as previously reported 
(30), and ExoS was not degraded or its activity inhibited by endogenous HL-60 proteins 
(data not shown). Similarly, treatment of HL-60 cells or TPA-HL-60 cells with the 
irreversible proteasome inhibitor MG132 (Sigma) or protease inhibitors did not enhance 
T3S-T-ExoS ADPRT substrate modification in either cell line (data not shown). 
Alternatively, in support of HL-60 cell resistance to T3S-T-ExoS occurring at the level of 
membrane translocation, time course analyses revealed only a minimal increase in 
ExoS ADPRT activity in the membrane fraction of HL-60 cells with time, and no activity 
was detected within the cytosol. In comparison, a linear increase in ExoS ADPRT 
activity was detected in the membrane fraction of TPA-HL-60 cells with time, and 
detectable but smaller amounts translocated into the cytosol. Similar results were 
obtained from tracking bacterial translocation of ExoS-HA. Combined, these data 
indicate that the differential sensitivity of HL-60 and TPA-HL-60 cells to ExoS reflect 
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cellular influences on the Pa T3S-T, rather than cellular properties that affect membrane 
permeability, bacterial adherence, T3S-T-induction or ExoS degradation. 
While these studies provided evidence that TPA differentiation of HL-60 cells 
altered cell line responsiveness to T3S-T-ExoS, the mechanism for this transition 
remains unknown. TPA induces HL-60 cells to differentiate into mature macrophages by 
activating protein kinase C (PKC) signaling pathways (232) and increasing protease 
activity (14). A hallmark of TPA differentiation is the ability of the cells to adhere to one 
another and to tissue culture substrates. This suggests the potential for TPA to induce 
alterations in HL-60 cell surface components that might affect T3S-responsiveness. 
Several receptors for Pa have been identified, including the cystic fibrosis 
transmembrane regulator (CFTR) (75, 180), asialo-GM1 (34, 41, 87, 123) and β1 
integrins (182, 195). However, the identity of the eukaryotic receptor that is required for 
Pa T3S-eukaryotic host cell interaction remains unknown. Interestingly, bacterial 
association with TPA-HL-60 cells decreases when compared to that of HL-60 cells, 
which might seem contradictory to the increased T3S-sensitivity of TPA-HL-60 cells. 
However, this could also be an indication that Pa adherence to TPA-HL-60 cells is more 
T3S-specific. Of note, candidate T3S-interactive proteins, such as α5β1 integrins and 
intracellular adhesion molecules-1 (ICAM-1) show enhanced expression and avidity, 
respectively, in response to TPA differentiation (14, 131, 195). Together, these draw 
attention to the potential use of comparisons of HL-60 and TPA-HL-60 cells to identify 
T3S-specific eukaryotic cell interactive components. 
Currently, little is known about the host cell contribution to Pa T3S. Studies 
described here identify a link between HL-60 cell resistance to T3S-T-ExoS to host cell 
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properties that prohibit the establishment of a functional T3S apparatus. While the 
mechanism for this T3S-resistance is not known, it appears to be reversed by 
treatments that affect cell dynamics and motility. Also of particular relevance to these 
studies is the identification of a T3S-resistant HL-60 cell line, which can be induced to 
become T3S-sensitive, and in so doing provides a model system to study eukaryotic cell 
mechanisms associated with alterations in Pa T3S-sensitivity. 
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Chapter 4: Contribution of the host cell to the molecular targeting of type III 
translocated ExoS 
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Abstract 
Both the GTPase activating activity (GAP) and the ADP-ribosyltransferase activity 
(ADPRT) of bacterially translocated ExoS (T3S-T-ExoS) target low molecular weight G-
proteins (LMWG-proteins) within the eukaryotic cell, which leads to interference of host 
cell function. We have identified differences in host cell responsiveness to ExoS, which 
now allows ExoS to be used as a tool to elucidate mechanisms by which the host cell 
can modulate Pa T3S effector function. Previous studies defined two main patterns of 
ExoS ADP-ribosylation: 1) a more restrictive pattern common to rodent cell lines, 
recognized as a less efficient modification of Ras and RalA, and 2) a more extensive 
pattern common to simian and human cell lines, recognized as a more efficient 
modification of Ras, RalA, Rabs 5, 7, 8 and 11, and Rac1. Residues 51-72 of ExoS 
define a membrane localization domain (MLD), which targets T3S-T-ExoS to eukaryotic 
membranes. Deletion of the MLD resulted in relocalization of ExoS to the cytosolic 
fraction. To examine the molecular basis for differences in ExoS substrate patterns, 
ExoS with mutations in its MLD (∆MLD), GAP (R146) and ADPRT (E379, E381) 
activities were examined for their influence on intracellular targeting of ExoS ADPRT 
activity. T3S-T-ExoS∆MLD and T3S-T-ExoS-E381A produced a restrictive pattern of 
substrate modification in human cell lines, but the mutations did not severely alter the 
targeting of T3S-T-ExoS ADPRT activity in rodent cell lines. In comparison, T3S-T-
ExoS-E379A was unable to ADP-ribosylate eukaryotic proteins. Mutation in the GAP 
region resulted in increased intracellular levels of T3S-T-ExoS, indicating the role of this 
region on translocation or clearance of ExoS. Together these studies identify molecular 
signals within ExoS that influence the targeting of its ADPRT activity and find that these 
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signals are interpreted differently in human and rodent cell lines. To understand the 
mechanism for the differential targeting of ExoS ADPRT activity within human and 
rodent cell lines, T3S-T-ExoS was co-immunoprecipitated from human and rodent cells. 
Differences in T3S-T-ExoS protein interactions were observed, providing a means to 
understanding differences in T3S-T-ExoS intracellular trafficking mechanisms. 
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Introduction 
Pa utilizes the type III secretion (T3S) system to translocate the virulence factor, 
ExoS, into eukaryotic cells (258). T3S-translocation (T3S-T) of ExoS escalates tissue 
damage in an acute lung infection model (212) and inactivates cell function in a tissue 
culture model of infection (169). Specifically, in analysis of human epithelial cells, T3S-
T-ExoS inhibits cell growth and adherence and causes permanent cell rounding (66, 
169). In J774 macrophages, T3S-T-ExoS protects Pa from phagocytosis (192). The 
complex, suppressive effects of T3S-T-ExoS on cell function are attributed to its 
bifunctional mode of action. The N-terminal portion of ExoS includes a GAP activity, 
which targets Rho, Rac and Cdc42, (77) and is required for the T3S-T-ExoS 
antiphagocytic phenotype (192). The C-terminal region of the molecule includes the 
ADPRT activity (117), which preferentially targets LMWG-proteins within eukaryotic 
cells (63, 65, 89), and is required for the effects of T3S-T-ExoS on DNA synthesis, 
adherence and permanent cell rounding (64). 
Subsequent studies have identified two main patterns of T3S-T-ExoS substrate 
ADP-ribosylation (197). The first, more restrictive, pattern is observed when ExoS is 
bacterially translocated into cells of rodent origin, which results in limited ADP-
ribosylation of Ras and RalA. The second, more extensive, pattern is observed when 
ExoS is bacterially translocated into cells of human or simian origin, which results in 
more efficient ADP-ribosylation of Ras, RalA, in addition to ADP-ribosylation of Rab5, 
Rab8, Rab11, Rab7 and Rac1. These findings suggest that the eukaryotic cell 
influences the intracellular targeting of T3S-T-ExoS ADPRT activity. 
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Integral to understanding the molecular mechanism of action of T3S-effector 
proteins is linking their functional activity to intracellular localization. To date little is 
known or understood about how T3S-T-ExoS is trafficked within the eukaryotic cell. 
Previous studies reported that T3S-T-ExoS ADP-ribosylates Rab proteins in a time 
course dependent manner (65). However, Rab proteins are not targeted in rodent cell 
lines, suggesting a link between assessiblity to vesicular trafficking mechanisms and the 
targeting of ExoS ADPRT activity. Other studies have indicated that transfected, 
enzymatically inactive ExoS is trafficked to the perinuclear region of eukaryotic cells 
(177). Recently, a membrane localization domain (MLD) was identified in the N-terminal 
region of ExoS, between amino acids 51 and 72. This region targets T3S-T-ExoS to 
eukaryotic membranes (176). The effect of this domain on ExoS subcellular localization 
is consistent with studies, which found that T3S-T-ExoS ADPRT is enhanced in 
membrane fractions of eukaryotic cells (64, 188, 197). 
In order to ADP-ribosylate substrates, ExoS requires a eukaryotic factor, a member 
of the14-3-3 family of proteins (68). 14-3-3 proteins are ubiquitously expressed in all 
eukaryotes and are responsible for the subcellular localization, stability and molecular 
activity of over 100 target proteins (46). While it is unknown with which 14-3-3 isoform(s) 
T3S-T-ExoS interacts within the eukaryotic cell, all isoforms are capable of stimulating 
ExoS ADPRT in vitro (268). Differences in substrate modification patterns in rodent 
versus human cells may be linked to potential host cell influences on T3S-T-ExoS 
subcellular localization and differential trafficking patterns, either through the vesicular 
network or 14-3-3 interactions. The goal of these studies is to characterize differences 
in intracellular targeting of T3S-T-ExoS. 
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We were able to explore the mechanism by which the host cell influences the 
intracellular activity of T3S-T-ExoS using MLD, GAP or ADPRT mutant forms of ExoS. 
Studies, which compare rodent and human cell lines, highlight the role of 1) the MLD in 
ExoS localization and substrate modification, 2) the GAP domain on T3S-T of ExoS, 3) 
the E379, E381 catalytic residues in ADPRT function, and 4) differences in protein 
interactions with T3S-T-ExoS in rodent and human cell lines. 
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Materials and Methods 
Bacterial strains and culture conditions. 
Strain T3S 
T3S-
T 
ExoS ExoT ExoU ExoY Reference
388 + + + + - + (106) 
388∆S + + - + - + (126) 
388∆PopD + - + + - + (235) 
38811 - - + + - + (258) 
PA103∆UT + + - - - - (235) 
Table 2. Pa strain phenotypes 
The + and – symbols indicate the presence or absence of the indicated phenotype, T3S, 
T3S-T or expression of the indicated T3S effector. 
 
Pa strains used were cultured as described in Chapters 2 and 3. Bacteria were 
added to eukaryotic cells at an MOI of 50-100. The phenotypes of the strains used in 
these studies are shown in Table 1. PA103∆UT strains expressing pUCP plasmid 
encoded ExoS and ExoS with mutations in the GAP (R146A) and/or ADPRT (E379A or 
E381A) were constructed as previously described (64, 141, 235). 
Construction of ExoS-HA mutants 
To assess how catalytic regions of ExoS affect its T3S-T, mutants of ExoS GAP 
and/or ADPRT activities were constructed using the pUCPExoS-HA template. pUCP 
vectors (211) encoding ExoS with an hemagglutinin tag (ExoS-HA) and ExoS with a 
deletion in the membrane localization domain (MLD) (residues 51-72) (ExoS∆MLD-HA) 
were kindly provided by Joseph Barbieri (Medical College of Wisconsin, Milwaukee, WI) 
(176). The pUCPExoS-HA encodes a PstI-BamHI fragment of ExoS cloned from strain 
388 (126, 258). When pUCPExoS-HA is expressed in strain PA103∆UT, it allows the 
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T3S-T of ExoS in the absence of other known T3S effectors. The addition of the HA tag 
to ExoS allows T3S-T-ExoS to be detected within eukaryotic cells by Western blot 
analysis, without affecting ExoS function (176). The R146A GAP mutation was 
introduced to pUCPExoS-HA (pUCPExoS-R146A-HA), essentially as previously 
described (64), using the QuikChange PCR-based site-directed mutagenesis system 
(Stratagene, La Jolla, CA). The primers used to introduce the mutation (indicated in 
bold) and an NheI restriction site (underlined) were as follows: forward, 5’-
CGGAGATGGGGCGCTAGCTTCGCTGAGCACCG-3’, and reverse, 5’-
CGGTGCTCAGCGAAGCTAGCGCCCCATCTCCG-3’. PCR reaction mixtures 
contained 200 ng of plasmid DNA, 25 µM primers, 625 µM mixture of deoxynucleotide 
triphosphate (dNTP’s), 5 µl Pfu reaction buffer and 2.5 U of Pfu DNA polymerase 
(Stratagene). The reaction mixtures were subjected to one denaturing cycle of 2 
minutes at 95ºC, and then 18 cycles under the following conditions: 30 sec denaturing 
cycle at 95ºC, 30 sec annealing cycle at 63ºC and a 12 minute extension cycle at 72ºC, 
and completed by a 1 hour extension cycle at 72ºC. The PCR product was digested with 
DpnI, then purified using an ethanol precipitation protocol. The entire precipitate was 
then electroporated into electrocompetent Escherichia coli DH5α electrocompetent cells 
(24). 
The E379A mutation was introduced into the pUCPExoS-HA vector to produce 
pUCPExoS-E379A-HA using the PCR-based GeneTailor Site Directed Mutagenesis 
system (Invitrogen, Carlsbad, CA). The primers used to introduce the mutation (bold) 
and an BsmI site (underlined) were as follows: forward, 5’-
GGGATATCGAACTACAAGAATGCAAAAGAGA-3’, and reverse, 5’-
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CATTCTTGTAGTTCGATATCCCGCTGA-3’. The E381A mutation was introduced into 
both pUCPExoS-HA and pUCPExoS-R146A-HA using the GeneTailor Site Directed 
Mutagenesis system, resulting in the construction of pUCPExoS-E381A-HA and 
pUCPExoS-R146A/E381A-HA. The following primers were used to introduce the E381A 
mutation (bold) and a BsrG1 site (underlined): forward, 5’-
CAAGAATGAAAAAGCGATTCTGTACAACAAAGAAAC-3’, and reverse, 5’-
CTTTTTCATTCTTGTAGTTCGATATCC-3’. To construct a pUCPExoS-E379A/E381A-
HA mutant, an E381A mutation was introduced to the pUCPExoS-E379A-HA template 
using the following primers: forward, 5’-
CTACAAGAATGCAAAAGCGATTCTGTACAACAAAGAAAC-3’, and reverse, 5’- 
TTTTGCATTCTTGTAGTTCGATATCC-3’. 
For all mutants created by the GeneTailor Site-Directed Mutagenesis system, prior 
to PCR reactions 100 ng of template DNA were methylated using 4 units of CpG 
Methylase (M.Sss I) (New England Biolabs, Beverly, MA). PCR reaction mixtures 
contained 12.5 ng methylated DNA, 300 µM dNTP’s, 10 µM primers, 1 mM MgSO4, 
High Fidelity PCR buffer, and 1.5 units of Platinum Taq High Fidelity enzyme 
(Invitrogen). The reaction mixtures were subjected to one 2 minute denaturing cycle at 
94ºC, followed by 35 cycles: 30 sec denaturing cycle at 94ºC, a 30 sec annealing cycle 
at 55ºC and a 8 minute extension cycle at 68ºC, and completed by a final 10 minute 
extension cycle at 68º. The PCR reaction (4µl) was then transformed into One-Shot 
Max Efficiency DH5α-T1R (Invitrogen), using a heat-shock method (13). 
pUCPExoS-R146A/E379A-HA and pUCPExoS-R146A/E379A/E381A-HA were 
constructed by digesting plasmids, pUCPExoS-R146A-HA, pUCPExoS-E379A-HA and 
109 
pUCPExoS-E379A/E381A-HA with enzymes EagI (which cuts in the middle of exoS) 
and BamHI (which cuts outside the C-terminal region of exoS). EagI-BamHI fragments 
from pUCPExoS-E379A-HA and pUCPExoS-E381A-HA were gel purified using the 
Wizard SV Gel and PCR Clean-Up system (Promega, Madison, WI) and ligated into the 
digested pUCPExoS-R146A-HA plasmid (100 ng vector; 115 ng insert) using T4 DNA 
ligase (Promega). The ligation reaction (5 µl) was transformed into One-Shot Max 
Efficiency DH5α-T1R (Invitrogen). 
Mutants were selected by plating transformed E. coli strains onto LB agar plates 
containing 100 µg/ml ampicillin. Clones were initially screened using restriction digests 
for added sites. ExoS mutations were confirmed by sequencing (Biotech Core, Inc., 
Sunnyvale, CA). pUCP vectors (150 ng) encoding mutant forms of ExoS-HA were 
electroporated into electrocompentent PA103∆UT (43). Transformed bacteria were 
selected on LB agar containing 400 µg/ml carbenicillin. Positive clones were tested for 
ExoS expression by growing cells in TSBD-N medium, harvesting cells and fractionating 
them into secreted supernatants and whole cell pellets. Samples were processed for 
SDS-PAGE and immunoblotted with anti-ExoS and anti-HA-tag antibodies (Covance, 
Berkeley, CA). To confirm that the transformed Pa contained the correct ExoS 
construct, plasmid was re-isolated from Pa using the Holmes and Quigley 
phenol/chloroform extraction protocol (97), transformed into DH5α, and subjected to 
restriction digest analysis. 
Eukaryotic cell culture 
Eukaryotic cells were cultured as described in Chapters 2 and 3. 
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Monitoring ADP-ribosylation of eukaryotic substrates 
In vitro analysis.  
Eukaryotic cells were grown to confluency, washed twice with Dulbecco’s 
phosphate buffered saline (DPBS) and lysed for 30 minutes on ice in a buffer containing 
0.03 M HEPES (pH 7.5), 1% Triton X-100, 10 mM NaCl, 10% glycerol, 1 mM EGTA, 25 
mM NaF, 1 mM Na3VO4, 10 mM β-glycerophosphate and supplemented with Protease 
Cocktail III (Calbiochem), proteosome inhibitor MG-132 (Sigma) and benzamidine, then 
stored at -70ºC. Before the in vitro ADPRT reaction, lysates were thawed at room 
temperature, and unbroken cells and nuclei were cleared by centrifugation at 16,000 x g 
for 5 minutes at 4ºC. To monitor ExoS ADP-ribosylation of eukaryotic substrates, 
supernatants, which were the sources of ExoS and mutant ExoS, from T3S-induced 
bacterial cultures (~1.7 µg of total protein) and 100 nM NAD were added to the 
aliquoted cleared lysates. Mixtures were incubated for 1 hour at room temperature, and 
reactions were stopped by the addition of 4X Laemmli sample buffer (129), and heating 
at 95ºC for 5 minutes. Samples were resolved by SDS-12% PAGE and immunoblotted 
for the appropriate proteins, as outlined in Chapters 2 and 3. 
In vivo analysis 
T3S-T-ExoS and T3S-mutant ExoS was determined as described in Chapters 2 and 3. 
 
Intracellular localization of T3S-T-ExoS 
i) Co-culture 
With the ability to detect intracellular ExoS through immunoblot analysis, several 
cellular fractionation techniques were developed to track T3S-T-ExoS’s cytosolic or 
membrane localization. To determine the intracellular localization of T3S-T-ExoS, 
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eukaryotic cells were seeded in 100 mm dishes at 105 cells/ml and grown to 60-80% 
confluency. Cells were co-cultured with Pa strains, expressing pUCPExoS-HA (MOI of 
20:1), for 5 hours. At the end of the co-culture period, cells were washed twice with 
DPBS, and detached with 2 ml 0.025% Tryspin-EDTA (GibcoBRL, Gaithersburg, MD). 
The trypsin served to both detach eukaryotic cells and proteolyze extracellular ExoS 
(non-T3S-T-ExoS). After 12 minutes, cells were removed from the dishes and the 
trypsin was neutralized with cell medium containing FBS. 
ii) Ultracentrifugation method 
The membrane or cytosolic localization of T3S-T-ExoS was initially determined by 
subjecting co-cultured eukaryotic cells to ultracentrifugation. Washed and trypsinized 
cells were pelleted by low-speed centrifugation and resuspended in 650 µl of HBII buffer 
(3 mM Imidazole, pH 7.4, 250 mM sucrose and protease inhibitors). Lysates were 
obtained by passaging cells through a 5/8 inch 27 gauge needle 14 times. Unbroken 
cells and nuclei were cleared by centrifugation at 800 x g for 5 minutes at 4ºC. Lysates 
were further fractionated into cytosolic (S100) and membrane (P100) fractions by 
ultracentrifugation at 116,140 x g for 40 minutes at 4ºC. The P100 fraction was 
equilibrated to the volume of the S100 fraction, and 4X Laemmli sample buffer was 
added to an aliquot of sample, which was processed for SDS-PAGE and immunoblotted 
for ExoS using an anti-HA antibody (Upstate, Lake Placid, NY). Additional aliquots of 
the same samples were examined for T3S-T-ExoS ADP-ribosylation of eukaryotic 
substrates, and ExoS ADPRT activity, as previously described in Chapters 2 and 3 
(197, 198). 
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iii) Digitonin extraction 
As a means to track T3S-T-ExoS ADPRT activity, the subcellular localization of 
substrates ADP-ribosylated by ExoS was determined by digitonin extraction. After the 
co-culture period, cells were lysed in 750 µl (60 mm dish) or 1 ml (100 mm dish) with 
digitonin extraction buffer (0.01% digitonin, 10 mM Pipes, 300 mM sucrose, 100 mM 
NaCl, 3 mM MgCl2, 5 mM EDTA; pH buffer to 6.8) for 20 minutes on ice. Cells were 
scraped into microfuge tubes and separated into cytosolic (supernatant) and membrane 
(pellet) fractions by centrifugation at 16,000 x g for 15 minutes at 4ºC. The volumes of 
supernatants and pellets were equilibrated with sample buffer and processed as 
previously described for SDS-PAGE and immunoblot analysis.  
iv) Modified digitonin extraction 
A limitation of the ultracentrifugation method was that only 6 samples could be 
processed at one time. To increase the throughput of the fractionation analysis, a 
modified-digitonin extraction method was developed. Washed and trypsinized 
eukaryotic cells (described above) were pelleted by low-speed centrifugation and 
resuspended in 750 µl modified digitonin extraction buffer (10 mM Imidizole, pH 7.4, 250 
mM sucrose, 3 mM MgCl2, 5 mM EDTA, 0.01% digitonin). (The new buffer recipe 
combined components of HBII and digitonin extraction buffers (both defined above) to 
maximize the detection of ExoS-HA in cellular fractions.) Cells were then processed, 
essentially as described by the digitonin extraction protocol. After the lysates were 
centrifuged at 16,000 x g for 15 mintues at 4ºC, the pellet (membrane fraction) was 
resuspended in 750 µl of HBII buffer containing 0.1% Triton X-100. Protein 
concentrations of cytosolic and membrane fractions were determined using the BCA 
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Protein Assay Kit (Pierce, Rockford, IL). Laemmli sample buffer was added to the 
remaining fraction volumes and samples were heated at 95ºC for 5 minutes. Equal 
amounts of protein were resolved by SDS-PAGE, and localization of T3S-T-ExoS to 
cytosolic or membrane fractions was determined by immunoblot analysis using an anti-
HA antibody (Covance). To monitor protein loading, immunoblots were probed with an 
antibody against heat shock protein 70, anti-HSP70, which is known to localize to 
mitochondrial, endoplasmic reticulum, nuclear and cytosolic fractions (BD Transduction 
Laboratories). The densities of protein bands were determined using Tiffany software 
(Humphrey Gardner, Scripps Institute, La Jolla, CA). 
Examination of T3S-T-ExoS intracellular processing 
i) Effect of protease inhibitors on T3S-T-ExoS ADPRT activity 
To determine if T3S-T-ExoS is processed by a eukaryotic protease, eukaryotic cells 
were treated with diffusible protease inhibitors, and cell lysates were examined for ADP-
ribosylation of eukaryotic proteins. In these studies, HL-60 cells were seeded and TPA-
differentiated as described in Chapter 3. One hour prior to co-culture with Pa strain 388, 
TPA-HL-60 cells were pretreated with a 1:500 dilution of a protease inhibitor cocktail 
(PIC), P8340, (Sigma), as well as, the appropriate concentrations of the individual 
protease inhibitor-components of the PIC. The 1:500 dilution of the PIC contains 208 
µM AEBSF (4-(2-aminoethyl)benzenesulfonyl fluoride) (serine PI), 160 nM aprotinin 
(serine PI), 4 µM leupeptin (serine and cysteine PI), 8 µM bestatin (aminopeptidase 
inhibitor), 3 µM pepstatin A (acid PI), and 2.8 µM E-64 (N-(trans-Epoxysuccinyl)-L-
leucine 4-guanidinobutylamide) (cysteine PI). The 1:500 PIC dilution was found to have 
an effect on ExoS ADP-ribosylation, without affecting bacterial growth. Pretreatment of 
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eukaryotic cells with PI solvents, including dH20 (AEBSF, aprotinin, leupeptin), DMSO 
(PIC, bestatin, E-64) and 10% acetic acid in methanol (pepstatin A), served as controls. 
After a 4 hour co-culture period with strain 388 or no bacteria, eukaryotic cells were 
lysed in Laemmli sample buffer, heated at 95ºC for 5 minutes, resolved by SDS-PAGE 
and examined by immunoblot analysis, as previously described. 
ii) Effect of PIC on Pa T3S 
To determine if the PIC and AEBSF had an effect on Pa T3S, strains 388, 388∆S, 
388∆PopD, and 38811 were cultured with the drugs and then monitored for the 
production of PopD, a protein required for T3S-T. In these studies, bacteria from frozen 
stock were initially cultured overnight in LB, then cultured for an additional 14 hours in 
dialyzed tryptic soy broth supplemented with 5 mM CaCl2 (to suppress T3S). For the 
experiment, 208 µM AEBSF, 1:500 dilution of PIC, and appropriate diluent controls 
(dH2O and DMSO) were added to 3 ml of dialyzed tryptic soy broth supplemented with 5 
mM EGTA (to induce T3S). The medium was then inoculated with 107 bacteria/ml and 
incubated for 4 hours in a 37ºC shaking water bath. At the end of the culture period, 300 
µl of the bacterial culture was removed and 100 µl of 4X Laemmli sample buffer was 
added to the sample. The samples contained bacteria and secretion products. The 
samples were processed for and resolved by SDS-PAGE and immunoblotted with an 
anti-PopD antibody (Dara Frank, Medical College of Wisconsin). 
Co-immunoprecipitation of T3S-T-ExoS 
To understand a mechanism associated with differences in T3S-T-ExoS substrate 
specificity between rodent and human cell lines, a co-immunoprecipitation (Co-IP) 
procedure was developed, which would allow for the purification of T3S-T-ExoS and 
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ExoS-associated proteins. In initial studies, Co-IP reactions were performed using 
ExoS-HA and anti-HA antibodies and protein A-sepharose beads to IP the protein 
complexes. However, several complications were associated with this approach: 1) 
significant background was caused by the heavy chain of IgG (which resolves similarly 
to ExoS by SDS-PAGE) and Protein A breakdown products, 2) the HA tag is a small 
epitope, limiting the specificity of the reaction, which made it difficult to identify unique 
T3S-T-ExoS interacting proteins. To address these problems, we were given an 
enzymatically inactive ExoS mutant constructed with a C-terminal triple FLAG tag 
(Sigma) by Joe Barbieri (Medical College of Wisconsin), which is encode on the pUCP 
plasmid and expressed by PA103∆UT (PA103∆UTpUCPExoS-R146K/E379D/E381D-
3XFLAG). The triple FLAG epitope is approximately 22 amino acids in length and 
includes two additional FLAG epitopes for recognition by the M2 anti-FLAG tag antibody 
(Sigma). 
T24, human epithelial cells, and TCMK-1, mouse epithelial cells, were seeded in 
100 mm dishes, as previously described, and grown to 70-95% confluencey. Eukaryotic 
cells were co-cultured with 107 PA103∆UTpUCP or PA103∆UTpUCPExoS-R146K-
E379D/E381D-3XFLAG for 4.5 hours. Cells were then washed twice with DPBS and 
detached with 0.25% trypsin-EDTA (HyClone, Logan, UT) for 10 minutes. Trypsinized 
cells were removed from the dishes, and dishes were washed an additional time with 
DPBS (to maximize harvest of eukaryotic cells). The trypsin was neutralized with the 
addition of 1 ml fetal bovine serum (CellGro, Mediatech, Inc. Herdon, VA). Eukaryotic 
cells were pelleted by low-speed centrifugation and then resuspended in 800 µl of HBII 
buffer (defined above). Cells were lysed by passage 20 times through a 27 gauge 
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needle or by passage 15 times through a 28 gauge needle. Unbroken cells and nuclei 
were pelleted by centrifugation at 16,000 x g for 5 minutes at 4ºC. A 24 µl volume of 5 M 
NaCl was added to lysates to obtain a final concentration of 150 mM NaCl. Protein 
concentrations in lysates were determined using a BCA Protein Assay (Pierce). Prior to 
the co-immunoprecipitation reaction, 30 µl of anti-FLAG M2-Agarose affinity resin 
(Sigma) was washed 3 times in HBII, pelleting the resin by centrifugation at 8,200 x g 
for 30 seconds at 4ºC between washes. Equal amounts of protein were added to the 
washed resin, and reactions were rotated at 4ºC for 2 hours. Resin was washed 5 times 
in Tris buffered saline (TBS, 50 mM Tris, 150 mM NaCl, pH 7.4 supplemented with 1% 
EDTA and PIC) centrifuging at 8,200 xg for 30 seconds at 4ºC between washes. To 
elute the co-immunoprecipitate, resin was resuspended in 100 µl of TBS containing 150 
ng of 3X FLAG peptide (Sigma) and rotated overnight at 4ºC. The supernatant 
containing the co-immunoprecipitate was obtained by pelleting the resin by 
centrifugation at 8,200 x g for 30 seconds at 4ºC. 4X Laemmli sample buffer was added 
to the supernatant and heated at 95ºC for 5 minutes. An aliquot of the sample was 
analyzed by SDS-PAGE and immunoblot analysis with the M2 anti-FLAG antibody 
(Sigma). The remainder of the sample was resolved by SDS-10% PAGE on an 13.0 cm 
X 14.5 cm gel, and protein was visualized by Imperial Protein Stain (Pierce), Gel Code 
Color Silver Stain Kit (Pierce) or SilverSNAP Stain for Mass Spectrometry (Pierce). 
Seven samples were excised from the gel and sent to James Carroll (Department of 
Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, 
Pittsburgh, PA) for tryptic digestion, and MALDI-MS (matrix-assisted laser 
desorption/inonization mass spectrometry) analysis using an ABI 4700 TOF-TOF 
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Proteomic analyzer (Applied Biosystems, Foster City, CA) located in the Genomics and 
Proteomics Core Laboratories at the University of Pittsburgh. As a negative control, a 
portion of the gel, which lacked discernible protein bands, was excised and processed. 
Results were analyzed using Prospector software, v 4.0.5 (Mass Spectrometry Facility, 
University of California at San Francisco, San Francisco, CA). 
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Results 
Effects of MLD, GAP and ADPRT mutations on T3S-T-ExoS eukaryotic substrate 
modification 
ExoS is a biglutamic ADP-ribosyltransferase, with E379 conferring the transfer of 
the ADP-ribose to target proteins and E381 conferring the action of cleaving the ADP-
ribose from NAD molecules (Figure 1A) (141, 186). Previous in vitro analyses indicated 
that an E381 ExoS mutant would not be able to ADP-ribosylate substrates (141). To 
corroborate previous studies and determine which residues were required for in vitro 
ExoS ADPRT, equal amounts of supernatant from T3S-induced Pa cultures that 
expressed wild-type or mutant ExoS were incubated with lysates from eukaryotic cells 
for 1 hour at room temperature. Mutation of either E379 or E381 resulted in lack of 
ADP-ribosylation of RalA or Rac1 in both rodent (TCMK-1) and human (T24) cell lysates 
(Figure 1B). These results were consistent with the previously observed lack of ExoS 
ADP-ribosylation of Ras in vitro by E379A and/or E381A ExoS mutants (64, 186). 
Previously it was shown that the eukaryotic cell influences which substrates T3S-T-
ExoS targets (65, 197). To better understand how the host cell specifically influences 
T3S-T-ExoS restrictive or extensive patterns of ADP-ribosylation, rodent (TCMK-1 or 
Swiss-3T3) and human (T24) cells were co-cultured with Pa strain PA103∆UT which 
expressed a pUCP plasmid encoding a wild type or mutant-form of ExoS (Figure 1C). 
Interestingly, T3S-T-ExoS-E381A was able to modify both Ras and RalA within 
eukaryotic cells, albeit to a more limited extent than ExoS. However, it was unable to 
ADP-ribosylate cellular Rabs and Rac1 (Figure 1B and Figure 2). The E381A mutation 
did not alter how T3S-T-ExoS targets substrates within rodent cell lines. 
119 
A. Linear model of ExoS
GALRSLA
146
E379/E381
GAP
domain
ADPRT
domain
MLD
9 52 71 253 453420 429
14-3-3
binding
region
Epitope tag
HA or 3XFLAG
B. In vitro
C. In vivo
Restrictive Pattern Extensive Pattern
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Effect of MLD, GAP and ADPRT mutations on ExoS ADP-ribosylation of 
cellular substrates. 
A. Linear model of ExoS showing the location of the MLD (residues 52-71) (176), 
GAP domain (residues 72-253) (77), ADPRT domain (residues 253-453) (117, 141, 
186), and the 14-3-3 binding domain (residues 420-429) (90). The location of the HA 
epitope tag (176) or the 3XFLAG epitope tag (J. Barbieri, personal communication) are 
also indicated. A detailed description of the linear map is included in Figure 6. B. In vitro 
analysis. Wild type or the indicated mutant ExoS, obtained from bacterial culture 
supernatants, was incubated with NAD and cell lysates for 1 hour at room temp, as 
previously described. Reactions were stopped with the addition of 4X Laemmli sample 
buffer, heated to 95ºC for minutes, and resolved by SDS-PAGE. The indicated proteins 
were immunoblotted with specific antibodies and developed by ECL. C. In vivo analysis. 
Eukaryotic cells were co-cultured with bacteria expressing wild type or mutant ExoS, 
harvested, and examined as described in B. ADP-ribosylated (M) and unmodified (U) 
proteins are indicated. M1 and M2 refer to the first and second modifications of RalA by 
T3S-T-ExoS. Cell lines with restrictive and extensive T3S-T-ExoS ADPRT-modification 
patterns are indicated. 
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Also evident in these studies was the lack of substrate modification by the E379A 
mutant, indicating the absolute requirement for the E379 residue for T3S-T-ExoS 
substrate ADP-ribosylation in vivo (Figure 21C). 
It was clear that the E379A and E381A affected how ExoS ADPRT activity was 
targeted within the cell, however, the mechanism for these differences were not clear. 
To help understand the cellular mechanism associated with the effects of E381 and/or 
E379 mutations on T3S-T-ExoS substrate specificity, patterns of T3S-T-ExoS ADP-
ribosylation or T3S-T-ExoS localization were monitored in cell lines exhibiting the 
restrictive (CHO, NIH-3T3, Swiss-3T3) or extensive pattern (Vero, T24, Wi38-SV40t). 
Cell fractionation was previously found to facilitate detection of subtle differences in 
ExoS ADPRT substrate ADP-ribosylation. For example, modification of Cdc42 was 
undetectable in whole HT-29 cell lysates, but became evident upon fractionation (65). In 
these studies, cells were fractionated by digitonin extraction after co-culture with Pa 
strains producing wild type or mutant ExoS constructs, and the resultant cytosolic and 
membrane fractions were examined for substrate modification of RalA, Rac1 and Rab5. 
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 Figure 22. Digitonin extraction of eukaryotic cells treated with Pa expressing wild 
type or mutant ExoS. 
After a 5 hour co-culture period with PA103∆UT expressing the indicated ExoS 
mutants or empty vector pUCP, eukaryotic cells were fractionated into cytosolic (C) and 
membrane (Mb) fractions. Samples were resolved by SDS-PAGE, followed by Western 
blot of the indicated proteins, and visualized using ECL. Cells lines belonging to the 
extensive or restrictive pattern of substrate modification are indicated. Rab5 
modification is shown only for cell lines having an extensive ADPRT substrate pattern 
(Vero, T24, and Wi38t). ADP-ribosylated (M) and unADP-ribosylated (U) proteins are 
indicated. 
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As evident in Figure 22, RalA remains predominately in the membrane fraction, 
Rac1 remained predominately in the cytosolic fraction, and Rab5 was equally 
distributed between the two fractions in cells treated with PA103∆UTpUCP. Elimination 
of ExoS GAP activity by mutation of the arginine at position 146 to an alanine 
(ExoSR146A) did not affect ExoS substrate specificity when it was bacterially 
translocated into eukaryotic cells (Figure 21 C and Figure 22). However, in cells with an 
extensive ADPRT substrate modification pattern, ADP-ribosylation of RalA and/or Rab5 
was more efficient in association with T3S-T of ExoSR146A, as compared to T3S-T of 
wild type ExoS. Consistent with analysis of whole cell lysates, T3S-T-ExoSE381A 
resulted in a single modification of RalA in both rodent and human cell lines and E379 
was absolutely required for T3S-T-ExoS ADP-ribosylation of substrates. Also, both the 
E379 and E381 residues were found to be required for T3S-T-ExoS ADP-ribosylation of 
Rab proteins and Rac1, and the more efficient ADP-ribosylation of Ras and RalA. 
These studies identified a role of the E381 residue in the extensive ADPRT substrate 
pattern observed in human and simian cell lines, but not for ADP-ribosylation in rodent 
cell lines. Differences observed in substrate modification by the R146A and E381A 
mutants in human and rodent cell lines further highlight eukaryotic cell influences on the 
targeting of T3S-T-ExoS ADPRT activity. 
Recently, a MLD has been identified to reside within amino acids 51-72 of ExoS and 
it functions to target ExoS to eukaryotic membranes (176). ExoS ADPRT activity has 
been found mainly within the membrane fraction, indicating that intracellular localization 
is important to T3S-T-ExoS ADPRT activity (64, 188). With the availability of the 
PA103∆UT strain to express the ExoS∆MLD-HA mutant, we asked how the  
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Figure 23. Effect of MLD on intracellular targeting and localization of T3S-T-ExoS 
ADPRT activity 
 A. Effect of MLD on T3S-T-ExoS substrate modification. Eukaryotic cells of 
restrictive or extensive patterns of substrate modification were co-cultured with 
PA103∆UT expressing wild type ExoS-HA (ExoS) or ExoS∆MLD-HA (MLD) or, pUCP 
(pU) vector, for 4 to 5 hours, and harvested and examined for the indicated proteins by 
Western blot analysis, as previously described. ADP-ribosylated (M) and unmodified (U) 
proteins are indicated. B. Effect of MLD on T3S-T-ExoS intracellular localization. After 
co-culture with PA103∆UT expressing either ExoS∆MLD-HA (MLD) or ExoS-HA (S), 
cell lines were harvested and fractionated by ultracentrifugation (refer to Methods and 
Materials), to produce cytosolic S100 (S) and membrane P100 (P) fractions. Fraction 
volumes were equilibrated and samples were resolved and immunoblotted using an 
anti-HA tag antibody, as previously described. ExoS (S) and ExoS∆MLD proteins have 
different mobilities by SDS-PAGE, as indicated. The cytosolic ADPRT activity, which is 
measured in fmol/µg min and corresponds to the data points displayed in Figure 3B, for 
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T3S-T-ExoS∆MLD-HA versus T3S-T-ExoS-HA are as follows: CHO, 116.305 ± 5.8 vs. 
31.69 ± 0.206; NIH-3T3, 61.78 ± 3.3 vs. 5.90 ± 0.187; Cos-1, 80.9 ± 0.233 vs. 17 ± 0.28; 
T24, 37.7 ± 2.1 vs. 1.68 ± 0.07. Restrictive pattern cell lines: CHO-K1 (CHO), NIH-3T3 
(NIH); Extensive pattern cell lines: Cos-1, T24. 
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MLD influenced the targeting of ExoS to eukaryotic substrates. In examining 
ExoS∆MLD in an in vitro analysis, using T3S-induced Pa supernatant as a source of 
ExoS and ExoS∆MLD, and eukaryotic lysates as a source of 14-3-3 and substrates, 
ExoS∆MLD-HA ADP-ribosylated proteins similarly to wild type ExoS (refer to Figure 21 
A). When we compared the ADP-ribosylation of ExoS substrates in rodent (CHO) or 
human (T24) cell lines after co-culture with Pa expressing ExoS-HA or ExoS∆MLD-HA 
(Figure 21 and Figure 23 A), T3S-T-ExoS∆MLD-HA reduced the efficiency of ExoS 
ADPRT substrate modification. In rodent cells, Ras and RalA were modified by T3S-
ExoS∆MLD, but much less efficiently than that observed in vitro (compare Swiss-3T3, 
Figure 21 C and CHO, Ras and RalA, Figure 23 A). In T24 human epithelial cells, T3S-
T-ExoS∆MLD-HA ADP-ribosylated substrates in a manner similar to that of wild type 
T3S-T-ExoS-HA in rodent cell lines. This was evident in the modification of Ras, a 
single modification of RalA, and no modification of Rabs 5 and 8 or Rac1 (Figure 21B 
and Figure 23 A). In addition, T3S-T-ExoS∆MLD-HA did not redirect ExoS to cellular 
targets, which are not normally ADP-ribosylated by T3S-T-ExoS-HA, such as Rab4 and 
Rho (Figure 23 A). These results indicate that the MLD may play a greater role in 
targeting ExoS to eukaryotic proteins in human cells, than in rodent cells. 
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   ExoS ADPr pattern Mutant ExoS ADPr 
Substrate Intracellular 
localization 
Extensive Restrictive E381A ∆MLD 
Ras PM +* + + + 
RalA PM +* + + + 
Rab5 CCV, EE + - - - 
Rab8 tG, SG + - - - 
Rab7 LE + - - - 
Rab11 pnRE, pgRE + - - - 
Rac1 Cyto/PM + - - - 
 
Table 3. Summary of ExoS ADP-ribosylation patterns and subcellular localization 
of target proteins 
Summary of targets of ExoS ADP-ribosylation within the eukaryotic cell. Extensive 
(human and simian cell lines) and restrictive (rodent cell lines) patterns are defined. The 
effect of E381A and ∆MLD mutations on substrate targeting in human cells is shown. 
The E381A and the ∆MLD mutations do not affect T3S-T ExoS targeting of substrates 
in rodent cell lines. + or – indicates whether proteins are ADP-ribosylated or not by 
ExoS. +* indicates a protein is more efficiently modified in human and simian cell lines, 
as compared to rodent cell lines. ADPr, ADP-ribosylation; PM, plasma membrane; CCV, 
clathrin coated vesicles; early endosomes, EE; trans-Golgi region, tG; secretory 
granules, SG; late endosomes, LE; perinuclear recycling endosomes, pnRE; perigolgi 
recycling endosomes, pgRE; cytosol, Cyto. 
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To further explore the mechanism for diminished ADP-ribosylation by the 
ExoS∆MLD mutant within eukaryotic cells, cytosolic and membrane fractions were 
compared for the presence of ExoS∆MLD-HA and ExoS-HA, by Western blot analysis 
(Figure 23 B) and by quantification of ExoS ADPRT within cytosolic and membrane 
fractions. T3S-T-ExoS∆MLD-HA localized to the cytosolic fraction, while wild type T3S-
T-ExoS-HA localized mainly to the membrane fraction of both rodent and human cell 
lines. These results correlated with the greater amount of ExoS ADPRT activity 
detected in cytosolic fractions of cells treated with PA103∆UT-pUCPExoS∆MLD-HA, as 
compared to the cytosolic fractions of cells treated with PA103∆UT-pUCPExoS-HA. 
Also evident from these results was that the decreased ADP-ribosylation of substrates 
by ExoS∆MLD-HA did not relate to a defect in the T3S-T of ExoS∆MLD-HA. In general, 
greater total amounts of T3S-T-ExoS∆MLD-HA were detected in total lysates of all cell 
lines (data not shown); however, bacteria also secreted ExoS∆MLD-HA more efficiently 
than ExoS-HA (data not shown), indicating that this domain may be important for T3S of 
ExoS, as well as, intracellular targeting of T3S-T-ExoS. Most importantly, these results 
indicate that without localization to the membrane fraction, T3S-T-ExoS can not 
efficiently ADP-ribosylate substrates. 
Examining intracellular processing of T3S-T-ExoS 
While examining the intracellular localization of ExoS, we often noticed multiple 
forms of ExoS in total lysates of cells treated with ExoS-HA producing bacteria (Figure 
24 A). Although the heterogeneity in molecular mass and charge of ExoS had been 
noted previously (151), the function of these different forms of ExoS within eukaryotic 
cells remains unclear. In our studies we have observed three forms of T3S-T-ExoS by 
SDS-PAGE followed by Western blot analysis: a form which has a lower mobility than 
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T3S-secreted ExoS, a form which has a similar mobility to T3S-secreted ExoS, a form 
which has a higher mobility than T3S-secreted ExoS (Figure 24 A and Figure 25). ExoS 
has been reported to have a processing site within the first 78 amino acids (177) and to 
ADP-ribosylate itself (auto-ADP-ribosylated) within the cell (189). Hence, we 
hypothesized that the lower mobility form of T3S-T-ExoS to be a processed form, and 
the higher mobility form to be the auto-ADP-ribosylated form. The processed form and 
the ADP-ribosylated form of T3S-T-ExoS have never been observed within the same 
sample. The ADP-ribosylated form is also more commonly observed than the processed 
form, suggesting that the lower mobility form may be an intermediate state or unstable 
form that precedes the self-ADP-ribosylated form of T3S-T-ExoS (personal 
observation). In addition, T3S-T-ExoS auto-ADP-ribosylation has been observed in both 
rodent and human cells, but was not observed when E379A and/or E381A mutants 
were bacterially translocated into the host cell, indicating that this event requires both 
glutamic acid residues (Figure 5). 
To better understand the processed, intermediate form of T3S-T-ExoS, eukaryotic 
cells were treated with membrane permeable protease inhibitors and then co-cultured 
with ExoS producing bacteria. Initial results indicated that a 1:500 dilution of the 
protease inhibitor cocktail (PIC), eliminated ADP-ribosylation of Rab5 (Figure 24 B). The 
1:500 dilution of the PIC did not have an effect on eukaryotic cell viability or bacterial 
cell growth (data not shown). In examining the individual components of the PIC, 208 
µM AEBSF, which is a serine protease inhibitor, was the component which was  
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Figure 24. Effect of protease inhibitors on the intracellular targeting and T3S-T of 
ExoS ADPRT activity. 
A. Cellular processing of T3S-T-ExoS. Eukaryotic cell lysates (TL) were prepared from 
the indicated cell lines and resolved by SDS-PAGE and immunoblotted for ExoS, using 
the anti-HA tag antibody. The asterisk denotes the lower, processed form of ExoS 
observed in TL but not in bacterial supernatants (Pa sup). B. Effect of components of 
the PIC on ExoS ADP-ribosylation of Rab5. TPA-HL-60 cells were treated with 
individual components of the PIC, prior to incubation with Pa strain 388. Samples were 
resolved by SDS-PAGE, followed by Western blot analysis for Rab5 and visualized by 
ECL. ADP-ribosylated (M) and unmodified (U) forms of Rab5 are indicated. No drug, 
ND; AEBSF, A; Aprotinin, Ap; Leupeptin, L; Bestatin, B; Pepstatin A, P; E-64, E; 
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Protease inhibitor cocktail, PIC; DMSO, DM; 10% Acetic acid, Ac; dH2O, dH. C. Effect of 
PIC and AEBSF on production of PopD. Pa strain 388 was incubated with no drug, PIC, 
AEBSF or carrier controls for 4 hours, prior to the combined harvest of bacterial cells 
and bacterial supernatants. Samples were resolved by SDS-PAGE, followed by 
Coomasie staining or immunoblot analysis for PopD (shown). To ensure equal protein 
loading, densitometry analysis was performed on the Coomasie stained gel and raw 
densitometry values for total bacterial supernatant are as follows: ND, 24.56; A, 25.31; 
PIC, 26.28; DM, 27.73; dH, 28.04. D. Effect of AEBSF and PIC on T3S-Tof ExoS. After 
treatment with the indicated drugs or controls, T24 cells were trypsinized and processed 
for SDS-PAGE and immunoblot analysis. Membranes were incubated simultaneously 
with antibodies against heat shock protein 70 (HSP70), HA tag, RalA and Rac1, and 
visualized by ECL. ADP-ribosylated (M) and unmodified (U) proteins are indicated. No 
bacteria, NB. 
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responsible for the inhibition of ADP-ribosylation of Rab5 in TPA-differentiated HL-60 
cells (Figure 24 B). As a control, bacterial cells were cultured in the absence of 
eukaryotic cells and examined for production of a protein required for Pa T3S, PopD. 
Unexpectedly, AEBSF and the PIC, lessened bacterial production of PopD (Figure 24 
C). These data suggested that the drugs affected the assembly/production of the 
bacterial T3S apparatus. Unexpectedly, T3S-T-ExoS was more evident in cells treated 
with either AEBSF or PIC, than control cells treated with carrier compounds or no drug. 
Despite greater amounts of T3S-T-ExoS, modification of RalA or Rac1 or ExoS auto-
ADP-ribosylation was not evident (Figure 24 D). Also, despite a less robust production 
of PopD in AEBSF-treated Pa strains, there was enough PopD produced to allow T3S-
T. These results could indicate that only a minimal amount of PopD is required for T3S-
T or that another Pa T3S protein can substitute for function. Overall, these results 
indicate that AEBSF interfered with both Pa PopD production, and with T3S-T-ExoS 
ADPRT activity. 
Role of the R146 GAP residue in T3S-T of ExoS 
Seven ExoS-HA tagged mutants, which included single or combination mutations in 
the GAP (R146) and ADPRT (E379, E381) activities of ExoS, were constructed using 
the pUCP-ExoS-HA construct provided by Joe Barbieri (Medical College of Wisconsin, 
Milwaukee, WI). These mutants allowed further exploration of mechanisms associated 
with their recognized differences in substrate specificity (refer to Figures 21 C and 22), 
and also to examine the effects of the mutations on the T3S-T of ExoS. For these 
studies, eukaryotic cells were co-cultured with PA103∆UT expressing wild-type or 
mutant forms of ExoS-HA. Following the co-culture, eukaryotic cells were harvested and 
fractionated into cytosolic and membrane fractions. 
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Figure 25. Effect of GAP and ADPRT mutations on the T3S-T of ExoS. 
Membrane fractions were obtained by the digitonin extraction method (described in the 
Methods and Materials) from eukaryotic cells after co-culture with PA103∆UT 
expressing wild type ExoS (wtS), the indicated mutant ExoS, or empty vector control, 
pUCP (pU). Samples were resolved by SDS-PAGE and immunoblotted for loading 
control, HSP70, and ExoS-HA. Auto-ADP-ribosylated forms of ExoS are indicated by an 
asterisk. 
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T3S-T-ExoS was predominately found in the membrane fraction. In examining, the T3S-
translocation of ADPRT mutants, both E379 and E381 mutants were T3S-T into 
membrane fractions similarly to wild type ExoS in both rodent and human cell lines 
(Figure 25). These results indicated that the limited or lack of ADP-ribosylation of 
substrates by the E381A and E379A ExoS mutants, respectively, was not due to the 
lack of T3S-T. Interestingly, auto-ADP-ribosylated forms of ExoS were detected only for 
wild-type T3S-T-ExoS and T3S-T-ExoSR146A (asterisks, Figure 25). Mutation of 
R146A, in the absence or in combination with E379A and/or E381A mutations, resulted 
in more efficient T3S-T of ExoS as compared to wild type ExoS (Figure 25). Results for 
the T3S-T of R146A/E379A were consistent with R146 contributing to increased T3S-T 
of ExoS (data not shown). These results support a role of the R146 residue in either 
regulation of T3S-T or in signals that mark T3S-T-ExoS for degradation. 
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Figure 26. Immunoprecipitation of T3S-T-ExoS. 
T24 (extensive pattern) or TCMK-1 (restrictive pattern) cells were co-cultured with 
PA103∆UT expressing empty vector pUCP (pU) or pUCP-ExoS-R146K-E379/81D-
3XFLAG (S). A. Cells were harvested and T3S-T-ExoS was immunoprecipitated with 
M2 FLAG antibody immobilized to resin (Sigma) as described in the Methods and 
Materials. As a negative control, the IP procedure was performed using lysis buffer only 
(Blank, Bl). Eluates from the IP reaction were resolved by SDS-PAGE, followed by 
Western blot analysis using the M2 FLAG mouse monoclonal antibody (Sigma) and 
anti-HSP70 antibody (BD Transduction Labs) (followed by anti-mouse IgG::HRP) or 
only, anti-mouse IgG, conjugated to HRP. B. Total lysates samples were resolved by 
SDS-PAGE and immunoblotted with M2 anti-FLAG tag (Sigma) and anti-HSP70 (BD 
Transduction Labs). 
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T3S-T-ExoS protein interactions within rodent and human cell lines 
An important objective of these studies was to identify a mechanism for the 
differential targeting of T3S-T-ExoS ADPRT activity in rodent and human cell lines. 
Initially we attempted to localize T3S-T-ExoS-HA within the eukaryotic cell by 
immunofluorescence and flow cytometry, but the high background precluded meaningful 
interpretations of results. We next performed co-immunoprecipitation (Co-IP) assays to 
identify proteins that interact with T3S-T-ExoS, as a means to understand how 
intracellular ExoS ADPRT activity is targeted. 
Originally, Co-IP studies were attempted with ExoS-HA constructs, but there were 
difficulties in interpreting the results due to high background from immunoglobulin G 
(IgG) heavy and light chains, and protein A as well as limited T3S-T of wild type ExoS-
HA (refer to Figure 25). Given these limitations, we chose to use an enzymatically 
inactive construct of ExoS, with mutations in the GAP and ADPRT regions (R146K, 
E379D, E381D) that included a C-terminal triple FLAG tag (ExoS-KDD-3XFLAG) (gift 
from Joe Barbieri, Medical College of Wisconsin) for these studies. Mutation of R146 
has been shown to facilitate T3S-T of ExoS (refer to Figure 25). The use of the 3X 
FLAG epitope in combination with the M2 FLAG antibody immobilized to resin for the 
Co-IP reaction, eliminated the background from Protein A and reduced background from 
IgG. However, using an enzymatically inactive form of ExoS, potentially compromised 
the detection of protein interactions directed by key catalytic residues in ExoS.  
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Figure 27. Silver stain analysis of T3S-T-ExoS IP eluates. 
IP eluates were obtained from T24 (extensive pattern) and TCMK-1 (restrictive pattern) 
cells co-cultured with PA103∆UT expressing pUCP or pUCP-ExoS-R146K-E379/81D-
3XFLAG (ExoSi). As a negative control (Bl), lysis buffer alone was added to the M2 
FLAG antibody-immobilized resin. Samples were resolved by SDS-10% PAGE and gels 
were silver stained using A. the Gel Code Color Silver Stain Kit (Pierce) and B. 
SilverSNAP Stain for Mass Spectrometry (Pierce). Molecular weights of standards are 
indicated. A single asterisk indicates proteins identified in IP eluates from both ExoSi 
treated cell lines. A double asterisk indicates proteins found in either T24 or TCMK-1 
cells treated with ExoSi producing bacteria. All astericked proteins in B. were excised 
for MALDI-MS analysis. The SilverSNAP Stain for Mass Spectrometry was found to 
lightly stain gels, but unique proteins in T24-ExoSi (40 and 45 kDa) and TCMK-1-ExoSi 
(70 and 85 kDa) IP eluates were more easily identifiable. 
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Figure 28. T3S-T ExoS co-immunoprecipitates with 14-3-3. 
As previously described, total lysates and Co-IP eluates were obtained from T24 and 
HT-29 cells (extensive pattern), and TCMK-1 and Swiss-3T3 (Swiss) cells (restrictive 
pattern) after co-culture with PA103∆UT expressing empty vector pUCP (p) or pUCP-
ExoS-R146K-E379/81D-3XFLAG (S). Samples were resolved by SDS-12% PAGE, 
followed by Western blot analysis using an anti-14-3-3 rabbit polyclonal antibody 
(Upstate Biotechnology), which recognizes ζ, γ, and η 14-3-3 isoforms. 
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We co-cultured rodent and human cell lines with PA103∆UT expressing ExoS-KDD-
3XFLAG and T3S-T-ExoS and interacting proteins were extracted in a CoIP reaction. 
Samples were resolved by SDS-PAGE and either processed for Western blot analysis 
or silver stain analysis. Western blot analysis revealed that ExoS was successfully 
being immunoprecipitated from eukaryotic cells, albeit in the presence of a minimal IgG 
background (Figure 26). As a negative control, Co-IP eluates were immunoblotted for 
HSP70, which was not evident (data not shown). In comparison of Co-IP samples from 
rodent and human cell lines, two bands, which were approximately 27 and 30 kDa in 
size, were present in both samples treated with ExoS-KDD-3XFLAG expressing 
bacteria (Figure 27). The 30 kDa protein was identified by MALDI-MS to be the ε 
isoform of the 14-3-3 protein family by matching 13 out of 214 peptides, with 50% 
coverage and a MOWSE score of 5.065e + 05 (J. Carroll, personal communication). 
The 27 kDa protein was tentatively identified as a 14-3-3 protein (ζ, γ, or η isoform) by 
Western blot analysis (Figure 28). The identification of 14-3-3 proteins in Co-IP eluates 
from cells treated with ExoS-KDD-3XFLAG expressing bacteria served as a positive 
control. Additionally it is currently unknown which 14-3-3 isoform(s) interact with T3S-T-
ExoS. ExoS also purified with 40 kDa and a 45 kDa human protein, and a 70 kDa and 
an 85 kDa rodent protein. The identification of different T3S-T-ExoS interactive proteins 
in rodent and human cells supports the hypothesis that the differential targeting of T3S-
T-ExoS ADPRT activity within human and rodent cell lines is due to differential protein 
interactions. 
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Discussion 
To further explore the mechanism underlying the differential targeting of T3S-T-
ExoS to substrates in rodent and human cell lines (197), we designed studies to: 1) 
further characterize the differences in substrate specificity, and 2) identify mechanisms 
responsible for the differences in substrate specificity. All of these studies were based 
on the perspective that the host cell contributes to Pa T3S process. An example of host 
cell influence on the targeting of ExoS ADPRT activity is in the comparison of the 
repertoire of proteins that ExoS ADP-ribosylated in rodent cell extracts in vitro, including 
Ras, RalA, Rab proteins and Rac1, to the limited proteins that T3S-T-ExoS ADP-
ribosylated in the cell, including only Ras and RalA (197). 
Analysis of substrates targeted by wild type or mutant ExoS in vitro revealed that 
mutation of either glutamic acid, 379 or 381, resulted in a lack of substrate modification 
and lack of auto-ADP-ribosylation of ExoS (personal observation) in both rodent and 
human cell extracts. These results confirmed previous in vitro studies, which 
characterized E381 as the critical residue for ExoS ADPRT activity (141). Unexpectedly, 
T3S-T-ExoSE381A ADP-ribosylated Ras and RalA in both rodent and human cell lines, 
but did not target Rab proteins or Rac1 in human cells. An auto-ADP-ribosylated form of 
ExoS-E381A-HA also was not observed in either rodent or human cell lines. These 
results indicated that the ExoS-E381A mutant exhibited ADPRT activity only after T3S-T 
into eukaryotic cells. These results were consistent with previous studies that indicated 
that the host cell could limit and influence the molecular targeting of T3S-T-ExoS 
ADPRT activity (65, 193, 197), which led to the examination of the influence of 
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intracellular localization and protein interactions on the targeting of ExoS ADPRT 
activity in rodent and human cells. 
It was observed that ExoS ADPRT activity is found mainly in the membrane fraction 
of eukaryotic cells (64, 188). Concordantly, a membrane localization domain (MLD) was 
found to reside within residues 51-72 of ExoS and to localize T3S-T-ExoS to eukaryotic 
membranes. Loss of the MLD caused T3S-T-ExoS to localize to the cytosolic fraction of 
eukaryotic cells (176). The restrictive pattern of substrate modification was observed in 
human cells following T3S-T of ExoS∆MLD, and there was a modest decrease in the 
ability of T3S-T-ExoS to ADP-ribosylate proteins in rodent cells, which intrinsically 
exhibit the restrictive pattern of substrate modification. The ability of ExoS∆MLD to 
ADP-ribosylate target proteins was similar to results observed upon T3S-T of the ExoS-
E381A mutant, which resulted in a restrictive substrate modification pattern in human 
cells, but did not alter the substrate modification pattern observed in rodent cells. The 
decreased ability of ExoS∆MLD to ADP-ribosylate cellular proteins was linked to the 
inappropriate localization of ExoS to the cytosol. In contrast, T3S-T-ExoS-E381A 
localized to membrane fractions similarly to wild type ExoS in both rodent and human 
cell lines. These data indicated that inappropriate intracellular localization or 
handicapped ADPRT activity can lead to similar restrictive patterns of substrate 
modification, which suggests that there may be more than one mechanism affecting the 
intracellular targeting of ExoS ADPRT activity. 
As mentioned previously, the functional role of T3S-T-ExoS auto-ADP-ribosylation, 
observed both in vitro and within the cell, has not yet been described (189). Auto-ADP-
ribosylation by other bacterial ADPRT toxins, such as E. coli heat labile enterotoxin 
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(LTA), has been noted to occur in in vitro reactions, but not within the cell and 
seemingly without any functional consequence to the toxin (223). In contrast, studies 
examining mammalian ADPRT’s have found that auto-ADP-ribosylation affects enzyme 
function. For example, auto-ADP-ribosylation of ADP-ribosyltransferase 5 (ART5) was 
shown to decrease NADase activity, while increasing ADPRT activity of the molecule, 
implicating a role of auto-ADP-ribosylation in the regulation of the enzyme’s function 
(244). ExoS has been shown to closely resemble mammalian ADP-ribosyltransferases, 
as evident in: 1). the sequence homology between the catalytic domain of ExoS and 
domains of vertebrate ADPRTs, 2) both ExoS and eukaryotic ADPRT’s ADP-ribosylate 
cellular proteins at more than one site, and 3). ExoS, like eukaryotic ADPRTs, targets 
multiple proteins (72). These similarities suggest that ExoS auto-ADP-ribosylation may 
regulate ExoS ADPRT activity. 
Initial studies indicated that the purpose of ExoS auto-ADP-ribosylation was to down 
regulate ExoS GAP activity by auto-ADP-ribosylating the R146 residue (189). However, 
the GAP activity of ExoS was hard to discern in non-macrophage, mammalian cell lines 
(64, 192, 193), and the recorded effect of ExoS auto-ADP-ribosylation of the GAP 
region was unimpressive (189). In these studies, auto-ADP-ribosylation was observed 
to occur with ExoS-R146A GAP mutant, confirming that the R146 residue was not the 
only potential arginine target of auto-ADP-ribosylation. ExoS auto-ADP-ribosylation was 
observed following the T3S-T of wild type or R146A mutant ExoS in rodent and human 
cells, and appeared to require both E379 and E381 residues. Linking these results to 
previous observations about the role of E381 in the intracellular targeting of ExoS 
ADPRT activity indicate that the E381 residue of ExoS may contribute to ExoS auto-
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ADP-ribosylation in all cells lines, the extensive pattern of ExoS substrate modification 
in human and simian cell lines, but not to ExoS substrate ADP-ribosylation in rodent cell 
lines. Therefore, upon T3S-T of ExoS into rodent cells, the activity of E381 may be 
limited to auto-ADP-ribosylation only, without influencing ExoS substrate ADP-
ribosylation. 
The observation that the T3S-T-ExoS-R146A mutant seemingly ADP-ribosylated 
substrates more efficiently than wild type T3S-T-ExoS, prompted studies which 
examined the T3S-T of ExoS-R146A mutants into eukaryotic host cells. These studies 
found that mutation of R146 (alone or in combination with ADPRT mutations) resulted in 
increased T3S-T of ExoS into both restrictive and extensive pattern cell lines. These 
data indicated that ExoS GAP activity may play a role in regulation of bacterial 
translocation or overall stability of the protein. Previous studies, which explored the 
T3S-T of YopE, found that the GAP activity of YopE (the GAP domain of YopE has 
sequence homology to that of ExoS (259)) acted in part to prevent actin polymerization, 
by downregulating RhoGTPase activity, to prevent the T3S apparatus from forming 
pores in the eukaryotic cell membrane (240). This was evident in that mutation of the 
GAP activity in YopE resulted in cell lysis by the pores formed by the T3S-apparatus. In 
our studies, mutation of the GAP activity did not result in cell lysis or death (data not 
shown). However, we wished to determine if the integrity of the eukaryotic cell 
cytoskeleton influenced the T3S-T of ExoS. To examine if the GAP region of ExoS 
functioned similarly to YopE by altering the status of the cytoskeleton, we treated T24, 
human epithelial, cells with cytochalasin D, which inhibited actin polymerization, and 
colchicine A, which inhibited microtubule polymerization, prior to co-culture with ExoS-
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HA or ExoS146-HA bacteria. Interestingly, both drugs influenced the T3S-T of wild type 
ExoS-HA, but not ExoS-R146A-HA. These results indicate that potentially both actin 
and microtubule components play a role in the T3S-T of ExoS. These results also 
suggest that the GAP activity controls the amount of ExoS which is T3S-T into 
eukaryotic cells, independently of the cytoskeleton. However, these results do not rule 
out the possibility that proper intracellular degradation of T3S-T-ExoS might rely on a 
functional actin or microtubule cytoskeleton. 
Results obtained by examining the T3S-T of both the R146A mutant and E381A 
mutant highlighted areas of the T3S-T process about which very little is known, but in 
which the host cell likely plays a role. These include: 1) the post T3S-translocation 
processing/folding procedure that must occur to form a functional T3S effector, 2) T3S-
T-ExoS turnover, and 3) intracellular trafficking of T3S-T-ExoS. Given the 2-3 nm 
diameter of the needle apparatus (18, 76, 94, 110), it has been hypothesized that all 
T3S-effectors remain in a partially unfolded state to be translocated through the T3S-
apparatus (220). This necessitates that the final folding of the T3S-effector occurs within 
the eukaryotic host cell. 
It has been hypothesized that ExoS is processed within the eukaryotic cell upon 
T3S-T (177), and what appears to be a processed form of T3S-T-ExoS has been 
observed in our studies. To better understand this process, we pretreated eukaryotic 
cells with cell permeable protease inhibitors prior to co-culture with ExoS producing 
bacteria. These studies identified the general serine protease inhibitor, AEBSF, as a 
drug that negatively affected production of PopD, yet seemingly enhanced the T3S-T of 
ExoS, but inhibited ExoS ADPRT activity. While these studies are curious, it is unclear if 
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AEBSF inhibits transcription, translation or secretion of PopD. It is unlikely that AEBSF 
acts as a global Pa T3S inhibitor, given that ExoS is produced and bacterially 
translocated. This data supports the notion that the T3S-apparatus is formed after 
treatment with AEBSF; however, the composition of the apparatus may be altered. 
Previous studies found that in addition to PopD, PcrV and PopB were required for Pa 
T3S-T, and that deletion of any one of the proteins inhibited T3S-T (67, 80, 81, 208, 
235). The stability and solubility of PopD and PopB required a chaperone protein, PcrH 
(210). Deletion of PcrH also resulted in inhibition of T3S-T (21). Since T3S-T of ExoS 
was still observed in cells treated with AEBSF, it is unlikely that the drug caused 
complete depletion of PopB, PcrV or PcrH. However it remains unknown if AEBSF 
affects the production of these proteins in a manner that would deregulate T3S-T of 
effectors. These studies were limited by the lack of examination of how AEBSF affected 
the T3S-T of other Pa effectors.  
The negative effect of AEBSF on T3S-T-ExoS ADPRT activity suggested that 
AEBSF interfered with the serine protease responsible for T3S-T-ExoS processing. 
AEBSF is a general serine protease inhibitor, which has been found to act as an 
inhibitor of eukaryotic cell differentiation (14), a caspase inhibitor (42), a tumor 
angiogenesis inhibitor (184), and lysosome associated protein cleavage disregulator 
(39). Therefore, the negative effects of AEBSF on T3S-T-ExoS ADPRT activity may be 
due to a wide-range of indirect effects, unrelated to T3S-T-ExoS intracellular 
processing. Interestingly, aprotinin and leupeptin, which are components of the PIC and 
serine protease inhibitors, did not affect T3S-T-ExoS translocation or ADPRT activity, 
indicating that there may be specificity in the action of AEBSF. 
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Critical to understanding how the host cell modulates T3S-T-ExoS ADPRT activity is 
gaining insight into how T3S-T-ExoS is trafficked within rodent and human cell lines. 
Previous studies found that T3S-T-ExoS ADP-ribosylated Rab proteins in a distinct 
order (65), providing a clue that T3S-T-ExoS may be trafficked via vesicles in human 
cells. Attempts at tracking T3S-T-ExoS by both immunofluorescence and flow cytometry 
did not yield meaningful data due to the high amounts of background staining in both 
assays. Subcellular fractionation of cells treated with ExoS-HA-producing bacteria has 
not been attempted. While these studies would be beneficial to understanding the 
intracellular localization of T3S-T-ExoS, very little wild type ExoS-HA could be 
visualized in cells fractionated into cytosolic and membrane fractions, indicating a 
potential difficulty in identifying T3S-T-ExoS within specific cellular compartments. 
Therefore, a proteomics approach was designed, which involved co-culturing eukaryotic 
cells with ExoS-producing bacteria and then co-immunoprecipitating ExoS with 
interacting proteins. The identification of T3S-T-ExoS-interacting proteins was 
hypothesized to lead to the identification of the intracellular location of ExoS. In 
comparisons of co-immunoprecipitates from human and rodent cell lines, different T3S-
T-ExoS-interacting proteins were isolated in both human and rodent cell lines. 
Preliminary results from MALDI-TOF indicate that the human ExoS-interacting proteins 
may be involved in lysosomal trafficking (J. Carroll, personal communication). These 
results support the hypothesis that T3S-T-ExoS ADP-ribosylates distinct eukaryotic 
proteins in a restrictive and extensive pattern cell lines, in part, because of differences in 
interacting proteins or intracellular location. 
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Two similar proteins co-immunoprecipitated with T3S-T-ExoS from rodent and 
human cells, and are thought to be 14-3-3 isoforms (J. Carroll, personal 
communication). There are seven different isoforms of 14-3-3 found in mammalian cells: 
ζ, ε, γ, β, σ,η, τ (1); all of which are capable of stimulating ExoS ADPRT activity in vitro 
(268). Little is known about which 14-3-3, isoform interacts with T3S-T-ExoS within 
cells. Since, 14-3-3 proteins regulate subcellular localization, stability and molecular 
activity of their target proteins (46), characterizing the interaction of 14-3-3 with T3S-T-
ExoS may be the key to understanding the intracellular targeting of ExoS ADPRT 
activity. Comparisons of the amino acid sequences of Homo sapiens and Mus musculus 
14-3-3 isoforms, found the ζ and ε isoforms to be identical, while all other isoforms 
displayed differences in one or more amino acids (personal observation). Differences in 
conserved proteins among mammals have previously been found to affect the outcome 
of infectious agents. One such example is the single residue difference between the 
human and mouse E-cadherin, which resulted in an abrogated infectivity of Listeria in 
mice (132).  
Further analysis of Co-IP samples by MALDI-TOF should reveal potential 
differences in T3S-T-ExoS-14-3-3 interactions as well as positive identification of the 
unique proteins which interact with T3S-T-ExoS in rodent or human cell lines. It is 
currently unclear if ExoS interacting with different proteins in rodent and human cells 
would have a direct affect on the intracellular targeting of ExoS ADPRT activity, but the 
identification of ExoS-interacting proteins is expected to reveal the intracellular location 
of ExoS in rodent and human cell lines. Defining the differences in how T3S-T-ExoS 
ADPRT activity is targeted within rodent and human cell lines will provide a better 
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understanding of how the host cell influences the T3S-T process and directs effector 
activity. 
148 
Chapter 5: Discussion 
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The bacterial T3S system allows the microbe to hijack host cell function to its 
advantage. In general, discussions and studies about T3S focus on the bacterial side of 
the process. Many elegant studies have shown that bacterial T3S effector proteins 
ingeniously mimic the function of eukaryotic proteins to manipulate the host cell (221). 
Currently, there is very little known about the eukaryotic cell contribution to the T3S 
process. Given the intimate nature of the bacterial-eukaryotic cell association required 
for T3S to occur, it is bold to assume that the eukaryotic cell is a passive participant in 
this process. However, in most studies, the role of the host cell in the T3S process is 
eclipsed by the overt pathogenicity of most Gram-negative organisms. An advantage to 
studying Pa is that this organism will only cause disease if the host is compromised. By 
nature, Pa colonization and infection of the host is a negotiation rather than a hostile 
takeover. Early studies of Pa T3S revealed that subconfluent monolayers of eukaryotic 
cells were sensitive to Pa T3S-T of ExoS, while confluent cells were less sensitive (58, 
115, 154). These were the first studies indicating that the status of the host cell 
influences T3S, corresponding to the opportunistic nature of Pa infections. 
In 1978, ExoS was characterized as a Pa ADPRT toxin distinct from exotoxin A 
(ETA) (106). In mouse models of infection, ExoS was noted to contribute to Pa 
dissemination (162, 163), but curiously, ExoS was nontoxic by itself to tissue culture 
cells and animals (25, 162, 170). The inability to assign a cellular effect to the ExoS 
prompted genetic analysis of its regulation and transcription. These studies led to the 
recognition that Pa harbors a T3S system, homologous to the Yersinia T3S system 
(258, 260). There are four known Pa T3S effector proteins (ExoS, ExoT, ExoU and 
ExoY), but ExoS is the best characterized effector. 
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ExoS is a bifunctional protein and serves both as a GAP targeting Rho, Rac and 
Cdc42 in vitro (77), and an ADPRT targeting mainly low molecular weight G-proteins in 
vitro (30, 63, 65). The broad range of target substrates of ExoS ADPRT activity 
differentiates ExoS from other bacterial ADP-ribosyltransferase toxins, which are highly 
specific. Transfer of an ADP-ribose moiety to a target protein typically alters or destroys 
the function of that protein. For example, ETA ADP-ribosylation of elongation factor-2 
(EF-2) inhibits protein synthesis in the eukaryotic cell (105). Endogenous eukaryotic 
ADPRTs have also been identified that regulate cellular processes. Coordinate to a 
eukaryotic ADPRT, a cognate ADP-ribose hydrolase may reverse the addition of ADP-
ribose moieties to target proteins. For instance, polymerization of a muscle cell 
cytoskeletal component, desmin, has been found to be controlled in part by ADP-
ribosylation. ADP-ribosylation of desmin results in the inability of desmin to form 
filaments, and the cognate ADP-ribosyl hydrolase allows desmin to re-form filaments 
(100, 101). EF-2, which is a target of Pa ETA and diphtheria toxin (DT) ADPRT activity 
(31, 105), has been found to be ADP-ribosylated by endogenous eukaryotic ADPRTs 
(35, 53). While this reaction has not been fully characterized, the eukaryotic ADPRT 
was found to ADP-ribosylate a subset of total cellular EF-2 and the ADPRT reaction 
was found to be reversible (53). These studies suggest that bacterial toxins mimic the 
actions of eukaryotic ADP-ribosyltransferases, but the lack of a cognate ADP-ribose 
hydrolase that renders the bacterial ADP-ribosylation permanent and consequently 
detrimental to eukaryotic cell function. 
In studies characterizing the functional effects of T3S-T-ExoS, the ADPRT activity of 
ExoS was found to be required for ExoS-specific inhibition of DNA synthesis, permanent 
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cell rounding, and inhibition of adherence processes (64). Notably, the effects of ExoS 
on cell function have not thus far been linked to the ADP-ribosylation of a particular 
substrate. Current theories suggest that T3S-T-ExoS effectively inactivates host cell 
function by the collective ADP-ribosylation of eukaryotic proteins. While ExoS targets 
multiple proteins, recent studies have found that the eukaryotic cell environment limits 
the substrates targeted by T3S-T-ExoS ADPRT activity (65, 89, 193, 197). Previous 
studies in our laboratory using the HT-29 human epithelial cell line, identified Ras, RalA, 
Rabs 5, 7, 8, 11, Rac1 and Cdc42 as targets of T3S-T-ExoS (63, 65). Importantly, Rab4 
or Rap proteins were identified as targets of ExoS ADPRT in vitro, but not within 
eukaryotic cells (30, 63, 65). In time-course co-culture studies, T3S-T-ExoS was found 
to ADP-ribosylate proteins in a specific order; Ras, RalA and Rab5 were targeted first, 
followed by ADP-ribosylation of Rabs 8 and 11, and lastly, Rab7 and Rac1 (65). 
Combined, these studies indicated that the host cell limits and specifies the substrates 
targeted by T3S-T-ExoS ADPRT activity. 
During studies of the cellular effects of ExoS ADPRT, further understanding of how 
the host cell contributes to and influences T3S-T-ExoS ADPRT activity began emerging. 
The goal of my studies was to characterize the role of the host cell in the Pa T3S-T of 
ExoS. Specifically, these studies have: 1) shown that cell origin influences T3S-T-ExoS 
ADPRT substrate specificity, 2) determined that the host cell influences Pa T3S at the 
level of membrane translocation, and 3) provided evidence that T3S-T-ExoS protein 
interactions might influence ExoS ADPRT intracellular trafficking. 
In studying the effects of T3S-T-ExoS on rodent fibroblasts and human epithelial 
cell function, it was found that the rodent fibroblasts were typically less sensitive than 
152 
human epithelial cells to the effects of ExoS on DNA synthesis, permanent 
morphological alterations and readherence. These results correlate with the 
identification of two patterns of T3S-T-ExoS ADP-ribosylation of substrates: 1) a 
restrictive pattern, showing a single modification of Ras and RalA; 2) an extensive 
pattern, recognized as more efficient modification of Ras and RalA and modification of 
Rabs 5, 7, 8, 11 and Rac1. The pattern of T3S-T-ExoS substrate modification was not 
linked to cell type or efficiency of T3S-T of ExoS, but to the species of origin, with rodent 
cell lines exhibiting the restrictive pattern of ADP-ribosylation, and simian and human 
cell lines exhibiting the extensive pattern of ADP-ribosylation (197).  
Previous studies identified another instance in which human and rodent cell lines 
displayed differential sensitivities to a bacterial ADP-ribosyltransferase. Studies which 
examined cellular sensitivity to DT found that cells of monkey origin were the most 
sensitive to DT, followed by human and hamster cells, while cells of mouse and rat 
origin being resistant (157). Further examination showed that mouse and rat cells lack 
the receptor required for DT fragment B binding and subsequent translocation of DT 
fragment A (48, 222). In contrast to DT, ExoS was T3S-T equally well taken up by cells 
of rodent origin, even though the end result was a restrictive pattern of substrate ADP-
ribosylation (197). With regard to T3S-T-ExoS cytotoxicity, the limiting factor does not 
appear to be bacterial binding or T3S-T of the effector protein, but instead related to 
how the toxin is targeted by the mammalian cell. 
The importance of the finding that T3S-T-ExoS targets proteins differently in rodent 
and human cells is the identification of a model system to study factors that determine 
intracellular T3S-effector targeting and may ultimately provide clues to understanding 
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eukaryotic cellular trafficking mechanisms. The rodent cell lines (NIH-3T3 and Swiss-
3T3) used in our studies were found to be less sensitive than the human cell lines (HT-
29 and LNCaP) to the effects of ExoS. Subsequent studies examining the effects of 
T3S-T-ExoS on morphological alterations found other rodent cell lines (TCMK-1, CHO-
K1) to be just as sensitive as HT-29 or LNCaP human cell lines to T3S-T-ExoS-induced 
cell rounding, and simian and human cell lines (Cos-1, Vero, WI-38) to show similar 
rounding patterns as NIH-3T3 and Swiss-3T3 cells (personal observation). Despite the 
differences in sensitivity of individual cell lines to the morphological effects of T3S-T-
ExoS, the patterns of ExoS ADP-ribosylation remained consistent within rodent 
(restrictive) and human and simian (extensive) cell lines. These qualitative comparisons 
highlight the notion that while cellular reactions to T3S-T-ExoS vary, ExoS substrate 
targeting remains constant and dependent on mammalian origin. 
In examining the effects of T3S-T-ExoS on different cell lines, HL-60 myeloid cells 
were found to be resistant to the effects of ExoS on cell function, which corresponded 
with a lack of ADP-ribosylation of eukaryotic proteins. Differentiation of HL-60 cells with 
a phorbol ester, TPA, induced HL-60 cell sensitivity to effects of ExoS on cell 
morphology and ExoS ADP-ribosylation of substrates. Studies examining mechanisms 
of resistance, including bacterial adherence, induction of Pa T3S and Pa T3S-T, 
revealed that the resistance and TPA-induced sensitivity to ExoS related to Pa T3S-T of 
ExoS (198). More bacteria were able to adhere to HL-60 cells than to TPA-HL-60 cells, 
and HL-60 cells were able to induce the production of PopD, a protein required for T3S-
T. The inability to detect intracellular ExoS-HA in HL-60 cells, which nevertheless bound 
Pa and induced PopD, indicated that an HL-60 cell property interfered with T3S-T of 
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ExoS. It remains unknown if a functional Pa T3S apparatus is formed when Pa is in 
contact with HL-60 cells. 
Previous discussion of HL-60 cell resistance focused on cell surface features that 
might be altered with TPA-differentiation (Chapter 3). Other studies examining 
pharmaceutical induction of Pa T3S sensitivity or resistance showed that treatment of 
HL-60 cells with colchicine A, which disrupts microtubules, prior to co-culture with ExoS 
producing bacteria, allowed ADP-ribosylation of Rab5 and RalA (E. Rucks, unpublished 
data). Treatment of cells with colchicine A did not affect normal cellular distribution of 
either Rab5 or RalA, as assessed by cell fractionation studies. In addition, treatment of 
T24 cells with colchicine A also resulted in increased T3S-T of ExoS, compared to 
untreated cells. Combined, these data suggest that a possible mechanism affecting 
T3S-T-resistance or sensitivity relates to the cytoskeletal structure of eukaryotic cells 
interacting with Pa. Polarized epithelial cells, like HL-60 cells, are resistant to Pa T3S-T 
(34, 58, 115, 154), and both cell types can be induced to become T3S-T-sensitive, 
through non-polarization or TPA-differentiation, respectively. Polarized epithelial 
monolayers exhibit an asymmetrical microtubule arrangement with the minus ends of 
microtubules being anchored at apical surface and plus ends being at the basal surface 
(9). In contrast, undifferentiated HL-60 cells exhibit a concentrically symmetrical 
microtubule organization, with microtubules radiating from a central location (136). Upon 
conversion to T3S-T-sensitivity, non-polarized epithelial monolayers exhibit properties of 
both symmetrical and asymmetrical microtubule organization, with microtubules 
radiating from the centrosome and Golgi complex (9, 160). Upon TPA differentiation and 
induction of T3S-T-sensitivity in HL-60 cells, the microtubule network stretches into 
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pseudopodia from the centriolar region, in association with a loss of symmetrical 
arrangement (112). While no obvious microtubule commonality is recognized in T3S-T-
resistant cells, alterations in microtubule symmetry may be a feature common to the 
induction of T3S-T-sensitivity by increasing the efficiency of the T3S-T process. 
Recent studies have drawn attention to possible modulatory influences the 
eukaryotic cell can have on ExoS function. Notably, T3S-T-ExoS ADPRT activity was 
found to be enhanced in the membrane compartment of epithelial cells (64, 188). The 
enhancement of ExoS ADPRT activity within the cell was further evident in the detection 
of Ras and RalA modification upon T3S-T of an ExoS ADPRT E381A mutant, which 
was unable to modify either protein in vitro (64) (Chapter 4). Correlating with these 
findings was the identification of ExoS having a membrane localization domain (MLD) in 
ExoS (176). T3S-T of ExoS∆MLD lacking this domain results in cytosolic ExoS 
localization and decreased ADP-ribosylation of euakaryotic substrates (176). These 
studies indicate the importance of ExoS membrane localization for ADPRT activity, 
which supports the hypothesis that ExoS membrane localization optimizes interaction of 
ExoS with eukaryotic cofactor required for ExoS ADPRT activity. 
Studies examining the cellular effects of an ExoS GAP R146A mutant also provided 
evidence that ExoS GAP activity modulates ADPRT function within the eukaryotic cell 
(64). The complex interactions of the domains is illustrated with Rac1, a LMWG-protein, 
which has been identified as a target of both ExoS GAP and ADPRT activities (65, 77, 
193). Rac1 regulates multiple cellular processes, including phagocytosis and cell 
motility, partly by controlling cytoskeleton dynamics. It is a primarily cytosolic protein, 
but upon activation, GTP-bound Rac1 localizes to the membrane where it interacts with 
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downstream effector PAK (229). After T3S-T of ExoS into human epithelial cells, ExoS 
was found to ADP-ribosylate Rac1, leading to Rac1 activation and membrane 
association, as indicated by ADP-ribosylated Rac1 interaction with PAK and cellular 
fractionation analysis, respectively (65, 193). In contrast, in macrophages, Rac1 was 
found to be a target of T3S-T-ExoS GAP, rather than ADPRT, activity, which resulted in 
inactivation of Rac1 and prevention of phagocytosis (192). Recent studies found that 
T3S-T-ExoS targeted Rac1 by either GAP or ADPRT activities, but not both, and that 
these differences in ExoS targeting correlated with subtle differences in Rac1 
subcellular localization within human epithelial and murine macrophage cells (193). 
Combined, these data indicate that the GAP and ADPRT domains of ExoS are 
modulated within the context of the host cell. 
A role of R146A in the GAP domain in the effectiveness of T3S-T of ExoS has also 
been identified. Mutation of R146A resulted in increased levels of T3S-T-ExoS in 
eukaryotic membrane and cytosolic fractions. The more efficient translocation of R146A 
ExoS did not lead to alteration of the substrate modification pattern of T3S-T-ExoS. 
These data indicate that R146A may have a regulatory role at the level of T3S-T of 
ExoS and/or subsequent ADPRT activity. Previous studies indicated that R146 was the 
preferential site of ExoS auto-ADP-ribosylation, but loss of this site does not completely 
abrogate auto-ADP-ribosylation activities in vitro (189). In our studies we found that the 
R146A mutant was still efficiently auto-ADP-ribosylated within the eukaryotic cell. It has 
been reported in eukaryotic ADPRT proteins, auto-ADP-ribosylation serves as a means 
of regulating enzymatic function (244). Therefore, with mutation of R146, T3S-T-ExoS 
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may be auto-ADP-ribosylating at an alternative site that results in disregulation of a 
feedback mechanism controling the amounts of ExoS that is T3S-T or ADPRT active. 
If R146 controls the amount of ExoS that is bacterially translocated, its mutation 
could have an effect on the translocation of other Pa T3S effector proteins. The R146A 
mutation does not result in greater bacterial secretion of mutant ExoS compared to wild 
type ExoS in eukaryotic cell-free bacterial cultures, suggesting that a host cell process 
influences altered amounts of T3S-T-ExoS-R146A. This abberation can be studied by 
monitoring the T3S-T of ExoT or ExoY in strains expressing ExoS-R146A-HA. If ExoS-
R146 serves as a general regulator of Pa T3S-T, an increase in the translocation of 
ExoT or ExoY would be expected in strains expressing ExoS-R146A, as compared to 
wild type ExoS. Interestingly, ExoT also harbors a GAP domain (114, 122), which could 
function similarly to that of ExoS. If ExoS GAP activity, in combination with a host cell 
process, regulated intracellular amounts of T3S-T-ExoS, then translocation of wild type 
ExoT or transfection of the ExoS GAP domain would be expected to result in normal 
intracellular levels of T3S-T-ExoS R146A GAP mutant relative to intracellular levels of 
wild type ExoS. In summary, current studies suggest that specific ExoS residues, in 
combination with host cell processes, influence the translocation and intracellular 
targeting of ExoS activity. 
Current data indicate that T3S-T-ExoS interacts with different proteins, in 
association with its different ADPRT substrate modification patterns in human and 
rodent cell lines. Using a Co-IP approach to identify ExoS-associated proteins within 
eukaryotic cells, ExoS was found to associate with 14-3-3 proteins in both rodent and 
human cell lines. This finding is consistent with the known interaction of Exos with its 
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14-3-3 cofactor in vitro and confirmed the utility of this Co-IP approach to identify ExoS 
interactive proteins. In addition, ExoS was found to interact with 40 and 45 kDa proteins 
in human cells and 70 and 85 kDa proteins in rodent cell lines. While the identity of 
these proteins has not been confirmed, it is expected that their identification will provide 
insight into the differential subcellular localization of T3S-T-ExoS within rodent and 
human cells. 
The identification of these proteins could also elucidate intracellular trafficking 
mechanisms of ExoS. In human cell lines, ExoS has been found to ADP-ribosylate Rab 
proteins, which are located in different subcellular compartments, in a distinct order: first 
Rab5, then Rabs 8 and 11, and lastly Rab7 (65). Rab5 resides in clathrin coated 
vesicles and early endosomes; Rab8 resides within the trans-Golgi region and on 
secretory granules; Rab11 is found within the perinuclear recycling endosomes and 
recycling endosomes from the Golgi apparatus; and Rab7 is found on late endosomes 
(267). The timing of ExoS ADP-ribosylation of these Rab proteins supports the notion 
that ExoS has sequential access to these subcellular locations. Interestingly, Rab4, 
which was not found to be a target of T3S-T-ExoS ADPRT activity, has been found 
associated with early sorting endosomes, and is also present on vesicles with Rab5 
(early sorting endosomes) and Rab11 (perinuclear recycling endosomes) (217, 267). 
Previous studies indicated that Rab4 is central to early endosomal pathways in the 
ability to facilitate the trafficking of Rab5 associated vesicles to Rab11 (217). It was also 
reported that ExoS ADP-ribosylation of Rab5 interfered with protein function, implicating 
a functional role of ExoS ADP-ribosylation in the targeting of Rab proteins (10). These 
observations, in combination with lack of ExoS ADP-ribosylation of Rab4, support the 
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notion that within human cells ExoS selectively targets Rab proteins in a manner that 
facilitates intracellular effector transport. 
It is currently unknown why ExoS ADPRT activity targeted Rab proteins in human 
and simian cell lines but not in rodent cell lines. The identification of ExoS-interacting 
proteins may be the first step to understanding a mechanism of these differences. ExoS 
requires interaction with the cofactor 14-3-3. These studies have confirmed the 
interaction of ExoS with 14-3-3 in both rodent and human cell lines, the specific 
isoforms have not yet been identified. The significance of this would be to determine if 
ExoS interacts with the same or different 14-3-3 isoforms in rodent and human cell 
lines. As mentioned previously, only two out of seven 14-3-3 isoforms have identical 
amino acid sequences in comparison of rodent and human. Any difference in ExoS-14-
3-3 interactions in rodent and human cells might result in different protein interactions 
and intracellular localization of ExoS. Therefore, understanding these differences would 
determine a mechanism for different intracellular trafficking of ExoS ADPRT in rodent 
and human cell lines. 
As mentioned previously, T3S-T-ExoS caused eukaryotic cell rounding within 3 to 4 
hours of co-culture (170). Initial cell rounding is thought to be caused by ExoS GAP 
activity disrupting actin filaments (178), while permanent cell rounding has been linked 
to ExoS ADPRT activity (64). When considering T3S-T-ExoS intracellular trafficking 
patterns, they must be considered in the context of a modified actin cytoskeleton. 
Treatment of eukaryotic cells with colchicine A, which disrupts microtubules, enhanced 
T3S-T of ExoS, similar to the effect of the R146A mutation on T3S-T of ExoS. 
Unexpectedly, in human epithelial cells that have been treated with colchicine A and co-
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cultured with ExoS producing bacteria, ADP-ribosylation of RalA, Rab5 and Rab7 was 
observed, indicating that ExoS could still gain access to these subcellular 
compartments. Recent advances in understanding vesicular trafficking have shown that 
Rab proteins, through interaction with kinesin-like motor proteins, direct the motility of 
vesicles and organelles by a microtubule-dependent mechanism (47, 167, 168, 209). 
Critical to linking T3S-T-ExoS intracellular trafficking to the microtubule cytoskeleton is 
further characterization of the effects of colchicine A on ExoS substrate targeting and 
pharmacological abrogation of vesicular trafficking mechanisms through the use of such 
agents as brefeldin A. It is my current hypothesis that ExoS specifically alters the actin 
cytoskeleton to allow for intracellular trafficking via a modified microtubule cytoskeleton, 
and that multiple Rab proteins are ADP-ribosylated in human cells leaving only a subset 
of Rab vesicles navigable. The subtle role of the host cell in this process is evident in 
the modulation of ExoS activity via interaction with 14-3-3 and subsequent protein 
interactions, which results in the restriction (rodent cell lines) or extension (simian and 
human cell lines) of ExoS intracellular trafficking (Figure 29). 
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Figure 29. Model of differential targeting of T3S-T-ExoS ADPRT activity 
The restrictive pattern characteristic of rodent cells, ExoS is sequestered from vesicles 
by interaction with a 70 kDa (unkp70) or 85 kDa (not depicted) protein. The extensive 
pattern, seen in simian or human cells, ExoS interaction with a 40 kDa (unkp40) or 45 
kDa (not depicted) protein aids in targeting ExoS to vesicles, which are then trafficked 
on microtubule filaments (light yellow cylinders) from the plasma membrane to other 
intracellular organelles, such as the trans Golgi region. ExoS ADP-ribosylation of itself 
and eukaryotic proteins is indicated in orange stars. EE, early endosome; SE sorting 
endosome; RE, recycling endosome. 
An recent review written by Marino Zerial and Heidi McBride summarized the function of 
Rab proteins, which provided the foundation required to relate ExoS ADP-ribosylation 
patterns to eukaryotic intracellular trafficking mechanisms (267). 
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In conclusion, studies described in this dissertation have recognized that the host 
cell can influence the Pa T3S-T of ExoS by: 1) determination of ExoS ADPRT-substrate 
restrictive or extensive modification pattern, 2) allowing of membrane translocation, and 
3) targeting intracellular ExoS GAP or ADPRT activity potentially through protein 
interactions or intracellular trafficking mechanisms. 
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